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ABSTRACT
Chronic kidney disease (CKD) results in significant morbidity and mortality in 
dogs, and urine protein loss is common in dogs with CKD. Currently available non-
invasive biomarkers for evaluating CKD in dogs cannot accurately predict the severity 
of glomerular and tubulointerstitial (TI) damage or the cause of CKD without renal 
biopsy. Non-invasive indicators of degree of renal damage, disease type, and prognosis 
would be ideal for clinicians and owners. Study goals were to evaluate novel protein 
biomarkers and electrophoretic banding patterns as indicators of glomerular and TI 
damage, specific disease type, and survival in dogs with naturally occurring proteinuric 
CKD. These retrospective studies used urine, serum, and renal biopsies from 200+ dogs 
with CKD. Selected urinary protein biomarkers (immunoglobulins G and M, retinol 
binding protein, neutrophil gelatinase associated lipocalin, and N-acetyl-β-D-
glucosaminidase (NAG)) and electrophoretic urinary protein banding patterns were 
evaluated and correlated with histologic damage on renal biopsies, and significant 
associations, sensitivities, and specificities of biomarkers for renal disease type were 
determined. The odds of altered urinary biomarkers and banding patterns being 
associated with increased risk of death due to renal disease were also determined.
Fractional excretions of immunoglobulin M (IgM) and immunoglobulin G 
correlated most strongly with glomerular damage based on light microscopy, while 
serum creatinine correlated most strongly with TI damage. Urinary IgM and NAG were 
significantly associated with immune complex-mediated glomerulonephritis (ICGN), 
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and urinary IgM in particular had high specificity for ICGN above 13.6 ng/ml or 14.4 
μg/mg. Electrophoretic protein banding patterns had excellent sensitivity and specificity 
for detection of glomerular damage and good sensitivity and excellent specificity for 
detection of TI damage, and banding patterns were moderately correlated with histologic 
severity of glomerular and TI damage. Increases in most protein biomarkers, degree of 
severity of electrophoretic protein banding patterns, and degree of histologic glomerular 
and TI damage were significantly associated with an increased risk of death due to renal 
disease.
Novel urine biomarkers and electrophoretic protein banding patterns are useful 
for detection of glomerular and TI damage, prediction of specific disease types (in 
particular, ICGN), and prediction of risk of death in dogs with proteinuric CKD.
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1CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW*
Chronic Kidney Disease in Dogs
Chronic kidney disease (CKD) occurs when one or both kidneys are structurally 
or functionally impaired for a minimum of 3 months.1 CKD leading to renal failure is a 
common cause of morbidity and mortality in dogs in which it is often a result of primary 
glomerular disease.2,3 Regardless of the initiating cause of CKD, progressive renal injury 
is characterized by interstitial fibrosis, peritubular capillary loss, and destruction of 
functional nephrons, and renal function most closely correlates with the degree of 
tubulointerstitial (TI) damage.4 Structural and functional evidence of kidney damage is 
prevalent, even in apparently clinically healthy dogs, and prevalence of damage 
increases with age, approaching 50-90% in some studies.5 However, most currently 
available, non-invasive clinical methods for detecting TI damage and fibrosis are 
relatively insensitive. In addition, specificity of these tests can be quite poor. There 
currently is no clinically available non-invasive marker that is sensitive and specific 
enough to detect ongoing tubular damage, decreased tubular function, and/or progressive 
fibrosis that ultimately leads to end-stage renal disease. Therefore, although TI damage 
is frequent in dogs,6,7 lesions often are not recognized clinically until they are at an 
* Portions of this Introduction and Literature Review are reprinted with permission from Renal Biomarkers 
in Domestic Species by J. Hokamp and M. Nabity, 2016, Veterinary Clinical Pathology 45, 28-56, 
Copyright 2016 by American Society for Veterinary Clinical Pathology and from Advances in the 
Evaluation of Canine Renal Disease by R. Cianciolo, J. Hokamp, and M. Nabity, 2016, The Veterinary 
Journal, doi: 10.1016/j.tvjl.2016.04.012, Copyright 2016 by Elsevier Ltd.
2advanced stage, when lesions are both severe and irreversible and options for successful 
therapy are limited. Furthermore, early treatment can help prolong survival in dogs with 
CKD; therefore, testing strategies that can better identify progressive disease at an early 
stage would improve a clinician’s ability to provide appropriate therapy in a timely 
fashion. The addition of these tests during serial monitoring may also improve a 
clinician’s ability to more appropriately adjust the treatment plan for each patient.
Renal Proteinuria
Establishing the Presence of Renal Proteinuria
The studies included in this dissertation focus on proteinuric CKD in dogs, 
particularly those due to primary glomerular diseases. Proteinuria is defined by the 
detection of an excessive amount of protein in the urine by means of semiquantitative 
tests on urinalysis (dipstick) or quantitative measurements of urine protein:creatinine 
(UPC) or urinary albumin concentration.8 The origin of proteinuria (renal, pre-renal, or 
post renal) as well as its persistence and magnitude must be established.8 Localizing the 
source of proteinuria and ruling out pre-renal proteinuria (e.g., due to an overload of 
hemoglobin, myoglobin, or Bence Jones proteins) or post-renal proteinuria (e.g., due to 
lower urinary tract infection, inflammation, or hemorrhage) is done by careful review of 
patient history, physical examination, and evaluation of hematology, serum/plasma 
biochemistry, and urinalysis findings.8,9 Persistent renal proteinuria (UPC ≥ 0.5 in at 
least three samples two or more weeks apart without a contributing pre-renal or post-
renal cause) could be glomerular, tubular, or both. Once proteinuria is deemed to be 
3persistent and renal in origin, evaluation and monitoring of the UPC are important steps 
in determining the presence and severity of glomerular damage. A persistent UPC 
between 0.2 and 0.5 is classified as borderline proteinuria while UPC ≥ 0.5 is considered 
proteinuric (http://www.iris-kidney.com/guidelines/grading.html). UPC values ≥ 2 are 
generally considered to be indicative of glomerular proteinuria, while values < 2 are 
thought to occur more often with tubular proteinuria.8,10 Certainly, in the author’s 
experience, a UPC ≥ 2 is typically associated with at least some injury to the glomerular 
filtration barrier, with significant glomerular lesions identified in 99.6% of 501 renal 
specimens from dogs biopsied for the clinical indication of proteinuria, typically with a 
UPC ≥ 2.11 However, a proportion of proteinuric dogs with UPC < 2 have primary 
glomerular damage discovered on renal biopsy.12 Conversely, a small proportion of dogs 
with UPC > 2 have primary TI damage. Therefore, the magnitude of the UPC cannot 
always localize renal proteinuria as primary glomerular or TI damage.
Renal proteinuria is commonly observed in dogs with kidney disease; however, 
the role of proteinuria in canine CKD is likely under-appreciated because affected dogs 
are often identified late in their disease course. Despite consensus statements and 
reviews about the importance of evaluating, monitoring, and treating for renal 
proteinuria, proteinuria is often still overlooked in small animals as an early marker of 
kidney disease.8,9,13,14 In some cases, this may lead to clinicians not detecting renal 
disease until development of azotemia, missing the opportunity for timely therapeutic 
intervention. 
4Pathophysiology of Renal Proteinuria
Glomerular Permselectivity
In the healthy kidney there are several mechanisms that prevent protein loss into 
the urine. The glomerular filtration barrier, composed of the fenestrated endothelium and 
glycocalyx, trilaminar glomerular basement membrane (GBM), and podocytes with slit 
diaphragms, is the main mechanism for preventing proteinuria.15 The glomerular 
capillary wall restricts passage of proteins from the blood into Bowman’s space on the 
basis of their molecular size, electrical charge, and sterical configuration. This 
discrimination of molecules is known as glomerular permselectivity and allows easier 
passage of small and neutral or positive proteins compared with large and negatively 
charged proteins.15,16 
Proteins must pass through the glomerular wall barriers, the first of which are the 
open pores of the glomerular endothelium. This is followed by the glomerular basement 
membrane, which is a collagenous network composed of type IV collagen, laminin, 
nidogen, and proteoglycans (e.g., chondroitin sulfate proteoglycan and heparin sulfate 
proteoglycan). The heparin sulfate proteoglycan imparts charge selectivity to the 
glomerular basement membrane.16 Finally, proteins must pass through the filtration slits. 
These are formed by foot processes of podocytes which are negatively charged (due to a 
surface coat of acidic glycoproteins) and interdigitate to form the slit diaphragm.15,16 The 
fenestrated endothelium acts as an electrostatic barrier for negatively charged proteins. 
The glomerular basement membrane can restrict movement of large plasma proteins and 
negatively charged proteins. The most selective barrier for most proteins is considered to 
5be the slit diaphragm, which is composed of several proteins that create a zipper-like 
filter. These proteins include nephrin, Neph1, Zona Occludens-1 (ZO-1), P-cadherin, 
catenins, CD2AP, and podocin. Nephrin and Neph 1 interact with each other to form the 
backbone of the slit diaphragm. These 2 proteins interact with intracellular adapter 
proteins podocin, CD2AP and ZO-1 that connect the slit diaphragm to the actin 
cytoskeleton of the podocyte foot processes.15,16 The basal side of the podocyte is 
attached to the glomerular basement membrane with α3-β1 integrin and the dystroglycan 
complex. α3-β1 integrin forms bonds with the actin cytoskeleton of the podocyte, while 
the dystroglycan complex is important for proper spacing of matrix proteins resulting in 
appropriate porosity and permeability of the glomerular basement membrane.15
In health, plasma proteins with a molecular weight < 40 kilodaltons (kDa) (low 
molecular weight (LMW) proteins) can freely pass through the glomerular filtration 
barrier to arrive at the tubular lumen (see below). Intermediate molecular weight (IMW) 
proteins, those approximately the size of albumin, face increased charge and size 
restrictions, and high molecular weight (HMW) proteins (> 100 kDa) are generally 
completely restricted due to their large size.15,17,18 
Protein Handling by Renal Tubular Epithelial Cells
In the healthy kidney, LMW proteins and albumin are filtered through the 
glomerular filtration barrier in significant amounts; however, very few of these proteins 
are retained in the final urine product. This is because the proteins are reabsorbed from 
the tubular fluid into the tubular epithelial cells and degraded in lysosomes. This is 
6followed by exocytosis of peptide products (from protein breakdown) back into the 
urine. Reabsorption of proteins is via receptor-mediated endocytosis, which involves 2 
major proteins, megalin and cubulin.15,16,18 These proteins are cooperative and relatively 
non-selective, as many proteins are able to bind to them.15 After binding to the receptors, 
albumin or other proteins are directed into coated pits for endocytosis, which might 
involve the protein amnionless. The proteins are then transferred to a lysosome and are 
degraded while the receptors are recycled.15,16 
Glomerular and Tubular Damage
When renal damage occurs, the mechanisms that prevent proteinuria are 
compromised. Glomerular damage increases the permeability of the filtration barrier, 
allowing increased filtration of IMW and HMW proteins.15 Tubular damage results in 
decreased protein reabsorption, leakage of proteins from damaged tubular epithelial 
cells, and upregulation of proteins involved in injury and repair.15,17 Glomerular damage 
often results in massive proteinuria whereas tubular damage is thought to result in mild 
proteinuria. Further discussion of the magnitude and patterns of proteinuria that occur 
with glomerular and TI damage will be found later in this introduction.
Patterns of Proteinuria
Few studies have analyzed urine protein banding patterns in dogs with renal 
injury using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 
sodium dodecyl sulfate agarose gel electrophoresis (SDS-AGE) or similar methods.19-26 
7Several of these studies have confirmed the limited number of protein bands in non-
proteinuric dogs, with primary urinary proteins in healthy dogs consistent with albumin 
and Tamm-Horsfall Protein.19-25 These studies have also established glomerular, tubular, 
and mixed banding patterns to determine if glomerular damage, tubular damage, or both 
are contributing to the proteinuria.15,26 Primary tubular damage with limited or no 
glomerular damage generates a pattern of predominantly LMW protein bands, while 
primary glomerular damage with minimal or no tubular damage generates a pattern of 
IMW and HMW protein bands.15,19,21,26 Mixed patterns with protein bands in LMW, 
IMW, and HMW ranges, however, are the predominant patterns seen in proteinuric 
dogs, as concurrent damage to both glomerular and tubular components commonly 
occurs.19,21,26 Figure 1 demonstrates different urine protein banding patterns from 
variably proteinuric dogs evaluated by the International Veterinary Renal Pathology 
Service (IVRPS).
8Figure 1. Image from Bis-Tris gel electrophoresis demonstrating urine protein banding 
patterns obtained from dogs with primary tubular damage (Lanes 2 and 3: low 
magnitude of proteinuria with predominantly low molecular weight bands), primary 
glomerular damage (Lanes 6, 7, 8 and 9: relatively large magnitude of proteinuria with 
predominantly intermediate and high molecular weight bands and few low molecular 
weight bands), and mixed glomerular and tubular damage (Lanes 4 and 5: mixture of 
prominent bands ranging from low to high molecular weight).27
While in some studies urine protein banding patterns have correlated well with 
histologic findings in dogs with renal disease,20,21 others have found that urine gel 
electrophoresis has good sensitivity but poor specificity for detection of glomerular and 
TI damage in comparison to biopsy.19,26 Of interest, presence of particular LMW protein 
bands appear to be associated with more severe renal disease in dogs, with LMW protein 
bands at 12 or 15 kDa being 100% specific for advanced TI damage in dogs.26 Along 
these lines, in humans with primary glomerulonephritides with normal renal function at 
9study entry, LMW band patterns with bands as low as 10 kDa were significantly 
associated with development of chronic renal failure and shorter time to end-stage renal 
disease.28 Furthermore, protein banding patterns were predictive of response to therapy 
in humans, which has not been assessed in dogs.28 
Urine protein patterns on SDS-AGE were also found to have high sensitivity but 
poor specificity for detection of dogs that are borderline proteinuric. While the authors 
concluded that SDS-AGE could misclassify the degree of proteinuria when compared 
with UPC, they did not normalize the urine samples to the concentration of the urine 
prior to running on the gel, confounding interpretation.19 These findings demonstrate the 
ability of gel electrophoresis to detect small amounts of protein in the urine and the need 
to appropriately normalize samples to accurately interpret results. In Chapter IV, the 
protocol used in our laboratory to normalize urine samples prior to electrophoretic 
analysis is discussed.
Protein banding pattern analysis has proven useful to clarify location of renal 
lesions in clinical studies of dogs with various nephropathies. Indeed, SDS-AGE was 
used to characterize the origin of proteinuria in clinically healthy Dogue de Bordeaux 
dogs, a breed with a familial glomerulonephropathy in which many clinically healthy 
dogs develop proteinuria.20 It was determined that the nephropathy was likely of 
glomerular origin, and in healthy dogs with proteinuria or borderline proteinuria, SDS-
AGE was deemed a good screening tool to rule out glomerular lesions in Dogue de 
Bordeaux dogs with consistently borderline proteinuria. Urine from dogs with infectious 
etiologies that can lead to nephropathies, including leishmaniasis, leptospirosis, and 
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pyometra, have also been evaluated by SDS-PAGE.23-25 Leishmaniasis was shown to 
generate a predominantly mixed protein pattern, which matched the presence of 
glomerular and tubular lesions on renal histopathology. Leptospirosis resulted in a 
predominantly tubular pattern of injury while pyometra resulted in a pattern of 
predominantly glomerular damage with lesser degree of TI damage. 
Although urine protein banding patterns can demonstrate glomerular and tubular 
damage, several factors can interfere with the interpretation of results. Perini et. al. 
explained that some LMW bands might not represent true tubular bands, as 
immunoblotting has demonstrated breakdown products of albumin and immunoglobulins 
in the LMW regions on SDS-PAGE.29 An increased proportion of 25 kDa proteins were 
indeed noted in the urine of dogs with leishmaniasis, babesiosis, and ehrlichiosis on non-
reducing SDS-AGE, and the authors hypothesized that these proteins were free 
immunoglobulin light chains.26 Intact male dogs have repeatedly demonstrated at least 
one LMW protein (often between 25 – 30 kDa) that is consistent with arginine esterase, 
a prostatic protein.20,30 Finally, although not previously reported in canine studies, 
presence of hemorrhage or urinary tract infections can introduce protein banding patterns 
in the glomerular and tubular protein regions that are not seen in healthy dogs with 
inactive urine sediments (author observations: JAH). Thus, while urine protein banding 
patterns can contribute to a better understanding of renal lesion localization, other factors 
can potentially alter correct interpretation. A more thorough discussion of banding 
pattern interpretation and interferences is provided in Chapter IV.
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Urinary Biomarkers of Kidney Disease
While measurement of the UPC is an important first step in the evaluation of 
renal proteinuria, its limitations include low specificity for determining the source of 
proteinuria and the severity of injury. Therefore, several specific urine proteins are being 
investigated as markers of glomerular or tubular damage.
When protein biomarkers are quantified in urine, their concentration is often 
indexed to urine creatinine (e.g., urinary biomarker divided by urine creatinine) or urine 
specific gravity. Indexing urinary biomarkers to urine creatinine assumes that the 
excretion of urine creatinine is constant between and within individuals, and that both 
urinary biomarkers and creatinine are inversely proportional to urinary flow rate. When 
these assumptions are met, an increased or decreased biomarker/creatinine ratio will 
reflect increased or decreased biomarker excretion.31 However, when an animal is not in 
steady state (i.e., when renal function is rapidly changing), the assumption of constant 
urine creatinine excretion may not be correct, as demonstrated in a study of human 
patients with acute kidney injury (AKI) and post-kidney transplantation.31 Because of 
this, the practice of indexing to urine creatinine in cases of AKI is questionable. 
Therefore, some authors have reported concentrations of biomarkers without indexing to 
creatinine. For purposes of this dissertation, biomarkers that are indexed to urine 
creatinine are denoted as uBiomarker/c, and those that are un-indexed concentrations in 
the urine are denoted as uBiomarker.
Most biomarkers that will be discussed in depth in this introduction are those that 
were measured in dogs for the studies included in this dissertation. However, multiple 
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other biomarkers have been evaluated in many domestic species, and therefore, Tables 
A-1, A-2, and A-3 in Appendix A provide an overview of urinary and serum/plasma 
biomarkers in domestic veterinary species.
 
Markers of Glomerular Damage/Dysfunction
Immunoglobulins
Immunoglobulins are large glycoproteins made by plasma cells in the spleen, 
lymph nodes, and bone marrow and are involved in antibody-mediated defense.15,32 The 
molecular weight of immunoglobulins G (IgG) and M (IgM) are 150 kDa15,32,33 and 900 
kDa,15,32 respectively. Serum immunoglobulin A (IgA) is present in monomeric, dimeric, 
and polymeric forms, with the monomeric form having a molecular weight of 160 kDa.34 
Thus, IgG, IgM, and IgA are HMW proteins that cannot pass through the glomerular 
filtration barrier in the healthy kidney. However, with glomerular damage, they may pass 
into the urinary filtrate; thus, they are considered markers of glomerular damage.15 
Measurement and Stability
Species-specific ELISAs are the most common and preferred method for 
detection of urinary immunoglobulins;35,36 however, thus far, detection of IgA in canine 
urine has only been reported using Western blot.23-25 Canine specific ELISA assays for 
IgG, IgM, and IgA are available (Bethyl Laboratories, Montgomery, TX and 
Immunology Consultants Laboratories (ICL), Portland, OR) and IgG and IgM ELISA 
assays have been validated in canine urine and serum showing acceptable mean 
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intraassay and interassay variabilities,35-38 spiking recovery,36,37 and dilutional 
linearity.36,37 True stability testing of IgG in urine has not been evaluated; however, 
uIgG/c in canine urine samples stored for 8 years at -80°C were similar to those stored 
for 2 years at -80°C.37 
Values in Healthy Animals
Mean urinary IgG/creatinine (uIgG/c) is generally < 3 mg/g, with maximum 
values < 10 mg/g observed in all but one study (Table A-1).35,37,39-43 Published studies 
currently are not available describing the urine concentration of IgM in healthy animals; 
however, in the author’s personal experience, urinary IgM concentration is low in 
clinically healthy dogs. IgA was undetectable in the urine of healthy dogs using Western 
blot (Table A-1).23-25 
Non-Renal Influences
A few studies found that urinary IgG concentration is not significantly altered by 
hematuria/hemoglobinuria35,42,43 or pyuria/urinary tract infection.35 However, in the 
author’s experience in dogs with primarily proteinuric CKD, uIgG/c was significantly 
higher in dogs with hematuria, and fractional excretion of IgG (IgG_FE) was higher in 
dogs with pyuria/bacteriuria compared with dogs with inactive urine sediment (Table A-
4; unpublished data: JAH, MBN). Similarly, urinary IgM/creatinine (uIgM/c) and 
fractional excretion of IgM (IgM_FE) were both significantly increased with hematuria 
and pyuria/bacteriuria in these dogs (Table A-4; unpublished data: JAH, MBN). 
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Acute Kidney Injury (AKI)
Urinary IgG is the main immunoglobulin evaluated in diseases known to cause 
AKI, with fewer studies evaluating urinary IgA. Dogs with AKI due to a variety of 
causes, including Babesia rossi, leishmaniasis, and leptospirosis, have demonstrated 
increases in uIgG/c35,39,40 or IgG and IgA on Western blot,23,24,35,39,40 supporting 
glomerular damage. However, as expected, canine leptospirosis resulted primarily in 
increased LMW proteins on sodium dodecyl sulfate polyacrylamide gel electrophoresis, 
consistent with interstitial nephritis.24 Interestingly, in dogs with snake envenomation, 
UPC was not increased despite significantly increased uIgG/c vs. control dogs at 
baseline and 24 h later.40 
Pyometra can cause significant increases in uIgG/c and UPC, with a positive 
correlation between UPC and uIgG/c.25,41,42 This increase is typically transient, 
decreasing significantly after ovariohysterectomy, and in some cases, uIgG/c returns to 
values that are not significantly different from healthy dogs.41 A low proportion of 
bitches with pyometra also had detectable urinary IgA.25 These studies support that 
altered glomerular permselectivity can be present in dogs with pyometra, and indeed, 
histopathology demonstrated glomerulosclerosis as the most common glomerular lesion 
in these dogs. However, tubular atrophy, interstitial inflammation, and fibrosis were 
often present as well, and the role of pyometra vs. previous underlying renal disease in 
these older dogs is uncertain.42 
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Currently there are no studies evaluating urinary IgM in companion animals with 
AKI.
Chronic Kidney Disease (CKD)
Urinary IgG36,37,44,45 and IgM36 have been shown to increase in dogs with CKD. 
In dogs with CKD due to X-linked hereditary nephropathy (XLHN), uIgG/c increased in 
early stages of renal disease while uIgG/c remained low in healthy age-matched 
littermates.37,45 uIgG/c often increased before UPC and continued to increase in mid to 
late stages of disease progression.37 Furthermore, uIgG/c was moderately to highly 
positively correlated with most glomerular and tubulointerstitial (TI) lesions based on 
histopathology.37 Urinary biomarker concentrations and their fractional excretions were 
measured in dogs with naturally occurring CKD to correlate biomarkers with types of 
renal damage (glomerular versus TI) and their association with survival.36 
Immunoglobulin G (uIgG/c and IgG_FE) and IgM (uIgM/c and IgM_FE) demonstrated 
moderate, positive correlations with glomerular damage based on light and electron 
microscopy (r = 0.44 – 0.58 and r = 0.41 – 0.58), respectively), which were similar to 
that observed for UPC (r = 0.45 – 0.57). Immunoglobulin M_FE also correlated 
moderately well with TI damage (r = 0.49). Markedly increased uIgM/c and uIgG/c were 
associated with immune complex mediated glomerulonephritis (ICGN), while lower 
uIgM/c was observed in juvenile nephropathies, non-immune complex mediated 
glomerulonephropathies, and primary tubular disease. Both IgM_FE and IgG_FE were 
significantly associated with faster time to death due to renal disease in these dogs.36 The 
findings from this study are discussed further in Chapter II of this dissertation. 
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Urinary IgG has been evaluated in several studies of dogs with increased cortisol 
due to either exogenous or endogenous sources, since excess cortisol causes proteinuria, 
likely by altering the glomerular filtration barrier. In aged Beagles treated over 24 weeks 
with hydrocortisone, uIgG/c and UPC progressively increased, while tapering and 
cessation of hydrocortisone treatment resulted in decreased uIgG/c and UPC.38 In dogs 
with hyperadrenocorticism, uIgG/c was significantly higher than in clinically healthy 
controls, supporting glomerular dysfunction.43 Finally, in dogs treated with trilostane or 
hypophysectomy for ACTH-dependent hyperadrenocorticism, uIgG/c decreased up to 15 
fold post-treatment. However, uIgG/c did not completely return to levels comparable to 
healthy dogs in all cases, with persistence of proteinuria in 38% of dogs 12 months post-
treatment.46 
Additional Urinary Proteins Indicating Glomerular Damage/Dysfunction
Albumin
The use of urinary albumin in dogs as a renal biomarker has recently been 
reviewed.47 Albumin is a negative acute phase, IMW (approximately 65 kDa) serum 
protein synthesized primarily by hepatocytes. It is considered primarily to be a marker of 
glomerular damage, but urinary albumin can also be present with tubular or vascular 
damage.14,15,48,49 Measurement of urinary albumin has been validated in dogs,50 and 
urinary albumin/creatinine is elevated in both AKI and CKD,44,45,50,51 including renal 
damage due to nephrotoxic drugs (methyl cantharadimide tablets and gentamicin),52,53 
snake envenomation,40 pyometra,41,42 and hypercortisolism.38,43,46 Pyometra caused 
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transient albuminuria that significantly decreased or returned to values not significantly 
different from healthy dogs after ovariohysterectomy.41,42 
Markers of Tubular Damage/Dysfunction
The proteins discussed in the next section are abnormally present in the urine due 
to decreased tubular reabsorption (retinol binding protein [RBP], neutrophil gelatinase-
associated lipocalin [NGAL], cystatin C), upregulation of proteins involved in injury and 
repair (NGAL), and decreased production by damaged tubules (Tamm-Horsfall protein 
[THP]). Proteins present due to release from damaged tubular epithelial cells are 
discussed in the urinary enzyme section. Additional examples of urinary biomarkers 
present due to these 4 mechanisms are presented in Table A-2. 
Retinol-Binding Protein (RBP)
Retinol-binding protein (RBP) is a 21 kDa lipocalin that acts as the transport 
protein for retinol in plasma.54 Retinol-binding protein is primarily produced in the liver 
but also in the kidney, lungs, spleen, brain, stomach, heart, and skeletal muscle.55-57 
Retinol-binding protein circulates in a complex with transthyretin (TTR), which has a 
molecular weight of 54 kDa.54,58,59 By itself, RBP is a LMW protein that can freely pass 
through the glomerular filtration barrier; however, the TTR-RBP complex is too large to 
pass through the glomerular filtration barrier in the healthy kidney.58 Retinol-binding 
protein in the renal filtrate is reabsorbed by tubular epithelial cells.60 Tubular damage 
and/or competition for reabsorption by the presence of abnormally large amounts of 
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protein (i.e., with glomerular damage) results in decreased reabsorption of RBP with 
subsequent loss of RBP into the urine.61,62  Glomerular damage could also contribute to 
urinary RBP due to loss of the TTR-RBP complex.
Measurement and Stability
Human RBP immunoassays have been validated for dogs with adequate 
intraassay and interassay variabilities (canine urine and plasma),35,37,63 spiking recovery 
(canine urine),37 and dilutional linearity along a specific range of the standard curve 
(canine urine).35,37 A canine-specific RBP ELISA was recently marketed (ICL); 
however, validation and use of this kit has not yet been published. Retinol-binding 
protein concentration is similar in cystocentesis vs. voided urine samples from clinically 
healthy dogs.64 Retinol-binding protein appears to be relatively stable in canine urine 
samples when frozen, ideally at -80°C.37,64 All but one study64 normalized urinary RBP 
concentration to urinary creatinine (uRBP/c [mg/g]).35-43,46,50,51,65-68
Values in Healthy Animals
In healthy dogs, RBP is generally undetectable or minimally detectable in the 
urine by Western blot.69,70 Using immunoassays to quantify urinary RBP in healthy 
dogs, the highest reported uRBP/c was 0.9 mg/g,43 with most studies reporting means 
and medians < 0.15 mg/g regardless of assay used (Table A-2).35,37-43,46,50,51,65 
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Non-Renal Influences
In dogs, age does not appear to be a major influence on uRBP/c, as no significant 
differences were found for uRBP/c between healthy young and older dogs.37,50 However, 
a mild but statistically significant negative correlation with age was found in young 
adolescent dogs, likely due to low creatinine excretion in very young dogs.37 Pyuria, 
bacteriuria or positive urine culture, and at least mild to moderate hematuria and 
hemoglobinuria do not seem to significantly affect uRBP/c;35,39,64 however, in one study, 
a mild increase in uRBP was seen in markedly hematuric samples.64 In the author’s 
experience, RBP_FE was significantly higher in pyuric/bacteriuric samples versus 
inactive sediments from dogs with proteinuric CKD (Table A-4; unpublished data: JAH, 
MBN). 
Renal Disease in Veterinary Medicine
AKI
Naturally occurring AKI (e.g., pyometra, babesiosis due to Babesia rossi, and 
envenomation by cytotoxic and neurotoxic snakes) transiently increases uRBP and 
uRBP/c in dogs, presumptively indicating tubular dysfunction.35,40,42,69 Histologic 
confirmation of tubular damage in dogs with pyometra found that dogs with severe TI 
lesions on histopathology had higher uRBP/c (in the 75th percentile) compared with dogs 
demonstrating milder lesions.42 Typically, uRBP/c decreased significantly after 
ovariohysterectomy in these dogs, often to values comparable to healthy dogs.35,42 
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CKD
More studies have evaluated urinary RBP for detection of tubular dysfunction in 
dogs with CKD than with AKI, and dogs with CKD have significantly increased 
uRBP,69 uRBP/c,35,37,44,45,50,51,63,70 and RBP_FE51,63 compared with healthy dogs. 
However, whether this increase is primarily present due to tubular damage as opposed to 
presence of proteinuria is controversial, as discussed below. 
In dogs with CKD due to XLHN, uRBP/c was increased prior to onset of 
azotemia but after onset of proteinuria, and urinary RBP increased with disease 
progression throughout all disease stages (based on sCr), with the most pronounced 
increase in mid to late stages of renal disease.37,45,70 Furthermore, uRBP/c had the 
strongest correlation with both glomerular and TI lesions compared with other 
biomarkers of renal function, and it correlated most strongly with conventional measures 
of disease severity (sCr, glomerular filtration rate (GFR), and interstitial fibrosis).37 
Despite this, uRBP/c was not a significant independent predictor of GFR based on 
multivariate analysis. It was concluded that uRBP/c might be useful for detecting early 
tubular damage before an obvious increase in sCr.37 
When biomarkers were correlated with histologically proven renal damage in 
dogs with naturally occurring CKD due to a variety of causes, uRBP/c and RBP_FE 
were moderately correlated with glomerular and TI damage, with RBP_FE having the 
second strongest correlation with TI damage following sCr.36 RBP_FE also increased 
significantly with each increase in IRIS stage, while uRBP/c only increased significantly 
in IRIS stages 3 and 4. Both uRBP/c and RBP_FE were significantly associated with 
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time to death due to renal disease when evaluated individually; however, in a 
multivariate analysis with other biomarkers, neither uRBP/c nor RBP_FE were 
significantly associated with survival.36 These results are discussed in greater depth in 
Chapter II of this dissertation. 
Despite the promise of urinary RBP for early detection of CKD and monitoring 
of progression, another study concluded that proteinuria influenced uRBP/c more than 
decreased renal function based on sCr and plasma creatinine clearance. This conclusion 
was based on finding uRBP/c to be significantly greater in dogs with proteinuria and 
borderline proteinuria compared with azotemic, non-proteinuric dogs and the inability of 
uRBP/c to detect reduced GFR.51 
Dogs with hyperadrenocorticism had higher uRBP/c compared with control dogs; 
however, UPC was also significantly higher in these dogs compared to controls.43 
Additionally, in dogs with ACTH-dependent hyperadrenocorticism, uRBP/c decreased 
significantly after treatment with hypophysectomy,46 such that post-treatment median 
uRBP/c values were within the range reported for healthy dogs. Urinary RBP/c also 
decreased after treatment with trilostane; however, the decrease was not significant, and 
several dogs had persistent proteinuria.46 These cumulative results suggest that ACTH-
dependent hyperadrenocorticism results in decreased tubular protein reabsorption; 
however, the degree of reversibility and post-treatment values for uRBP/c depend on the 
type of treatment (hypophysectomy versus trilostane) and persistence of proteinuria.46 
Finally, in aged dogs treated with hydrocortisone, uRBP/c increased with treatment and 
decreased post-treatment.38 
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Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Neutrophil gelatinase-associated lipocalin (NGAL) is a member of the family of 
lipocalin binding proteins originally isolated from the specific granules of human 
neutrophils,71,72 but it is also present in many normal tissues including the kidney.73 
Neutrophil gelatinase-associated lipocalin is upregulated in epithelial cells in 
neoplastic73,74 and inflammatory74 processes. The original proposed function of NGAL 
was as a bacteriostatic agent that binds bacterial siderophores to prevent iron 
acquisition.75 Neutrophil gelatinase-associated lipocalin has since been found to also be 
involved in many cellular mechanisms including renoprotection.76 Neutrophil gelatinase-
associated lipocalin is a LMW protein that freely passes through the glomerular filtration 
barrier and is reabsorbed almost completely by the proximal tubules in the healthy 
kidney.76 With either renal damage or protein overload, reabsorption of NGAL in the 
proximal tubules is impaired. In addition, there is increased synthesis of NGAL by 
damaged tubular epithelial cells.77 Three different molecular weight forms of NGAL are 
present in canine urine,78 including a 25 kDa monomeric protein that appears to originate 
from renal tubular epithelial cells and is associated with renal damage, a 45-50 kDa 
dimeric protein that is the predominant form released by neutrophils and appears most 
often with pyuria, and an NGAL/MMP-9 heterodimer complex that occurs with both 
renal injury and pyuria and hematuria.71,78,79 Although ELISAs that distinguish between 
different molecular forms of human NGAL are available, canine NGAL ELISAs are 
currently unable to make this discrimination.80 
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Measurement and Stability
NGAL has been evaluated in urine, serum, and plasma in dogs, and it has been 
partially validated using canine specific ELISAs with acceptable intraassay and 
interassay variabilities, dilutional linearity, and spiking recovery in canine urine and 
plasma.36,37,81,82 Neutrophil gelatinase-associated lipocalin has also been validated in 
canine serum, but results were not published.83 Neutrophil gelatinase-associated 
lipocalin appears to be relatively stable in canine urine, as there were minimal effects on 
uNGAL after 4 freeze thaw cycles, and no significant differences in uNGAL/c were 
observed in samples collected up to 8 years apart, stored at -80°C.37 No difference in 
uNGAL/c was apparent between cystocentesis and voided samples84 or between 2-hour 
spot urine samples and 15-hour collection samples.85 The 3 different molecular weight 
forms of NGAL can be differentiated in canine urine samples using Western blot.78 
Values in healthy dogs are reported in Table A-2. 
Non-Renal Influences
In one study, healthy dogs < 4 months of age often had much higher uNGAL/c 
than dogs > 4 months of age, but it was suggested that this was likely due to preputial 
neutrophil contamination from voided urine samples from the youngest dogs.37 In 
another study, there was no correlation of uNGAL/c with age in adult dogs, although 
uNGAL (not normalized) was weakly but positively correlated with age. Furthermore, 
this same study found that both uNGAL and uNGAL/c decreased with body mass.81 
Interestingly, peripheral WBC count does not correlate with overall serum NGAL 
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(sNGAL);86 however, dogs with monomeric uNGAL had significantly higher peripheral 
WBC and neutrophil counts than dogs without the uNGAL monomer.78 
Pyuria and urinary tract infections can markedly influence urinary NGAL 
concentrations. Several studies showed that both uNGAL and uNGAL/c were 
significantly higher in dogs with pyuria, urinary tract infections (UTI), and other lower 
urinary tract diseases (such as urothelial cell carcinoma and calcium oxalate urolithiasis), 
both with and without azotemia, compared with healthy controls.78,81,84 In the author’s 
experience in dogs with proteinuric CKD, uNGAL/c was higher in dogs with active vs. 
inactive sediments (Table A-4; unpublished data: JAH, MBN). Although dogs with 
lower urinary tract diseases had increased uNGAL/c compared with control dogs, values 
were still lower than dogs with renal diseases.78,84 A uNGAL/c cutoff of > 2.57 µg/g and 
a uNGAL cutoff of > 3.38 ng/ml had sensitivities and specificities in the 70-80% range 
for dogs with vs. without a UTI.81 Furthermore, the 50 kDa dimer form of NGAL was 
shown to be more common in urine from dogs with pyuria, while the NGAL/MMP-9 
complex was found in dogs with pyuria and hematuria.78
While one study reported that certain non-renal diseases (gastritis, PLE, hepatic 
disease, enteritis, portal shunt, bone fracture, intervertebral disk disease) do not appear to 
affect uNGAL,78 uNGAL and uNGAL/c were significantly increased in dogs with 
carcinoma and lymphoma compared to healthy dogs; however, it was acknowledged that 
it could not be ruled out that some of the study dogs with neoplasia also had early 
CKD.87 Thus, non-urinary diseases in dogs might increase urinary NGAL in dogs, and if 
so, this finding would further indicate lack of renal specificity of this biomarker.
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AKI
While studies of drug-induced AKI consistently demonstrate increases in urinary 
NGAL, mixed results are reported with regard to timing of this increase, which could 
partly be due to differing protocols, particularly with varying concentrations of 
gentamicin used. Three separate studies in dogs given gentamicin found that uNGAL/c 
and uNGAL increased early (as early as day 1 post-administration) compared with other 
markers of nephrotoxicity (such as sCr and urea nitrogen) and was correlated with the 
severity of tubular damage, including tubular cell necrosis, degeneration and 
regeneration, tubular cell hyaline droplet formation, and hyaline casts.85,88,89 
Furthermore, the decrease in uNGAL/c heralded recovery earlier than a decrease in sCr 
by a median of 2 days.89 It was concluded that uNGAL/c was a sensitive and predictive 
marker of gentamicin-induced nephrotoxicity.85,89 However, a fourth study found that 
although uNGAL/c was significantly correlated with GFR and increased at the first time 
point evaluated (4 days after gentamicin administration), the increase was not 
statistically significant until the second time point, at 8 days post administration. Thus, 
in this study, uNGAL/c was not superior to more traditional markers of renal function.53 
In AKI induced by administration of intravenous polymyxin B for 7 days, a dose 
dependent increase in uNGAL/c was observed, with significantly increased uNGAL/c in 
the mid- and high-dose groups on day 2.90 Finally, Beagle dogs administered methyl 
cantharidimide tablets over 30 days demonstrated significant increases in uNGAL in the 
26
high dose group, while middle and low dose groups did not have significant changes in 
uNGAL.52 
Repeatedly, studies have shown promise for NGAL as a marker of naturally 
occurring AKI in dogs. Urinary NGAL (not normalized), uNGAL/c, and plasma NGAL 
(pNGAL) were all significantly greater in dogs with azotemia from natural causes 
(whether due to AKI or CKD) versus healthy control dogs,78,82,84,86 and extremely high 
pNGAL differentiated AKI from CKD in one study82 while extremely elevated 
uNGAL/c was seen in dogs with AKI compared to both CKD and lower urinary tract 
diseases in another study.84 Furthermore, uNGAL/c was increased in non-azotemic (IRIS 
Grade I) AKI, indicating the presence of kidney injury before sCr increased outside of 
the reference interval.84 Similarly, in dogs that developed AKI post-operatively, median 
uNGAL was significantly greater 12 hours post-surgery and remained elevated for at 
least 3 days, while sCr did not show a significant increase until 24 hours post-surgery.91 
Urinary NGAL and uNGAL/c were also shown to be significantly increased (average of 
24-fold and 41-fold, respectively) from baseline within 2 hours of reperfusion using a 
hemorrhage and colloid fluid resuscitation model of renal injury in Greyhounds.92 Thus 
far, uNGAL/c, uNGAL, and sNGAL have not been shown to be predictors of survival in 
dogs with AKI.84,86 
CKD
Dogs with CKD have demonstrated increased uNGAL/c, uNGAL, sNGAL, and 
pNGAL compared with healthy dogs and dogs with UTI or other lower urinary tract 
diseases.37,78,82-84,86,87 Similar to findings in AKI studies, increases in uNGAL/c occurred 
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early in the development of CKD in dogs with XLHN.37 As will be discussed further in 
Chapter II, serum NGAL and fractional excretion of NGAL (NGAL_FE) also increased 
with increasing IRIS stages in dogs with proteinuric CKD.36 Furthermore, uNGAL/c and 
NGAL_FE correlated moderately to strongly with both glomerular and TI lesions in 
dogs with CKD.36,37 Finally, higher sNGAL and NGAL_FE are associated with shorter 
survival compared with lower values in dogs with CKD.36,86 Serum NGAL concentration 
was actually concluded in one study to be a better predictor of clinical outcomes than 
sCr for dogs with CKD that were already azotemic;86 however, this was not repeatable in 
a second study of dogs with CKD that were predominantly proteinuric but included both 
azotemic and non-azotemic dogs.36
N-acetyl-β-D-glucosaminidase (NAG)
Renal tubular epithelial cells contain enzymes which have been explored as 
biomarkers of tubular damage (Table A-2). One of the most commonly studied enzymes 
in domestic animals is N-acetyl-β-D-glucosaminidase (NAG), a lysosomal enzyme.93 
Two isoenzymes of NAG occur in the kidney: NAG-A and NAG-B. In people, only 
NAG-A can be detected in urine from patients without renal disease, whereas renal 
damage and disease results primarily in increased excretion of NAG-B.94-96 Although 
present in the serum and other tissues and cells, urinary NAG originates from the renal 
tubules in the absence of glomerular damage.97-100 
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Measurement and Stability
Activity of urinary enzymes is expressed as units per liter, and an activity index 
is typically calculated by normalizing to urinary creatinine concentration. Validation of 
assays for urinary NAG activity (uNAG) has been performed in dogs.37,101 In canine 
urine, overall intraassay and interassay variabilities, dilutional linearity, and spiking 
recovery for NAG were acceptable.37,50,101 However, canine urine samples with lower 
concentrations of NAG tended to show higher coefficients of variation.37 NAG activity 
is relatively stable at -80oC for at least one year; however enzyme degradation, which is 
not prevented by addition of a protease inhibitor, is still possible.37,64,101 Studies 
assessing stability at room temperature, 4°C, and -20°C have shown contrasting findings, 
although NAG appears to be stable for at least one month at -20°C in canine 
urine.37,64,101 Up to 4 - 5 freeze-thaw cycles have been shown to significantly affect 
urinary NAG activity in dogs.37 Thus it is recommended to keep urine samples frozen at 
-80°C and to limit the number of freeze-thaw cycles. No significant difference in uNAG 
activity was seen between voided and cystocentesis samples from dogs.64  
Values in Healthy Animals
Urinary NAG is generally present in low levels in healthy domestic animals 
(Table A-2). 
29
Non-Renal Influences
Age does not appear to affect uNAG/c in dogs.64,102 However, 3 out of 4 studies 
found uNAG/c was significantly higher in males than females.101,103-105 Additionally, 
uNAG/c decreased after castration of male dogs; therefore, the increase in NAG activity 
in males may be due to the enzyme content of sperm.101,104 
Spot measurements of uNAG/c were significantly correlated with 24-hour urine 
NAG excretion.106 However, large intra- and inter-individual variability was noted for 
uNAG/c.101 
Hematuria, pyuria, and bacteriuria/UTI without concomitant pyelonephritis does 
not appear to affect uNAG or uNAG/c in dogs.64,105 However, dogs with lower UTIs 
accompanied by pyelonephritis had markedly increased uNAG/c values, likely 
indicating the presence of tubular damage.105 Further studies are needed to determine if 
uNAG/c can accurately detect pyelonephritis. Additionally, changes in urine pH did not 
seem to affect uNAG/c in dogs.103
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AKI
NAG has been most extensively studied as an early marker of AKI by chemical 
(drug) induction in domestic species. Gentamicin, especially high doses, significantly 
increased uNAG/c in dogs as early as 24 hour post-administration, and uNAG/c 
continued to increase throughout the study period.53,88,106 Another study found that 
uNAG/c correlated with the severity of renal lesions and had high accuracy and 
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sensitivity for detection of renal injury compared with urea nitrogen.88 These and other 
studies support that urinary enzymes such as NAG are more sensitive and reliable for 
detecting acute renal tubular damage induced by gentamicin than markers of GFR.107  
Other nephrotoxic drugs that resulted in early increases in uNAG/c in dogs 
include polymyxin B90 and methyl cantharidimide.52 One study reported a marked 
increase in uNAG/c in 1 dog administered a therapeutic dose of ketoprofen, a non-
steroidal anti-inflammatory drug (NSAID), at day 6 of a 30-day study, but the uNAG/c 
returned to a clinically normal value at day 21 despite continued drug administration 
until day 30.108 Thus, administration of ketoprofen at a therapeutic dose did not appear to 
significantly increase uNAG/c in 4 out of 5 dogs.108 Additionally, dogs given 
intravenous polymyxin B for 7 days demonstrated dose dependent increases in uNAG/c, 
with significantly increased uNAG/c occurring in the mid- and high-dose groups on day 
2.90 
Few studies are available evaluating urinary NAG activity in cases of naturally 
occurring AKI in domestic animals. Dogs with pyometra have demonstrated increased 
uNAG/c that, in several studies, decreased back into the range of healthy dogs after 
ovariohysterectomy, supporting transient AKI in these dogs.41,42,102,105 Furthermore, 
markedly increased uNAG/c was associated with severe TI lesions and reduced GFR in 
dogs with pyometra.42,102  
CKD
Urinary NAG/c appears to be increased in most dogs with CKD as compared to 
healthy controls.37,50,105 In dogs with XLHN, mild increases were observed as one of the 
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earliest findings, even before increased UPC; however, it did not continue to increase 
with disease progression beyond mid-stage disease.37 Furthermore, uNAG/c was 
inconsistently associated with IRIS staging in dogs with proteinuric CKD.36,50 
Interestingly, in dogs with XLHN, uNAG/c correlated moderately to strongly with both 
glomerular and TI damage lesions.37 In contrast, uNAG/c at the time of biopsy in dogs 
with naturally occurring CKD (mostly proteinuric and variably azotemic) correlated 
moderately well with glomerular damage alone and did not correlate with TI damage, as 
will be discussed further in Chapter II.36 Additionally, uNAG/c correlated moderately to 
strongly with UPC and uIgG/c in both studies.36,37 These findings support that uNAG/c 
might be a better indicator of glomerular rather than tubular damage in canine 
proteinuric CKD.
Endocrine diseases may also influence urinary NAG activity, presumably due to 
renal damage. Dogs with hyperadrenocorticism had significantly higher uNAG/c 
compared with control dogs.43 Furthermore, while several other biomarkers (uALB/c, 
uIgG/c, uRBP/c, and UPC) demonstrated significant decreases after treatment for 
hyperadrenocorticism, uNAG/c did not decrease significantly even after treatment with 
trilostane and hypophysectomy.46 However, several dogs that were treated for 
hyperadrenocorticism had persistent proteinuria.46 Despite increased uNAG/c in dogs 
with increased cortisol due to naturally-occurring hyperadrenocorticism, uNAG/c was 
not increased in dogs treated with hydrocortisone, both in comparison to the control 
group and within the treatment group itself.38 In dogs with diabetes mellitus, increased 
uNAG/c was observed when the disease was not controlled (i.e., hyperglycemia, 
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glucosuria, and ketonuria were present) whereas uNAG/c values were comparable to 
healthy dogs when blood glucose was controlled.105 
Most studies show that urinary NAG largely trends with proteinuria. A possible 
reason behind the stronger correlation of urinary NAG with glomerular 
damage/proteinuria as compared with TI damage/azotemia could be increased lysosomal 
activity as opposed to active proximal tubular cell damage. However, when glomerular 
proteinuria is present, it is reasonable that increased uNAG/c at least partially represents 
loss of NAG from the blood due to altered glomerular permeability.
Tamm-Horsfall Protein 
Tamm-Horsfall protein (THP, otherwise called uromodulin) is a 100 kDa 
protein109 present in the thick ascending limb of the loop of Henle and the distal 
convoluted tubule.109,110 Tamm-Horsfall protein is one of the major urinary proteins 
present in healthy dogs.109 The biologic function of the protein is still not fully 
understood, but it is believed to have roles in water and electrolyte balance in the thick 
ascending limb of Henle’s loop, defense against urinary tract infections, prevention 
against the formation of kidney stones, and in innate immunity of the kidney.111 Normal 
urine has high concentrations of THP, and significantly reduced urinary THP 
concentrations and uTHP/c are seen in dogs with renal disease, including 
CKD.44,63,69,112,113 Furthermore, uTHP/c correlates negatively with plasma creatinine 
concentration and UPC.113 Therefore, reduced urinary THP might be a marker of distal 
tubular damage in dogs and. 
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Serum Biomarkers of Kidney Disease
As discussed, proteinuria is the earliest marker of glomerular disease, but urine is 
often not evaluated in many patients for a variety of reasons. Additionally, primary TI 
disease might not present with clinically evident proteinuria. Therefore, serum 
biomarkers remain important tools for the diagnosis of kidney disease, serving as 
endogenous markers of GFR. For decreased GFR to be clinically detectable, substantial 
losses of nephrons and decreases in overall kidney function are necessary, with estimates 
of up to 50% or more decrease in function occurring before azotemia develops. 
However, improved interpretation of sCr can lead to an earlier diagnosis of kidney 
disease, and new biomarkers of GFR show promise as early indicators of decreased 
kidney function. It is important to remember, however, that markers of GFR should 
always be interpreted in light of the urine specific gravity and clinical history, because 
hydration/blood volume status and urinary tract obstruction can influence these values.
Historically, sCr has been interpreted in the context of a reference interval. 
Particularly in dogs, where a variety of breeds and sizes are represented, use of a 
standard, laboratory-based reference interval is an insensitive method for determining 
whether sCr is increased in a particular patient, given that muscle mass is the major 
determinant of baseline sCr concentration. More appropriately, a baseline healthy adult 
measurement would be obtained, followed by monitoring at regular intervals (i.e. during 
routine yearly health checks). This allows for recognition of small, progressive increases 
that can indicate relatively large decrements in kidney function. Certainly, CKD can be 
detected much earlier by such ‘trending’ of sCr, as evidenced in one study in dogs with 
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CKD due to XLHN, where an average decrease in GFR of approximately 25% was 
identified compared with 50% when using a reference interval.114 Earlier identification 
of AKI is also possible using trending, and this is reflected by the IRIS AKI grading 
guidelines, wherein an increase in sCr of 0.3 mg/dL within 48 hours is used to diagnose 
Grade 1 or 2 AKI (http://www.iris-kidney.com/guidelines/grading.html). Of course, such 
subtle increases in sCr require excellent laboratory and instrument precision, and this can 
present a problem, particularly with benchtop instruments commonly used in veterinary 
clinics.115,116 Muscle wasting in a patient over time can also interfere with the ability to 
identify small, but clinically significant increases in sCr. For instance, one study found 
cats >15 years old to have lower sCr but also lower GFR than cats <15 years old.117
In an effort to overcome some of the limitations of sCr in evaluation of kidney 
function, cystatin C and symmetric dimethylarginine (SDMA) have been evaluated as 
new markers of GFR. Cystatin C is a small protein, while SDMA is a methylated amino 
acid of similar size to creatinine. In the few published studies on cystatin C in dogs, it 
correlated as well or better than sCr with measured GFR using clearance techniques in 
dogs with renal disease, and it was a more sensitive indicator of decreased GFR than 
sCr.118-120 Thus far, three studies have shown SDMA to be consistently more sensitive 
than sCr for detecting decreased GFR in both dogs and cats when sCr was interpreted 
based on a reference interval.117,121,122 It was also more sensitive than sCr based on 
trending in young, growing dogs,114 possibly because of SDMA’s lack of influence by 
muscle mass.117,123 While studies with both of these markers appear promising, they are 
thus far limited in the scope of non-renal injuries examined. Furthermore, non-renal 
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influences are still largely unknown, although the major limitation of sCr (muscle mass) 
does not appear to influence either cystatin C or SDMA. As we gain more experience 
with these new markers, and in particular, SDMA, we will learn more about their 
limitations as well as their advantages as compared with sCr.
A summary of serum and plasma biomarkers of kidney disease in dogs and cats 
can be found in Table A-3.
Study Objectives
Although renal biopsy is certainly the gold standard for evaluating the type of 
renal disease and severity of damage in dogs, many dogs are not candidates for the 
procedure due to health or financial reasons. The use of less invasive and inexpensive 
diagnostic methods, such as urinary electrophoretic protein banding patterns and serum 
and urinary biomarkers, can provide evidence for the presence or absence of glomerular 
disease and/or tubulointerstitial disease and might also influence the decision to perform 
a renal biopsy. 
As discussed earlier, Nabity et. al. previously evaluated several urinary 
biomarkers, including uIgG/c, uRBP/c, uNGAL/c, and uNAG/c in dogs with XLHN and 
found that each of these biomarkers was moderately to strongly correlated with most of 
the glomerular and tubulointerstitial lesions that developed during progression of CKD.37 
The studies presented in this dissertation focus on evaluation of novel non-invasive tests 
of renal damage in dogs with naturally occurring CKD in order to expand the work 
performed in the XLHN dog model of CKD to a cohort of dogs more representative of 
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those in a veterinary clinical setting. Patterns of proteinuria and specific urinary proteins 
were evaluated in dogs with a variety of naturally occurring renal diseases to determine 
their usefulness as markers of renal damage and predictors of specific types of renal 
diseases and prognosis as compared with conventional clinical tests and the current gold 
standard, histologic evaluation. The rationale for performing these studies is that 
conventional non-invasive tests of renal function and damage are unreliable for 
determining the extent of glomerular and TI injury. Certain urinary tests in people, 
however, have resulted in improved detection and localization of clinically significant 
renal injury, and they have provided better severity and prognostic information than 
standard clinical testing. The urinary analytes evaluated in this investigation have 
previously been studied either minimally or not at all in veterinary medicine. The studies 
presented in this dissertation are some of the largest and most extensive to evaluate 
urinary biomarkers in dogs with naturally occurring CKD to date. The hypotheses in 
initiating these studies were that certain urinary proteins and protein banding patterns 
will provide improved detection of glomerular and TI damage and specific disease types, 
correlation with histologic severity of damage, and prediction of prognosis in dogs with 
renal diseases as compared with conventional non-invasive tests such as UPC, sCr, and 
urine specific gravity.
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CHAPTER II 
CORRELATION OF URINE AND SERUM BIOMARKERS WITH RENAL 
DAMAGE AND SURVIVAL IN DOGS WITH NATURALLY OCCURRING 
PROTEINURIC CHRONIC KIDNEY DISEASE*
Introduction
Chronic kidney disease (CKD) is a common cause of morbidity and mortality in 
dogs,124,125 and current non-invasive methods of diagnosis often lack sensitivity, 
specificity, or both for early disease detection and for identification of the underlying 
disease process. Clinically, CKD in dogs is typically detected by the presence of renal 
azotemia, persistent renal proteinuria, or both, often in conjunction with decreased urine 
concentrating ability, abnormal findings on urine sediment examination (such as 
presence of casts in the sediment), and abnormal appearance of the kidneys on 
ultrasound. Persistent renal proteinuria, typically quantified by measuring urine 
protein:creatinine (UPC), can be an early indicator of CKD in dogs,8,124 and it is a 
negative prognostic factor in dogs with CKD.126 However, when mildly increased, UPC 
cannot differentiate glomerular from tubular damage. Renal biopsy is considered the 
gold standard for determining type of renal damage,127 but it is an invasive procedure 
and is not feasible in every case due to financial constraints or animal health. Therefore, 
* Portions of this chapter are reprinted with permission from Correlation of Urine and Serum Biomarkers 
with Renal Damage and Survival in Dogs with Naturally Occurring Chronic Kidney Disease by J.A. 
Hokamp, R.E. Cianciolo, M. Boggess, G.E. Lees, S.L. Benali, M. Kovarsky, and M. B. Nabity, 2016. 
Journal of Veterinary Internal Medicine 30, 591-601, Copyright 2016 by Wiley Periodical, Inc.
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less invasive, inexpensive, sensitive and specific methods to evaluate the presence, 
character, and severity of kidney damage in dogs are needed.
Urine and serum biomarkers can be useful in human and veterinary medicine for 
early identification and localization of renal damage and as more sensitive and specific 
indicators of disease. In proteinuric kidney diseases, differently sized proteins are 
present in urine secondary to damage to different regions of the nephron (e.g., glomeruli 
vs. tubules). For example, the presence of high molecular weight proteins, such as 
immunoglobulins, in urine is indicative of glomerular damage.15 In contrast, low 
molecular weight proteins and tubular enzymes are thought to be more specific for renal 
tubular damage.15 Of these urine proteins, a few have been recently evaluated in 
veterinary medicine. Urine immunoglobulin G (uIgG) and urine retinol binding protein 
(uRBP) were increased in dogs with primary CKD37 and those with renal dysfunction 
secondary to various systemic diseases including pyometra, babesiosis, and snake 
envenomation.37,39-42,50,51,69,70 Urine, plasma, and serum neutrophil gelatinase-associated 
lipocalin (NGAL) and urine N-acetyl-β-D-glucosaminidase (uNAG), a renal tubular 
enzyme, are tubular markers increased in both acute and chronic kidney disease in 
dogs.37,41,42,50,82-86,88,105 NGAL originates not only in the renal tubules, but also from 
neutrophil granules and many other organs.73 Novel urine biomarkers are not regularly 
used as diagnostic tools for evaluation of renal disease in veterinary medicine, and few 
veterinary studies correlate biomarkers with histologically-proven renal damage37,42,70,85 
and case outcome.126 
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The objective of our study was to determine correlations of promising novel 
urine biomarkers of renal damage (IgG, immunoglobulin M (IgM), RBP, NGAL, and 
NAG) with pathologic assessment of glomerular and tubulointerstitial (TI) damage in 
dogs with naturally occurring, primarily proteinuric CKD due to a variety of causes. Our 
goal was to determine if the biomarkers provided an indication of the presence and 
severity of glomerular and/or TI damage, which would support their use as non-invasive 
tests to detect and monitor proteinuric CKD. We also determined sensitivities and 
specificities of the biomarkers for detection of specific types of renal disease and 
evaluated follow-up information from these dogs to determine if the biomarkers might 
be useful as survival indicators. 
Materials and Methods
Sample Collection and Processing
This retrospective study used canine samples of urine supernatant, serum, and 
kidney tissue collected by the dog’s veterinarian and submitted to the International 
Veterinary Renal Pathology Service (IVRPS) for diagnostic purposes between January 
2008 and September 2013. All samples were shipped on ice and were typically received 
and processed the day following collection. Urine supernatant and serum were aliquoted 
and stored at -80oC until analysis. Cases were categorized as having inactive urine 
sediment, an active urinary tract infection (based on culture or sediment findings), 
hematuria (grossly or microscopically (>100 red blood cells per 40× field)), or pyuria 
(>10 white blood cells per 40× field), identified either on the submitted sample, if 
40
available, or within 4 weeks of renal biopsy. Cases with an active sediment were 
excluded from analysis. Renal biopsies were routinely processed for light (LM) and 
transmission electron microscopy (TEM) as previously described.11 Criteria for 
diagnosis of renal disease included persistent proteinuria, azotemia, or both. Cases were 
categorized as having CKD, acute kidney injury (AKI), both CKD and AKI, or not 
enough information available to determine chronicity of renal disease. CKD was defined 
by evidence of renal disease for at least 3 months or evidence of chronicity on renal 
ultrasound or histology. 
Histopathological Analysis and Scoring
Renal biopsies were evaluated by a single pathologist (REC) for glomerular and 
TI damage. Glomerular damage was evaluated with LM and TEM, and TI damage was 
evaluated with LM. A variation of the scoring system developed for the World Small 
Animal Veterinary Association Renal Standardization Project128 was used to indicate the 
amount and severity of glomerular and TI damage (Tables A-5, A-6, and A-7). For TI 
damage, the final score consisted of an average of individual scores for each component 
of TI damage (interstitial fibrosis, tubular atrophy, degeneration/necrosis/regeneration, 
and interstitial chronic inflammation). Figures 2, 3, and 4 provide examples of the 
glomerular and TI damage scoring systems used in for evaluation of renal biopsies with 
LM and TEM. 
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Figure 2. Light microscopic (LM) images from 1 dog with normal glomeruli and 3 dogs 
with varying severities of glomerular damage due to glomerular amyloidosis. A) Normal 
glomerulus; B) mild glomerular amyloidosis, LM glomerular biopsy score = 1; C) 
moderate glomerular amyloidosis, LM glomerular biopsy score = 2; D) severe 
glomerular amyloidosis, LM glomerular biopsy score = 3.
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Figure 3. Transmission electron microscopic (TEM) images from 1 dog with normal 
glomeruli and 3 dogs with varying severities of membranous glomerulonephritis (MGN - 
a type of immune complex-mediated glomerulonephritis). A) Normal glomerulus; B) 
mild MGN, TEM glomerular biopsy score = 1; C) moderate MGN, TEM biopsy score = 
2; D) severe MGN, TEM glomerular biopsy score = 3.
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Figure 4. Light microscopic images from 1 dog with normal tubulointerstitium and 4 dogs with varying severities of 
tubulointerstitial (TI) damage. A (Periodic acid-Schiff (PAS) and B (trichrome): Interstitium and tubules are within normal 
limits; interstitial fibrosis score = 0, tubular atrophy score = 0, tubular degeneration score = 0, interstitial chronic 
inflammation score = 0; C (PAS) and D (trichrome): Mild to moderate multifocal interstitial fibrosis with tubular degeneration 
and atrophy; interstitial fibrosis score = 0.3, tubular atrophy score = 0.1, tubular degeneration score = 0.7, interstitial chronic 
inflammation score = 0.1; E (PAS) and F (trichrome): Moderate to severe interstitial fibrosis and tubular degeneration and 
atrophy; interstitial fibrosis score = 2.8, tubular atrophy score = 1.9, tubular degeneration score = 2.0, interstitial chronic 
inflammation score = 0.4; G (PAS) and H (trichrome): Severe diffuse interstitial fibrosis with tubular atrophy and 
degeneration; interstitial fibrosis score = 4.7, tubular atrophy score = 2.9, tubular degeneration score = 3.2, interstitial chronic 
inflammation score = 1.4; I (PAS) and J (trichrome): Severe diffuse chronic active lymphoplasmacytic interstitial nephritis 
with tubular degeneration, necrosis, and regeneration and extensive intraepithelial and intrahistiocytic gold brown pigment; 
interstitial fibrosis score = 3.4, tubular atrophy score = 0.1, tubular degeneration score = 4.1, interstitial chronic inflammation 
score = 4.3.
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Assay Validation
Commercial assay kits for each biomarker (IgG,a IgM,b RBP,c NGAL,d NAGe) 
were used. The IgG, RBP, and NAG assays were previously validated using canine 
urine.37 Assay validation for IgM and NGAL can be found in the appendix.
Biomarkers
All urine and serum biomarkers were analyzed in duplicate. Freeze-thaw cycles 
were limited to ≤5 per sample. Conventional biomarkers (serum creatinine (sCr),f,g urine 
protein:creatinine (UPC),f,g,h and urine specific gravity (USG)i) and novel biomarkers 
(urine and serum IgG (uIgG and sIgG), IgM (uIgM and sIgM), RBP (uRBP and sRBP), 
and NGAL (uNGAL and sNGAL) and urine NAG (uNAG)) were measured in our 
laboratory. Standards were optimized according to the manufacturer for detection of 
RBP in canine samples. Urine biomarker concentrations were normalized to urine 
creatinine concentration (e.g., uIgG/c). Using the spot sample approach,129 fractional 
excretion (FE) of IgG, IgM, RBP, and NGAL (IgG_FE, IgM_FE, RBP_FE, and 
NGAL_FE) were calculated using the formula: 
FEanalyte=(Analyteurine/Analyteserum)×(sCr/Creatinineurine)×100. Cases were classified into 
a Dog IgG ELISA Quantitation Set, Bethyl Laboratories Inc., Montgomery, TX
b Dog IgM ELISA Quantitation Set, Bethyl Laboratories Inc., Montgomery, TX
c Human Retinol Binding Protein ELISA Kit, Immunology Consultants Laboratory, Inc., Newberg, OR
d Dog NGAL ELISA Kit, Immunology Consultants Laboratory, Inc., Newberg, OR
e N-acetyl-β-D-glucosaminidase (NAG) Assay, Diazyme Laboratories, Poway, CA
f Creatinine LiquiColor Test (Endpoint), Stanbio Laboratory, Boerne, TX
g Sirrus Clinical Chemistry Analyzer, Stanbio Laboratory, Boerne, TX 
h Protein, Micro LiquiColor Test (CSF and Urine), Stanbio Laboratory, Boerne, TX
i Rhino VET360 Veterinary Clinical Refractometer, Reichert Technologies, Depew, NY
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CKD stages 1–4 based on the International Renal Interest Society (IRIS) guidelinesj, 
realizing that some cases could represent acute or acute on chronic disease and therefore 
not be in steady state.
Survival Data
The referring veterinarian or owner for each dog was contacted from 6 months to 
6 years post-biopsy. If deceased, the following information was recorded: time to death 
post-biopsy, whether death was spontaneous or due to euthanasia, and cause of death 
(renal-related or otherwise).
Statistical Analysis
Biomarker Correlations
Simple linear regression on standardized continuous variables was used to 
estimate the correlation between biomarkers and also between each biomarker and 
biopsy damage scores to determine which biomarker correlated best with renal injury. 
Standardization was performed by subtracting the mean of the variable from an 
individual result and dividing by the standard deviation of that variable. Simple linear 
regression was also used to estimate the correlation between glomerular and TI damage 
scores. Correlation strength was defined as follows: weak: r = 0.0-0.39; moderate: r = 
0.4-0.69; strong: r = 0.7-1.0. The Kolmogorov-Smirnov test was used to assess normality 
j http://www.iris-kidney.com/guidelines/staging.shtml
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of the residuals, and data were natural log or square root transformed as necessary. 
Simple linear regression modeling for groups was used to determine significant 
differences in biomarkers between IRIS stages.
Disease Type Prediction
Logistic regression was used to determine presence of significant associations 
between biomarkers and specific types of kidney diseases, based on histopathological 
diagnosis, including: immune complex-mediated glomerulonephritis (ICGN), 
glomerulosclerosis, amyloidosis, other nephropathies, and tubular disease. “Other 
nephropathies” included juvenile nephropathies (e.g., maldevelopment) and 
nephropathies other than ICGN, glomerulosclerosis, amyloidosis, and primary tubular 
disease, such as cases with glomerular basement membrane and podocyte damage 
without immune complex deposition, cases with glomerular atrophy, and cases with 
primarily interstitial fibrosis. Receiver operator characteristic (ROC) analysis was 
performed to determine sensitivities and specificities for each biomarker with each 
disease type, and cutoff values for each biomarker were calculated based on that which 
maximized sensitivity and specificity. Sensitivities and specificities for disease types 
were also calculated for selected pairs of biomarkers. For each disease type, a 
dichotomous variable was created to be the response for the logistic model and ROC 
analysis (1 indicated the disease type of interest and 0 was otherwise).
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Survival Analysis
For each biomarker and damage score, a survival model was fit, using a Cox 
semi-parametric model (accounting for the biomarker/damage score and age as 
covariates) to estimate median time to death due to renal disease post-biopsy using all 
follow-up data obtained (n = 98 dogs). Hazard ratios (HR) were used to describe the 
association of the biomarker and age with time to death. All data were also evaluated 
together in a multivariate Cox model to determine which combination of biomarkers and 
biopsy damage scores had the most significant association with time to death due to 
renal disease post-biopsy as described by HR. For the Cox models, TEM glomerular 
damage scores were re-categorized into “no damage to mild damage” (0 and 1) versus 
“moderate to severe damage” (2 and 3). 
All statistical analyses were carried out using Stata version 13, setting P<0.05.k 
Results
Dogs/Samples
Urine supernatant, serum, and kidney tissue from 203 dogs were initially 
analyzed. Of these, 130 (64%) urine samples had urinalyses performed on the submitted 
sample by the referring veterinarian or on a sample within 4 weeks of biopsy collection. 
Twenty-three dogs had evidence of an ongoing or recent bacteriuria, pyuria, or 
k Stata Corp. LP, College Station, TX
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hematuria, and these cases were completely excluded leaving 180 cases for further 
analysis. 
Of the remaining 180 cases, there were 80 (44.4%) spayed females, 57 (31.7%) 
neutered males, 25 (13.9%) intact males, and 18 (10.0%) intact females.
Numerous breeds were represented; the most common breeds were: Labrador 
Retrievers/Labrador Retriever-mixes: 19 (10.6%); Golden Retrievers/Golden Retriever-
mixes: 9 (5.0%); Yorkshire Terrier/Yorkshire Terrier-mixes: 9 (5.0%); Miniature 
Schnauzers: 7 (3.9%); Doberman Pinschers: 6 (3.3%); and Rottweiler/Rottweiler-mixes: 
5 (2.8%).
The age range was 2 months to 14 years old, with a median of 7 years old. Ten 
dogs (5.6%) were 0 to <1 year; 45 (25.0%) were 1 year to <5 years; 101 (56.1%) were 5 
to <10 years; and 22 (12.2%) were 10 years. Two dogs were of an unknown age.  
Follow-up information was collected for 98 (54%) dogs; information regarding 
time from biopsy to death and cause of death was collected for 62 dogs, 51 of which 
died or were euthanized due to renal-related causes. Median time to death due to renal 
disease post-biopsy (excluding submitted necropsy samples) was 179 days (range: 2–
1,349 days).
Kidney disease was diagnosed based on persistent proteinuria in 87 dogs 
(48.3%), azotemia in 19 dogs (10.6%), and both proteinuria and azotemia in 74 dogs 
(41.1%). CKD was confirmed for 165 (91.7%) of dogs, while 3 dogs (1.7%) had 
concurrent CKD and AKI. Five dogs (2.8%) had AKI, and for 7 dogs (3.9%) chronicity 
of renal disease was unable to be determined.
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Histopathologic Findings and Scores
Of 180 dogs included in the study, glomerular and TI damage were assessed in 
176 dogs, whereas the remaining 4 did not have renal tissue available for evaluation. 
One hundred-fifty-one dogs had glomeruli available for evaluation by TEM, and the 
remaining 29 dogs did not have TEM performed for various reasons (e.g. LM evaluation 
was sufficient for diagnosis, a TEM sample was not submitted, or glomeruli were not 
present in the TEM sample). Table 1 demonstrates that this study cohort overall had 
worse glomerular damage than TI damage. Cases were divided into 5 disease categories 
with the following distribution: ICGN: 62 (34.4%); glomerulosclerosis: 47 (26.1%); 
amyloidosis: 18 (10.0%); other nephropathies: 32 (17.8%); and primary tubular disease: 
15 (8.3%). Biopsies from 6 (3.3%) dogs were not assigned a disease category because 
the biopsied regions were either normal or insufficient to make a complete disease 
diagnosis; these cases were removed from the disease type prediction analysis. However, 
for 4 of these 6 cases, there was adequate tissue for either glomerular evaluation (n = 2), 
or TI evaluation (n = 2). Correlation between TI and LM glomerular damage scores was 
moderate (r = 0.45, P < 0.001), whereas there was no correlation between TI and TEM 
glomerular damage scores (r = -0.03). 
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Table 1. Percentage of cases in each category of glomerular damage biopsy scores based 
on LM and TEM and TI damage biopsy scores based on LM.12
Score 0 - < 1 Score 1 - < 2 Score 2 - < 3 Score ≥ 3
LM Glomerular Damage Score
N = 176 8.5% 26.7% 40.3% 24.4%
TEM Glomerular Damage Score
N = 151 2.0% 24.5% 43.7% 29.8%
TI Damage Score
N = 176 58.5% 30.1% 10.8% 0.6%
LM, light microscopy; TEM, transmission electron microscopy; TI, tubulointerstitial.
Assay Validation
Analytical performance of the NGAL and IgM assays was acceptable (Table A-
8). 
Biomarker Findings
On average, dogs were mildly to moderately azotemic (107 dogs (59.4%) had 
sCr ≥ 1.4 mg/dL) and moderately to markedly proteinuric (137 dogs (76.1%) had UPC ≥ 
2.0) (Table 2). Twenty-seven (15%) dogs had a UPC 0.5-2.0 and 16 (9%) had UPC < 
0.5. Of these 43 dogs with UPC < 2.0, 23.3% had primary glomerular disease as 
determined by histopathology. Of the dogs with UPC < 0.5 (n=16), 1 dog (6.3%) had 
primary glomerular disease. 
Biomarkers demonstrated a large range of values, and typically urine biomarkers were 
higher than have previously been reported in clinically healthy dogs.37,50,82,83,86,103 For 
66.6% of the 180 cases included in the study, all biomarkers were measured; the 
remaining 33.4% of cases did not have a complete biomarker set. uIgG, uIgM, and 
uRBP were measured for 100% of the cases. sIgG, sIgM, and sRBP were measured for 
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all cases which had submitted serum samples (76.1% of cases). sNGAL and uNGAL 
were measured for 68.9% and 85% of cases, respectively. uNAG was measured for 
94.4% of cases. When only cases that had a complete set of biomarker data were 
included in the statistical analyses, results of each analysis were similar to results when 
all cases (i.e., those with and without a complete biomarker set) were included (data not 
shown). While FE for most biomarkers was <100%, NGAL_FE ranged from 0-506%. 
With regard to IRIS stages, only RBP_FE and NGAL_FE demonstrated significantly 
progressive increases with higher IRIS stages, although all novel biomarkers except 
uIgG/c and uNAG/c tended to increase with higher stages of disease (Table A-9).
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Table 2. Median (range) of biomarker values in dogs with naturally occurring chronic kidney disease. For biomarkers that were significantly associated with specific categories of disease according to logistic 
regression, optimal cutoff values and corresponding sensitivities and specificities, as determined by receiver operator characteristic (ROC) analysis, are displayed.12
All Dogs ICGN Glomerulosclerosis Amyloidosis Other Nephropathies Tubular Disease
n Median (Range) n Median (Range) n Median (Range) n Median (Range) n Median (Range) n Median (Range)
Cutoff (Se%, Sp%) Cutoff (Se%, Sp%) Cutoff (Se%, Sp%) Cutoff (Se%, Sp%) Cutoff (Se%, Sp%)
sCr (mg/dL) 179 1.5 (0.3 - 21.8) 61 1.5 (0.3 - 9.3) 47 1.4 (0.3 - 12.0) 18 1.1 (0.5 - 4.9) 32 1.7 (0.6 - 21.8)* 15 2.1 (0.5 - 13.0)*
>2.5 (37.5, 78.2) >3.2 (46.7, 87.2)
USG 180 1.017 (1.003 - 1.048) 62 1.019 (1.005 - 1.046)** 47 1.017 (1.003 - 1.048) 18 1.013 (1.003 - 1.027)* 32 1.014 (1.005 - 1.047) 15 1.013 (1.005 - 1.026)*
>1.014 (80.6, 47.5) <1.013 (50.0, 73.5) <1.014 (60.0, 69.1)
UPC Ratio 180 5.0 (0.0 - 36.8) 62 8.6 (0.4 - 36.8)** 47 5.2 (0.5 - 31.6) 18 11.0 (1.7 - 21.3) 32 1.5 (0.0 - 14.3)** 15 0.5 (0.0 - 6.0)**
>2.5 (95.2, 40.7) <2.5 (71.9, 81.8) <2.0 (86.7, 81.2)
IgG
uIgG/c (µg/mg) 180 554.0 (0.6 - 37,649.0) 62 1,212 (27 - 37,649)** 47 562.5 (48.7 – 7,070.3) 18 727.0 (128.9 - 6,589.0) 32 104.1 (0.6 - 1,938.5)** 15 37.3 (0.7 - 489.3)**
>729.0 (62.9, 72.9) <374.7 (87.5, 71.6) <211.0 (86.7, 80.0)
sIgG (µg/ml) 137  11,320 (3,199 – 41,798) 48  11,288 (3,199 – 29,686) 36  11,280 (6,482 – 41,798) 12  9,251 (3,669 – 20,185) 27  10,670 (3,742 – 26,785) 10  14,933 (9,098 – 31,108) 
IgG_FE% 137 0.1 (0.0 - 8.6) 48 0.1 (0.0 - 8.6) 36 0.1 (0.0 - 1.4) 12 0.2 (0.0 - 3.2) 27 0.0 (0.0 - 4.7) 10 0.0 (0.0 - 0.2)
IgM
uIgM/c (µg/mg) 180 6.4 (0.3 - 557.0) 62 14.6 (2.1 - 557.0)** 47 5.6 (0.5 - 26.9)* 18 5.7 (3.1 - 24.3) 32 3.1 (0.4 - 20.2)** 15 2.0 (0.3 - 28.3)*
>8.0 (74.2, 75.4) <13.5 (87.2, 32.3) <5.6 (75.0, 60.1) <3.5 (73.3, 74.5)
sIgM (µg/ml) 137  2,864 (867 – 20,070) 48  3,130 (867 – 20,070)* 36  2,468 (1,033 – 7,512) 12  3,057 (1,051 – 7,717) 27 2,774 (1,185 – 3,906) 10  3,503 (2,056 – 10,921) 
                            >4433.0 (31.3, 89.9)    
IgM_FE% 137 0.003 (0.000 - 0.172) 48 0.008 (0.000 - 0.145)* 36 0.002 (0.000 - 0.022)* 12 0.002 (0.001 - 0.019) 27 0.002 (0.0 00 - 0.172) 10 0.001 (0.000 - 0.033)
>0.005 (62.5, 76.4) <0.005 (83.3, 45.5)
RBP
uRBP/c (µg/mg) 180 8.7 (0.0 - 1,013.4) 62 9.3 (0.1 - 243.8) 47 10.0 (0.0 - 1,013.4) 18 2.1 (0.0 - 78.4) 32 4.0 (0.0 - 402.9) 15 1.6 (0.0 - 306.1)
sRBP (µg/mL) 137 105.5 (22.9 - 414.2) 48 90.1 (22.9 - 280.5)* 36 139.6 (30.9 - 258.2)** 12 80.9 (44.2 - 126.0) 27 109.2 (26.7 - 414 .2) 10 96.2 (39.3 - 160.1)
<112.8 (70.8, 55.1) >112.2 (75.0, 64.4)
RBP_FE% 137 0.1 (0.0 - 24.9) 48 0.2 (0.0 - 18.0) 36 0.1 (0.0 - 2.7) 12 0.1 (0.0 - 3.2) 27 0.0 (0.0 - 14.3) 10 0.0 (0.0  - 24.9)*
>1.5 (30.0, 89.8)
NGAL
uNGAL (ng/mg) 153 93.6 (0.0 - 1,533.4) 53 107.5 (8.2 - 1,533.4) 41 102.6 (9.7 - 842.1) 13 92.2 (13.1 - 321.7) 29 63.1 (0.0 - 660.6) 11 43.5 (4.2 - 496.9)
sNGAL (ng/mL) 124 12.1 (2.4 - 149.1) 44 14.0 (2.6 - 65.7) 34 13.1 (3.3 - 149.1) 10 11.0 (4.8 - 23.4) 24 8.9 (2.4 - 106.8) 7 8.3 (2.8 - 24.7)
NGAL_FE% 124 10.8 (0.0 - 505.9) 44 11.7 (0.5 - 82.8) 34 10.1 (1.9 - 86.1) 10 13.3 (2.2 - 40.4) 24 7.5 (0.0 - 505.9) 7 3.6 (0.2 - 26.8)
uNAG (U/g) 170 13.5 (0.4 - 427.7) 57 26.5 (3.0 - 427.7)** 46 12.7 (2.0 - 76.7) 18 20.4 (3.3 - 67.2) 30 7.4 (0.6 - 37.7)** 13 2.8 (0.4 - 10.3)**
>23.8 (56.1, 85.0) <9.4 (63.3, 71.4) <6.9 (92.3, 79.6)
Biomarker is significantly associated with type of kidney disease according to logistic regression: *P<0.05, **P<0.01; Outcome for ROC analysis in determining sensitivity and specificity was presence of a particular 
disease. Cutoff values were determined by those which maximize the area under the ROC curve, and greater or less than the cutoff value was determined by the increased probability of having the disease when above 
or below the cutoff value. ICGN, immune complex-mediated glomerulonephritis; Se%, sensitivity; Sp%, specificity; sCr, serum creatinine; USG, urine specific gravity; UPC, urine protein:creatinine ratio; uIgG/c, 
urine immunoglobulin G/urine creatinine; sIgG, serum immunoglobulin G; IgG_FE, fractional excretion of immunoglobulin G; uIgM/c, urine immunoglobulin M/urine creatinine; sIgM, serum immunoglobulin M;  
IgM_FE, fractional excretion of immunoglobulin M; uRBP/c, urine retinol binding protein/urine creatinine; sRBP, serum retinol binding protein; RBP_FE, fractional excretion of retinol binding protein; uNGAL/c, 
urine neutrophil gelatinase-associated lipocalin/urine creatinine; sNGAL, serum neutrophil gelatinase-associated lipocalin; NGAL_FE, fractional excretion of neutrophil gelatinase-associated lipocalin; uNAG/c, urine 
N-acetyl-β-D-glucosaminidase/urine creatinine.
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Biomarker Correlations
Of 45 combinations of urine protein biomarkers (normalized urine concentration 
or FE), 82.2% showed moderate to strong correlations with each other and with UPC 
(Table A-10). In contrast, serum protein biomarker concentrations (sRBP and sNGAL) 
generally demonstrated weak correlations with other biomarkers, and the highest 
correlation was observed with the urine concentration of the same biomarker (e.g., sRBP 
with uRBP/c). sCr correlated only weakly to moderately with FE of the biomarkers, with 
the strongest (but still moderate) correlation for sCr being with RBP_FE. 
Glomerular damage based on LM correlated best (albeit moderately) with FE of 
high molecular weight (i.e., “glomerular”) biomarkers (IgM_FE: r = 0.58; IgG_FE: r = 
0.56), and both IgM_FE and IgG_FE had stronger correlations with glomerular damage 
than did UPC (r = 0.45) (Figure 5). The remaining urine protein biomarkers (urine 
concentrations and FEs) correlated less strongly with glomerular damage (range: r = 
0.32-0.47). Correlations of many biomarkers with glomerular damage were stronger 
when based on TEM compared with LM (Figure 6). 
For TI damage, sCr had the strongest correlation (r = 0.7, Figure 7). RBP was the 
only biomarker where all measurements (urine and serum) significantly correlated with 
TI damage, with RBP_FE demonstrating the strongest, albeit moderate, correlation (r = 
0.58). The only other significant correlations with TI damage were FEs of the other 
biomarkers as well as USG, which demonstrated a weak, negative correlation. 
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Figure 5. Correlations of biomarkers with glomerular damage based on light microscopy, with 
95% confidence intervals. Circles represent a statistically significant correlation and 
triangles represent no significant correlation. **P<0.01; n=176. sCr, serum creatinine; 
USG, urine specific gravity; UPC, urine protein:creatinine ratio; uIgG/c, urine 
immunoglobulin G/urine creatinine; sIgG, serum immunoglobulin G; IgG_FE, fractional 
excretion of immunoglobulin G; uIgM/c, urine immunoglobulin M/urine creatinine; 
sIgM, serum immunoglobulin M; IgM_FE, fractional excretion of immunoglobulin M; 
uRBP/c, urine retinol binding protein/urine creatinine; sRBP, serum retinol binding 
protein; RBP_FE, fractional excretion of retinol binding protein; uNGAL/c, urine 
neutrophil gelatinase-associated lipocalin/urine creatinine; sNGAL, serum neutrophil 
gelatinase-associated lipocalin; NGAL_FE, fractional excretion of neutrophil gelatinase-
associated lipocalin; uNAG/c, urine N-acetyl-β-D-glucosaminidase/urine creatinine.12
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Figure 6. Correlations of biomarkers with glomerular damage based on transmission electron 
microscopy with 95% confidence intervals. Circles represent a statistically significant correlation 
and triangles represent no significant correlation. **P<0.01; n=151. sCr, serum creatinine; USG, 
urine specific gravity; UPC, urine protein:creatinine ratio; uIgG/c, urine immunoglobulin 
G/urine creatinine; sIgG, serum immunoglobulin G; IgG_FE, fractional excretion of 
immunoglobulin G; uIgM/c, urine immunoglobulin M/urine creatinine; sIgM, serum 
immunoglobulin M; IgM_FE, fractional excretion of immunoglobulin M; uRBP/c, urine retinol 
binding protein/urine creatinine; sRBP, serum retinol binding protein; RBP_FE, fractional 
excretion of retinol binding protein; uNGAL/c, urine neutrophil gelatinase-associated 
lipocalin/urine creatinine; sNGAL, serum neutrophil gelatinase-associated lipocalin; NGAL_FE, 
fractional excretion of neutrophil gelatinase-associated lipocalin; uNAG/c, urine N-acetyl-β-D-
glucosaminidase/urine creatinine.12
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Figure 7. Correlations of biomarkers with tubulointerstitial damage based on light microscopy 
with 95% confidence intervals. Circles represent a statistically significant correlation and 
triangles represent no significant correlation. *P<0.05; **P<0.01; n=176. sCr, serum creatinine; 
USG, urine specific gravity; UPC, urine protein:creatinine ratio; uIgG/c, urine immunoglobulin 
G/urine creatinine; sIgG, serum immunoglobulin G; IgG_FE, fractional excretion of 
immunoglobulin G; uIgM/c, urine immunoglobulin M/urine creatinine; sIgM, serum 
immunoglobulin M; IgM_FE, fractional excretion of immunoglobulin M; uRBP/c, urine retinol 
binding protein/urine creatinine; sRBP, serum retinol binding protein; RBP_FE, fractional 
excretion of retinol binding protein; uNGAL/c, urine neutrophil gelatinase-associated 
lipocalin/urine creatinine; sNGAL, serum neutrophil gelatinase-associated lipocalin; NGAL_FE, 
fractional excretion of neutrophil gelatinase-associated lipocalin; uNAG/c, urine N-acetyl-β-D-
glucosaminidase/urine creatinine.12
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Disease Type Prediction
We used logistic regression to determine if any of the biomarkers was 
significantly associated with each diagnostic category (Table 2). ROC analysis and 
sensitivity and specificity calculations for each disease type were also performed for 
each biomarker. Individually, increased uIgM/c, uIgG/c, uNAG/c, and UPC were 
significantly associated with ICGN based on logistic regression, and these demonstrated 
the highest sensitivities and specificities for ICGN. A ROC analysis of pairs of 
biomarkers revealed uIgM/c and uNAG/c to be the only combination of biomarkers 
significantly associated with ICGN. This combination, using cutoff values of uIgM/c 
>7.3 µg/mg and uNAG/c >7.0 U/g, had a sensitivity and specificity for detection of 
ICGN of 75% and 78%, respectively, which was similar to that of uIgM/c alone. 
Individually, low UPC, uIgG/c, and uNAG/c were most significantly associated with 
primary tubular disease; however, ROC analysis did not reveal a combination of 
biomarkers that was significantly associated with primary tubular disease. 
Survival Analysis
In this cohort of dogs with primarily proteinuric CKD, increases in sCr, IgM_FE, 
uRBP/c, RBP_FE, NGAL_FE, and IgG_FE, as well as TI, LM and TEM glomerular 
damage scores were all significantly associated with shortened time to death due to renal 
disease according to Cox survival models including age as a covariate (Table 3). For 
example, an increase in sCr of 1 mg/dL resulted in an increased hazard of death of 40%, 
while an increase of 0.01% for IgM_FE resulted in an increased hazard of death of 45%. 
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An increase in TI damage score or LM glomerular damage score of 1 point (e.g., 0 to 1 
or 1 to 2) resulted in increased hazards of death of 160% and 60%, respectively, while an 
increase in TEM glomerular damage score from 0/1 to 2/3 resulted in an increased 
hazard of death of 158%. Age also had a significant association with time to death when 
combined in the survival models for IgM_FE, RBP_FE, and IgG_FE (i.e., a 1-year 
increase in age increased the hazard of death associated with these biomarkers). Age did 
not have a significant association with time to death when combined in survival models 
for sCr, uRBP/c, NGAL_FE, TI damage score, and LM or TEM glomerular damage 
scores. 
To determine which combination of biomarkers and damage scores was 
significantly associated with time to death due to renal disease in this cohort of dogs, all 
biomarkers were evaluated together in a multivariate Cox survival model. Notably, sCr, 
IgM_FE, and TEM glomerular damage scores were the only parameters that were 
significantly associated with time to death due to renal disease post-biopsy (Table 4). 
Survival graphs for these three variables demonstrate the probability of survival for a 
dog of median age (7 years) based on different starting levels of each biomarker or 
damage score (Figure 8). Survival graphs also demonstrate the probability of survival for 
dogs with varying combinations of SCr and IgM_FE values based on a TEM glomerular 
damage score of either 0/1 or 2/3 (Figure A-1).
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Table 3. Association of biomarker/damage score and age with time to death due to renal disease in dogs from multivariate 
Cox survival models. The unit increase for each biomarker/damage score and age is depicted in parentheses in the first 
column. Each row depicts a separate survival model that includes 2 covariables (biomarker or damage score and age).12
HR for Biomarker/Damage Score HR for Age
HR (95% CI) P value HR (95% CI) P value
Biomarker + Age (1 year) N
sCr (1 mg/dL) 82 1.40 (1.26-1.56) <0.001 1.10 (0.99-1.22) 0.072
IgM FE (0.01%) 66 1.45 (1.25-1.69) <0.001 1.15 (1.00-1.32) 0.047
uRBP/c (10 µg/mg) 83 1.07 (1.03-1.10) <0.001 1.07 (0.98-1.18) 0.14
RBP FE (1%) 66 1.17 (1.07-1.28) 0.001 1.16 (1.01-1.33) 0.034
NGAL FE (25%) 59 1.23 (1.07-1.41) 0.003 1.09 (0.95-1.25) 0.20
IgG FE (1%) 66 1.47 (1.11-1.95) 0.007 1.15 (1.00-1.31) 0.044
Damage Score + Age (1 year)
TI Damage Score (1 Score Point) 82 2.60 (1.59-4.24) <0.001 1.07 (0.97-1.17) 0.17
LM Glomerular Damage Score (1 Score Point) 82 1.60 (1.12-2.29) 0.009 1.08 (0.98-1.20) 0.13
TEM Glomerular Damage Score (0/1 vs. 2/3) 72 2.58 (1.03-6.44) 0.042 1.05 (0.94-1.18) 0.37
HR, hazard ratio; CI, confidence interval. Abbreviation explanations in Table 1 and 2 legends.
Table 4. Association of biomarkers and TEM glomerular damage score with time to death due to renal disease in dogs from a 
multivariate Cox survival model (n=84). The unit increase for each biomarker/damage score is depicted in parentheses in the 
first column.12
Biomarker/Damage Score HR (95% CI) P value
sCr (1 mg/dL) 1.40 (1.15-1.70) 0.001 
IgM_FE (0.01%) 1.28 (1.07-1.55) 0.008 
TEM Glomerular Damage Score (0/1 vs. 2/3) 4.80 (1.32-17.50) 0.017 
Abbreviation explanations in Table 1, 2, and 3 legends.
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Figure 8. Probability of survival by biomarker/damage score for a dog at median age (7 years) at different starting values of 
biomarkers/damage scores for A) sCr (n=83); B) IgM_FE (n=67); C) TEM Glomerular Damage Score (n=73). 25p: 25th 
percentile; 50p: 50th percentile; 75p: 75th percentile; 90p: 90th percentile; 95p: 95th percentile. Additional abbreviation 
explanations in Table 1 and 2 legends.12 
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Discussion
This study evaluated 5 novel biomarkers in 180 dogs with naturally occurring 
kidney disease, primarily proteinuric CKD typically due to primary glomerular disease. 
Several of these urine biomarkers and their FEs correlated with pathologic severity of 
glomerular damage, TI damage, or both. Increased uIgM/c and uNAG/c were most 
significantly associated with ICGN. Furthermore, increased sCr, IgM_FE, uRBP/c, 
RBP_FE, NGAL_FE, and IgG_FE, as well as TI damage scores and LM and TEM 
glomerular damage scores were associated with reduced survival when variables were 
modeled separately. However, in a multivariate model, only sCr, IgM_FE, and TEM 
glomerular damage scores were associated with time to death due to renal-related causes. 
Our findings support that conventional markers of kidney disease (sCr, UPC) correlate 
with kidney damage either similarly to or better than the novel biomarkers evaluated in 
this study. However, novel biomarkers can provide useful additional information to 
support the presence of glomerular or tubular damage, to help distinguish between 
disease categories, and to inform prognosis.
This study did not reveal superiority of any novel biomarker to sCr with regard to 
TI damage or survival. However, sCr is often not optimally interpreted, with diagnosis 
of azotemia based on exceeding a reference interval rather than what is “normal” or 
baseline for a particular animal. This is especially problematic for small breed dogs and 
animals with concurrent muscle wasting, the latter of which is a common finding in 
CKD and will complicate monitoring for disease progression.117 Therefore, having 
additional non-invasive markers of TI damage and dysfunction would be useful to 
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confirm sCr interpretations. Additionally, even though sCr demonstrated the best 
correlation with TI damage, the majority (59%) of dogs evaluated in this study were 
already at least mildly azotemic at the time of biopsy, and it is possible that evaluation of 
urine biomarkers might help identify TI damage earlier than sCr.
IgG_FE and IgM_FE correlated slightly stronger than UPC with severity of 
glomerular damage when evaluated with LM; however, when glomerular damage was 
assessed with TEM, IgG_FE, UPC, and uIgG/c provided the best indications of 
ultrastructural glomerular damage. Thus, UPC is likely an effective conventional marker 
of ultrastructural glomerular damage. Of interest is the use of uIgM/c, uIgG/c, and 
uNAG/c, particularly the combination of uIgM/c and uNAG/c, for the identification of 
ICGN (discussed further below). Increased IgM_FE was also associated with a 
significantly increased hazard of death. This is similar to studies in humans, where 
increased uIgM/c excretion in diabetic glomerulonephropathy was shown to be 
associated with increased risk of renal failure and death.130,131 Because IgM is a large 
protein (~900 kDa), its presence in the urine might reflect more severe and possibly 
irreversible damage to the glomerular filtration barrier. In contrast to a previous study in 
dogs,126 UPC was barely associated with survival (P = 0.03; HR = 1.04). This could be 
because this previous study included dogs with sCr ranging from 2.0 – 8.0 mg/dL,126 
whereas many of the dogs in the present study were not azotemic, and some had 
reversible glomerular injury. Treatment to reduce proteinuria both before and after renal 
biopsy might have also influenced results in our study.
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The tubular markers sCr, RBP_FE, uRBP/c, and NGAL_FE typically correlated 
more strongly with TI than glomerular damage. However, all but sCr also correlated 
moderately well with glomerular damage. Similarly, IgM_FE correlated moderately with 
TI damage, although a stronger correlation was observed with glomerular damage. This 
is similar to a study of urine biomarkers in dogs with X-linked hereditary nephropathy, 
where sCr, uRBP/c, uNGAL/c, uNAG/c, and uIgG/c all correlated moderately to 
strongly with both glomerular and tubular lesions.37 One possible explanation is that 
concurrent glomerular and tubular damage commonly occurs in dogs with CKD, and 
certainly, damage to one compartment will affect the other. 
The use of TEM in our study identified biomarkers that were better for 
differentiating glomerular from tubular disease, including UPC, uIgG/c, uIgM/c, 
uNAG/c, and IgG_FE. Notably, most “glomerular” biomarkers had a stronger 
correlation with the TEM assessment of glomerular damage compared to LM evaluation, 
suggesting that TEM is better for determining the severity of glomerular filtration barrier 
damage. Furthermore, glomerular damage based on TEM, but not LM, was significantly 
associated with survival time in a multivariate survival model and therefore may be more 
predictive of prognosis. However, both LM and TEM are needed for the comprehensive 
assessment of kidney biopsies. LM allows for evaluation of many glomeruli, which is 
particularly important for identification of scattered sclerotic or obsolescent glomeruli. 
TEM provides a more detailed structural view of the glomerulus, particularly the 
glomerular filtration barrier, but is not routinely performed outside a specialized biopsy 
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service. In addition, it is usually performed on small tissue samples in which glomeruli 
may be absent. 
Interestingly, uNAG/c correlated as strongly with glomerular damage as the 
glomerular markers but did not significantly correlate with TI damage. NAG is a tubular 
lysosomal enzyme recognized as a marker of tubular injury, wherein tubular damage 
causes release of NAG and subsequent elevation of enzyme activity in urine.47,132 NAG, 
which is approximately the size of IgG, does not pass through a normal glomerular 
filtration barrier, and the upper reference limit for uNAG/c in healthy dogs (3.63 U/g)103 
is well below the mean in our study. Previous studies have shown increased uNAG/c in 
dogs with CKD, presumed to be due to tubular damage or increased lysosomal turnover 
secondary to proteinuria.37,50,105 While it is still possible that NAG leakage is occurring 
without histologic evidence of tubular damage, the strong correlation with glomerular 
damage and lack of correlation with TI damage in our study supports the possibility that 
NAG can pass through an injured glomerular filtration barrier. Therefore, while uNAG/c 
has been used to detect tubular damage in cases of acute kidney injury, it might also be 
useful to detect glomerular damage in chronic proteinuric nephropathies. 
Another unexpected finding was the similar correlation of IgM_FE with both TI 
and glomerular damage. This is particularly intriguing given that uIgM/c did not 
correlate with TI damage. Fractional excretions of RBP, NGAL, and IgG also correlated 
more strongly with TI damage than their urine concentrations. This suggests that 
determination of FE could be more valuable than urine concentration of these markers 
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for assessment of tubular damage, possibly due to the decreased ability of damaged 
tubular epithelial cells to reabsorb these proteins. 
Maximum FEs observed for most biomarkers were <100%, except for 
NGAL_FE which reached 506%. This could indicate a large amount of secretion or loss 
of NGAL from damaged tubular cells. Alternatively, pyuria might have been present in 
samples that did not have a concurrent sediment examination despite recent results 
indicating inactive urine sediments. However, NGAL_FE in samples with known pyuria 
only reached up to 227% (data not shown).
An intriguing aspect of our study is the possibility that certain biomarkers might 
be able to predict specific disease types. In particular, markedly increased uIgM/c, 
uNAG/c, uIgG/c, and UPC were significantly associated with ICGN, which may be due 
to immune deposits creating large “holes” within the glomerular filtration barrier. A 
combination of uIgM/c and uNAG/c had a sensitivity and specificity for ICGN of 75% 
and 78%, respectively. While these values are not considerably high, they demonstrate 
promise in our ability to detect ICGN without a renal biopsy. However, further studies 
with larger populations of dogs are needed. While low UPC, uIgG/c, and uNAG/c were 
significantly associated with primary tubular disease on individual analysis, bivariate 
analysis did not reveal a combination of biomarkers with improved sensitivity or 
specificity over the individual analyses. It is possible that this might be due to an 
insufficient number of cases with primary tubular disease.
It was expected that TI damage score and sCr would be significantly associated 
with prognosis since TI damage is most closely associated with clinical parameters 
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(glomerular filtration rate and sCr).133 However, many parameters (uRBP/c, RBP_FE, 
IgM_FE, IgG_FE, and NGAL_FE, and LM and TEM glomerular damage scores) were 
also significantly associated with survival time. Since uRBP/c was shown to increase 
earlier than sCr,37 increases in urinary biomarkers might provide an earlier indication of 
prognosis in dogs with renal disease. In a multivariate survival model, sCr was the most 
informative biomarker. However, IgM_FE and TEM glomerular damage scores were 
also significantly associated with survival time, and IgM_FE was more strongly 
associated than TEM findings. This suggests that the combination of sCr and IgM_FE 
might better predict prognosis than biopsy findings, although renal biopsy remains the 
gold standard for diagnosis and guide to therapy. Even very small changes in IgM_FE 
predicted significant changes in prognosis. This could be because IgM is a very large 
protein, likely requiring more severe damage to the glomerulus in order to pass into the 
urine filtrate. TI damage score, on the other hand, was not significantly associated with 
survival time in the multivariate analysis, possibly because many of the cases in this 
study were biopsied for suspected nonazotemic glomerular disease and therefore had low 
TI damage scores. Finally, increasing age was irrelevant to survival time once biomarker 
values and damage scores were known. Given that these survival predictions are based 
primarily on a population of dogs with proteinuric CKD, typically due to glomerular 
disease, these biomarkers may not hold the same prognostic value in dogs with other 
etiologies of kidney disease.
Because most of the dogs in this study had proteinuric CKD, there was a bias for 
dogs with glomerular disease, which is a limitation of this study. Even so, 43 dogs (24%) 
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had UPC < 2, which is not typically considered indicative of primary glomerular disease, 
and 16 of these dogs (9% of the entire cohort) had a UPC < 0.5. Of the 43 dogs with 
UPC < 2, 23% had histologic evidence of primary glomerular disease. Of those with 
UPC < 0.5 (n=16), only 1 dog (6%) had primary glomerular disease. The distribution of 
the inciting cause of CKD in the general canine population is currently unknown, as it 
has not been comprehensively studied using clinicopathologic data, LM, and TEM; 
however, glomerular damage and proteinuria is common in dogs with CKD. While this 
study cohort does not completely represent the general population of dogs with CKD, a 
wide variety of naturally occurring kidney diseases were included.
A second limitation of the study is that not all urine samples had a corresponding 
urinalysis. The majority (64%) of the samples had a corresponding urinalysis performed 
either on the urine sample submitted with the biopsy or within 4 weeks of the biopsy. 
Most samples were collected by internists at referral centers who performed a complete 
medical evaluation, minimizing the likelihood that significant sediment abnormalities 
were present when urinalysis results were not provided. However, studies have 
demonstrated that urinary tract infections and hematuria might alter biomarker levels,81 
and presence of infection could potentially increase systemic immunoglobulins. 
Therefore, all cases with known or suspected pyuria, bacteriuria, and/or marked 
hematuria were excluded from analyses to avoid interpreting increases in biomarkers 
that might be due to infection or hematuria. 
Additional limitations include the unknown stability of the urine biomarkers, the 
variable time between collection and processing (although typically just one day), and 
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the variability in length of sample storage prior to biomarker determination. The use of 
spot samples for calculation of FE, while an accepted method, is considered less accurate 
than the clearance approach for calculation of FE.129 However, the spot sample approach 
is more feasible in clinical practice. Additionally, not all biomarkers were measured in 
each dog; however, this was unlikely to have skewed the data as results were similar 
even if analysis was performed only for those cases with a complete biomarker set. 
In conclusion, use of conventional biomarkers that are currently available for the 
diagnosis and monitoring of kidney disease, particularly sCr and UPC, are reasonable for 
assessment of kidney disease if used appropriately. A number of novel biomarkers are 
useful to detect glomerular or TI damage and potentially predict specific disease types 
and survival in dogs with naturally occurring CKD. Additionally, analysis of quantitative 
pathologic biopsy scores, as based on the recently published World Small Animal 
Veterinary Association manuscript128 can aid in prognostication in dogs with CKD. 
More studies are needed using a larger cohort of dogs to determine if specific 
biomarkers such as uIgM/c and uNAG/c can help non-invasively diagnose ICGN in 
dogs. Furthermore, although uNAG/c has been reported as a marker of TI damage, it 
might be better suited as a marker of glomerular damage in dogs with proteinuric 
nephropathies.
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CHAPTER III 
URINARY IMMUNOGLOBULIN M AS A NOVEL BIOMARKER OF IMMUNE 
COMPLEX MEDIATED GLOMERULONEPHRITIS IN DOGS
Introduction
Glomerular disease has been reported as a common cause of chronic kidney 
disease (CKD), found in approximately 50% to 70% of dogs with naturally occurring 
kidney diseases.11,134-137 Glomerular disease in dogs is often believed to be immune-
mediated (immune complex mediated glomerulonephritis (ICGN)), with nearly 50% of 
cases of dogs with suspected glomerular disease having evidence of immune complexes 
present in the glomerulus.10,11,138-141 Canine ICGN is generally not a true auto-immune 
disease, in which antibodies are produced against glomerular antigens. Rather, the term 
“immune-mediated” is used to denote the presence of circulating immune complexes 
being deposited in the glomerulus or forming in the glomerulus secondary to deposited 
or entrapped foreign antigen.141,142 While infectious diseases and inflammatory diseases 
can incite glomerular deposition of immune complexes, the source can also be 
idiopathic.141 The light microscopy findings of the glomeruli and the locations of 
immune complex deposition determine the pattern of ICGN.142 In general, the following 
classifications of ICGN are used in dogs: membranous ICGN – displays presence of 
subepithelial electron dense immune complex deposits without significant glomerular 
hypercellularity, and the deposits eventually lead to remodeling and thickening of the 
capillary walls; membranoproliferative ICGN – displays diffuse global capillary wall 
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thickening and mesangial expansion due to the presence of electron dense immune 
complex deposits in subendothelial and mesangial zones, increased production of 
mesangial matrix/mesangial hypercellularity, endocapillary hypercellularity (due to 
numerous circulating leukocytes and hypertrophied endothelium), and mesangial 
interpositioning into the capillary wall that eventually results in a glomerular basement 
membrane with double contours; mesangioproliferative ICGN – displays mesangial 
expansion/hypercellularity with electron dense immune complex deposits limited to the 
mesangial zones; and mixed ICGN – displays features that are a mixture of the ICGN 
forms described (e.g., large numbers of  immune complexes in more than one location of 
the glomerulus).143-145 Although ICGN is a common cause of glomerular disease in dogs, 
other common causes of glomerular disease include amyloidosis, focal segmental 
glomerulosclerosis (FSGS) (e.g., intraglomerular hypertension), with structural 
abnormalities and maldevelopment less commonly observed.11,141 
Standard therapy for renal disease rarely completely resolves renal injury in cases 
of ICGN; therefore, treatment recommendations include attempting to identify and 
correct any underlying disease process that may be inciting the production of antigen-
antibody complexes and suppressing the immune system to decrease immune complex 
formation.141,146 In human studies, immunosuppressive treatment appears effective in 
many cases of glomerulonephritis.147-152 While there are no placebo controlled, biopsy-
documented studies to support the use of immunosuppressives in dogs with ICGN, 
immunosuppressive therapy has anecdotally been beneficial in some cases of canine 
ICGN.146,153 A number of contraindications exist for the use of immunosuppressives in 
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some dogs. Ideally, evidence of an active immune-mediated mechanism promoting 
glomerular disease in the kidney would be obtained prior to starting treatment.146,153 
Currently there are no non-invasive biomarkers available for dogs that can 
diagnose the presence of ICGN. Therefore, a renal biopsy with light microscopy (LM), 
transmission electron microscopy (TEM), and immunofluorescence (IF) analysis is 
needed to establish the presence of immune complexes in the glomeruli and to guide 
therapy.146 For many canine patients, a renal biopsy is not an option due to patient 
health, financial, or other constraints.153 While use of minimally invasive biomarkers is 
not expected to replace all of the information gleaned from a renal biopsy, identification 
of biomarkers that suggest the presence of ICGN would be extremely helpful for guiding 
therapy when a biopsy cannot be performed.
A previous study found that several minimally invasive urinary biomarkers might 
be useful for identification of ICGN without the need for biopsy.12 In particular, 
markedly increased urine immunoglobulin M (IgM), a high molecular weight (HMW) 
protein suggestive of glomerular damage, and urine N-acetyl-β-D-glucosaminidase 
(NAG), a lysosomal enzyme suggestive of tubular and potentially glomerular damage, 
were associated with ICGN.12,15,93 The goal of the current study was to evaluate these 
biomarkers in a larger cohort of dogs with corresponding renal biopsies in order to 
provide a more accurate assessment of the association of urinary IgM and NAG with the 
presence of ICGN in dogs. Additionally, we aimed to determine the ability of these 
biomarkers to predict prognosis in dogs with ICGN and determine whether they differed 
according to ICGN subtype. 
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Materials and Methods
Sample Collection and Processing of Samples 
Dogs with Renal Disease
Urine supernatant, serum, and kidney tissues collected from dogs were submitted 
to the International Veterinary Renal Pathology Service (IVRPS) for diagnostic purposes 
between January 2008 and September 2014. All samples were collected and processed as 
previously described.12 Cases were categorized as having an inactive urine sediment, 
hematuria (grossly or microscopically (> 5 red blood cells per 40× field)), pyuria (> 5 
white blood cells per 40× field)/bacteriuria (based on culture or sediment findings of 
bacteria), or both hematuria and pyuria/bacteriuria, identified either on the submitted 
sample, if available, or within 4 weeks of the biopsy. Cases were excluded from analysis 
if an active urine sediment was identified. Renal biopsies were routinely processed for 
LM and TEM as previously described.11 Renal disease was diagnosed based on presence 
of persistent proteinuria, azotemia, or both. Dogs were determined to have CKD (based 
on evidence of renal disease for ≥ 3 months or chronic changes on renal ultrasound or 
histology), acute kidney injury (AKI), AKI superimposed on CKD, or insufficient 
information to determine renal disease chronicity. 
Sample Collection and Processing of Control Samples from Healthy Dogs
Urine and serum samples were collected from 9 client owned dogs and one 
unaffected (normal) dog from a colony with X-Linked Hereditary Nephropathy 
(XLHN)154 that were healthy and had inactive urine sediments. Client consent was 
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obtained for the client-owned dogs. The dogs were determined to be healthy based on 
history, physical examination, complete blood count, serum chemistry, complete 
urinalysis, and urine protein:creatinine (UPC). Urine was collected as voided samples or 
by cystocentesis, and urinalysis was performed within 2 hours of collection. Urine 
supernatant and serum were stored at -80oC prior to analysis. 
Histopathological Analysis and Scoring
Renal biopsies were assessed by one nephropathologist (REC), and biopsies were 
assigned an overall histologic diagnosis as previously described,12 including: immune 
complex-mediated glomerulonephritis (ICGN), glomerulosclerosis, amyloidosis, other 
glomerulonephropathies, and tubular disease. “Other nephropathies” included those that 
affected the entire kidney, such as juvenile nephropathy (e.g., renal maldevelopment), as 
well as glomerulopathies, such as glomerulocystic atrophy, glomerular lipidosis, and 
glomerular basement membrane and podocyte abnormalities without immune complex 
deposition. For cases diagnosed as ICGN, subcategories were determined as described in 
the introduction, including membranous, membranoproliferative, mesangioproliferative, 
or mixed ICGN. Cases that were not diagnostic were excluded from further analysis.
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Biomarkers
Commercial assay kits for IgMl and NAGm were used and have previously been 
validated in canine urine.12,37 Biomarkers were measured in duplicate. Each sample 
received ≤ 5 freeze-thaw cycles. Conventional biomarkers (serum creatinine (sCr),n,o 
UPC,n,o,p and urine specific gravity (USG)q) and novel biomarkers (urine and serum IgM 
(uIgM and sIgM), and urine NAG (uNAG)) were measured in our laboratory. Urine 
biomarker concentrations were normalized to urine creatinine concentration (e.g., 
uIgM/c). Using the spot sample approach,129 fractional excretion (FE) of IgM (IgM_FE) 
was calculated using the formula: 
FEanalyte = (Analyteurine/Analyteserum) × (sCr/Creatinineurine) × 100. 
Survival Data
Owners and veterinarians for each dog were contacted between 2 months to 8 
years post-renal biopsy. If the dog had died since biopsy, the amount of time to death 
post-biopsy, type of death (spontaneous versus humane euthanasia), and cause of death 
or decision to euthanize (e.g., renal disease progression) were recorded.
l Dog IgM ELISA Quantitation Set, Bethyl Laboratories Inc., Montgomery, TX
m N-acetyl-β-D-glucosaminidase (NAG) Assay, Diazyme Laboratories, Poway, CA
n Creatinine Liquicolor Test (Endpoint), Stanbio Laboratory, Boerne, TX
o Sirrus Clinical Chemistry Analyzer, Stanbio Laboratory, Boerne, TX
p Protein, Micro Liquicolor Test (CSF and Urine), Stanbio Laboratory, Boerne, TX
q Rhino VET360 Veterinary Clinical Refractometer, Reichert Technologies, Depew, NY
75
Statistical Analysis
Biomarker values were not normally distributed; thus, non-parametric analyses 
were performed.
Comparison of Biomarkers Between Dogs with Inactive versus Active Urine 
Sediments
Although only cases with inactive urine sediments were used for most analyses, 
we were interested in determining if biomarker values differed significantly between 
dogs with inactive and active urine sediments. Using the 2-sample Wilcoxon rank sum 
(Mann-Whitney) test, urine protein biomarkers (UPC, uIgM, uIgM/c, IgM_FE, uNAG, 
and uNAG/c) were compared between dogs with inactive urine sediments and dogs with 
hematuria, pyuria/bacteriuria, or both. Further analyses excluded cases with active urine 
sediments.
Comparison of Biomarkers Between Healthy Dogs and Dogs with Renal Disease
Using the 2-sample Wilcoxon rank sum test, conventional biomarkers (sCr, USG, 
and UPC) and novel urine protein biomarkers (uIgM, uIgM/c, IgM_FE, uNAG, and 
uNAG/c) were compared between healthy dogs and dogs with ICGN and non-ICGN 
renal disease to determine biomarker differences between healthy and ill dogs. These 
same comparisons were also performed to determine differences between dogs with 
ICGN and non-ICGN and among the 4 different categories of ICGN.
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Prediction of ICGN
Receiver operator characteristic (ROC) analysis was performed to determine the 
area under the ROC curve (AUC), and sensitivities and specificities were calculated for 
each urine protein biomarker for the ability to detect renal disease due to ICGN. These 
same determinations were made based on grouping of the data according to presence or 
absence of azotemia and for dogs biopsied for suspicion of glomerular disease (i.e., if the 
clinical history mentioned suspicion of nephritic syndrome, nephrotic syndrome, or 
glomerulonephritis, UPC was > 2, or persistent renal proteinuria was identified in cases 
without obvious non-glomerular diseases). The presence of ICGN on histology was set 
as the gold standard (1 was positive presence of disease, 0 was otherwise). Cutoff values 
for conventional and novel biomarkers were determined based on that which maximized 
the sum of the sensitivity and specificity. 
Survival Analysis
For each urine protein biomarker, a survival model was fit using a Cox semi-
parametric model (accounting for the biomarker and age as covariates) to estimate 
median time to death due to renal disease post-biopsy. Hazard ratios (HR) were used to 
describe the association of the biomarker and age with risk of death due to renal disease. 
All statistical analyses were carried out using Stata version 11, setting P<0.05.r 
r Stata Corp. LP, College Station, TX
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Results
Dogs and Samples
Samples were initially analyzed from 267 dogs with renal disease, most of which 
were proteinuric. Urinalysis results were available on the submitted urine samples or on 
a sample within 4 weeks of biopsy collection in 71% of cases. Of these, 32 had 
hematuria, 4 had pyuria/bacteriuria, and 10 had both hematuria and pyuria/bacteriuria. 
These were excluded from all analyses except the comparison of active vs inactive 
sediments. An additional 8 cases were non-diagnostic on histologic analysis of the 
submitted renal biopsy and were also excluded. The remaining 213 cases represented a 
wide variety of breeds. Retriever breeds (Labrador retrievers, Golden retrievers, and 
mixes) were the most commonly represented with 37 dogs (17.4%), followed by 
Yorkshire terriers and Yorkshire terrier mixes with 12 dogs (5.6%). Ninety spayed 
females (42.3%), 73 castrated males (34.3%), 31 intact males (14.6%), and 19 intact 
females (8.9%) were included in the study. Nine dogs (4.3%) were < 1 year of age; 60 
dogs (28.4%) were ≥ 1 to ≤ 5 years; 117 dogs (55.5%) were ≥ 5 to ≤ 10 years; and 25 
dogs (11.9%) were ≥ 10 years. 
Presence of kidney damage was diagnosed by clinicians based on persistent 
proteinuria in 105 (49.3%) dogs, azotemia in 22 (10.3%) dogs, and both proteinuria and 
azotemia in 86 (40.4%) dogs. Based on known timeframe of disease symptoms and/or 
presence of chronicity seen on ultrasound and renal histology, CKD was confirmed for 
225 (87.6%) dogs. Seven dogs (2.7%) had AKI superimposed on CKD, 5 dogs (2%) had 
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AKI, and in 20 dogs (7.8%) there was not enough information available to determine the 
chronicity of the renal disease.
Outcome/prognostic information was available for 120 (56.3%) of the dogs with 
renal disease included in the analysis. Cause of death following biopsy was ascertained 
for 79 dogs of which 58 died or were euthanized due to progression of renal disease. For 
these 58 dogs, median time to death due to renal disease following biopsy (not including 
samples obtained at necropsy (6 samples)) was 183 days (range: 2 – 1,460 days). 
Histopathological Analysis
Figure 9A illustrates the percentages of different histologic diagnoses (ICGN, 
glomerulosclerosis, amyloidosis, other glomerulonephropathies, and primary tubular 
disease) in the 213 dogs included in the analysis. Figure 9B illustrates the percentages of 
the different categories of ICGN (membranous (MGN), membranoproliferative 
(MPGN), mesangioproliferative, and mixed) in the 85 dogs that were diagnosed with 
ICGN.
Comparison of Biomarkers Among Dogs 
Healthy Dogs versus Dogs with Renal Disease
All urine protein biomarkers were significantly higher in dogs with ICGN 
compared to healthy dogs, while all except for uNAG were greater in dogs with non-
ICGN renal disease compared to healthy dogs (Table 5). sCr was significantly lower and 
USG was significantly higher in healthy dogs compared to dogs with non-ICGN renal 
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Figure 9. A) Proportion of 213 dogs included for histologic analysis of renal biopsies 
that were diagnosed with immune complex-mediated glomerulonephritis (ICGN), 
glomerulosclerosis, amyloidosis, other glomerulonephropathies, or primary tubular 
disease; B) proportion of the 85 ICGN dogs that had membranous glomerulonephritis 
(MGN), membranoproliferative glomerulonephritis (MPGN), mesangioproliferative 
ICGN, or mixed ICGN.
disease. Neither sCr nor USG was significantly different between healthy dogs and dogs 
with ICGN. For most biomarkers, there was some overlap in values for dogs without 
evidence of renal disease and those with renal disease due to ICGN or non-ICGN. 
However, for UPC and uIgM/c, there was no overlap in values between healthy dogs and 
those with ICGN.
Although cases with active urine sediments were excluded from most analyses, 
we were interested in determining if there was an evident difference in biomarker values 
in dogs with renal disease with and without active urine sediments. Table 6 displays the 
median and range of each urinary biomarker categorized by whether the case had an 
inactive urine sediment, hematuria, pyuria/bacteriuria, or both hematuria and 
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pyuria/bacteriuria. All 3 of the IgM biomarkers (uIgM, uIgM/c, and IgM_FE) were 
significantly increased in cases with hematuria and with both hematuria and 
pyuria/bacteriuria. NAG and UPC were not significantly different among groups.
Non-ICGN versus ICGN Dogs
All urine protein biomarkers were significantly higher in dogs with renal disease 
due to ICGN versus non-ICGN, although substantial overlap was present for all 
biomarkers between these categories (Table 5 and Figures 10 - 15). Additionally, USG 
was significantly higher in ICGN versus non-ICGN dogs, while there was no significant 
difference in sCr between the categories.
Comparison Between ICGN Classifications
Several biomarkers displayed significant differences between categories of ICGN 
(Table 7). Of particular interest, uIgM, uIgM/c, and IgM_FE were significantly greater 
in MPGN than the majority of other ICGN categories. UPC, uNAG, and uNAG/c were 
significantly greater in both MGN and mixed ICGN compared with 
mesangioproliferative ICGN. 
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Table 5. Comparison of biomarkers in healthy dogs versus dogs with ICGN and non-ICGN renal disease based on analysis 
using the 2-sample Mann-Whitney test.
Healthy Non-ICGN ICGN
N Median (Range) N Median (Range) N Median (Range)
sCr (mg/dl) 9 1.0 (0.7 - 1.3) 128 1.5 (0.3 - 21.8)a 81 1.5 (0.3 - 6.7)
USG 9 1.022 (1.012 - 1.054) 128 1.015 (1.003 - 1.048)a 85 1.020 (1.005 - 1.046)c
UPC 9 0.0 (0.0 - 0.2) 128 3.7 (0.0 - 31.6)a 85 8.0 (0.4 - 36.8)b,c
uIgM (ng/ml) 9 0.7 (0.5 - 1.2) 128 3.2 (0.1 - 44.5)a 85 13.6 (1.2 - 403.8)b,c
uIgM/c (μg/mg) 9 0.3 (0.1 - 0.8) 128 4.1 (0.3 - 28.3)a 85 14.4 (2.2 - 557.0)b,c
IgM_FE (%) 9 0.000 (0.000 - 0.000) 100 0.002 (0.000 - 0.172)a 64 0.006 (0.000 - 0.089)b,c
uNAG (U/L) 8 5.8 (2.0 - 21.6) 128 7.6 (0.1 - 59.9) 85 24.4 (1.6 - 159.5)b,c
uNAG/c (U/g) 8 1.5 (1.0 - 5.9) 128 9.9 (0.4 - 80.4)a 85 24.1 (3.0 - 427.7)b,c
P < 0.05 significantly different between ahealthy and non-ICGN dogs; bhealthy and ICGN dogs; cnon-ICGN and ICGN dogs; 
sCr, serum creatinine; USG, urine specific gravity; UPC, urine protein:creatinine; uIgM, urine immunoglobulin M; uIgM/c, 
urine immunoglobulin M/creatinine; IgM_FE, fractional excretion of immunoglobulin M; uNAG, urine N-acetyl-β-D-
glucosaminidase; uNAG/c, urine N-acetyl-β-D-glucosaminidase/creatinine; ICGN, immune complex-mediated 
glomerulonephritis.
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Table 6. Comparison of urinary biomarkers in dogs with inactive versus active urine sediments based on analysis using the 2-
sample Mann-Whitney test.
Inactive Sediment Hematuria Pyuria/Bacteriuria Hematuria and Pyuria/Bacteriuria
N Median (Range) N Median (Range) N Median (Range) N Median (Range)
UPC 213 5.1 (0.0 - 36.8) 30 7.0 (0.7 - 26.7) 4 7.0 (0.5 - 8.9) 10 6.0 (1.3 - 23.6)
uIgM (ng/ml) 213 5.1 (0.1 - 403.8) 30 8.9 (0.4 - 335.2)a 4 2.5 (1.1 - 3.4) 10 12.0 (2.7 - 163.8)b
uIgM/c (μg/mg) 213 6.5 (0.3 - 557.0) 30 10.4 (0.8 - 546.1)a 4 4.3 (2.4 - 6.3) 10 31.2 (5.3 - 240.8)b
IgM_FE (%) 164 0.003 (0.000 - 0.172) 17 0.010 (0.002 - 0.163)a 2 0.005 (0.003 - 0.007) 8 0.045 (0.006 - 0.122)b
uNAG (U/L) 213 12.6 (0.1 - 159.5) 30 21.0 (1.3 - 122.0) 4 11.2 (3.3 - 27.1) 10 17.3 (2.5 - 48.1)
uNAG/c (U/g) 213 13.9 (0.4 - 427.7) 30 16.0 (2.6 - 110.3) 4 19.6 (10.3 - 39.2) 10 34.1 (6.4 - 92.5)
P < 0.05 significantly different between ainactive sediment and hematuria; binactive sediment and hematuria/pyuria/bacteriuria; 
UPC, urine protein:creatinine; uIgM, urine immunoglobulin M; uIgM/c, urine immunoglobulin M/creatinine; IgM_FE, 
fractional excretion of immunoglobulin M; uNAG, urine N-acetyl-β-D-glucosaminidase; uNAG/c, urine N-acetyl-β-D-
glucosaminidase/creatinine.
83
Table 7. Comparison of biomarkers in different ICGN classifications based on analysis using the 2-sample Mann-Whitney 
test.
Membranous Membranoproliferative Mesangioproliferative Mixed
N Median (Range) N Median (Range) N Median (Range) N Median (Range)
sCr (mg/dl) 25 1.4 (0.3 - 6.7) 13 2.0 (0.7 - 3.3)d 20 1.1 (0.6 - 3.2)d 23 1.7 (0.4 - 4.5)
USG 27 1.021 (1.005 - 1.041) 13 1.018 (1.010 - 1.045) 20 1.018 (1.005 - 1.044)f 25 1.028 (1.015 - 1.046)f
UPC 27 9.8 (0.5 - 20.9)b 13 7.4 (2.5 - 25.2) 20 5.0 (0.4 - 15.3)b,f 25 9.1 (2.8 - 36.8)f
uIgM (ng/ml) 27 13.1 (1.2 - 97.1)a 13 42.3 (5.1 - 403.8)a,d 20 7.0 (1.8 - 33.5)d,f 25 19.9 (2.5 - 226.6)f
uIgM/c (μg/mg) 27 9.3 (2.4 - 48.3)a,c 13 52.3 (10.8 - 557.0)a,d,e 20 9.5 (2.4 - 61.3)d,f 25 18.3 (2.2 - 129.5)e,c,f
IgM_FE (%) 16 0.004 (0.000 - 0.025)a,c 13 0.018 (0.002 - 0.089)a,d 17 0.003 (0.001 - 0.027)d,f 18 0.017 (0.001 - 0.064)c,f
uNAG (U/L) 27 44.3 (4.4 - 130.1)b 13 18.4 (4.1 - 159.5) 20 12.3 (1.6 - 65.5)b,f 25 35.7 (7.0 - 139.4)f
uNAG/c (U/g) 27 30.3 (7.1 - 131.3)b 13 17.4 (7.0 - 124.7) 20 15.2 (3.0 - 55.3)b,f 25 30.2 (4.2 - 427.7)f
P < 0.05 significantly different between amembranous and membranoproliferative ICGN; bmembranous and 
mesangioproliferative ICGN; cmembranous and mixed ICGN; dmembranoproliferative and mesangioproliferative ICGN; 
emembranoproliferative and mixed ICGN; fmesangioproliferative and mixed ICGN; sCr, serum creatinine; USG, urine 
specific gravity; UPC, urine protein:creatinine; uIgM, urine immunoglobulin M; uIgM/c, urine immunoglobulin M/creatinine; 
IgM_FE, fractional excretion of immunoglobulin M; uNAG, urine N-acetyl-β-D-glucosaminidase; uNAG/c, urine N-acetyl-β-
D-glucosaminidase/creatinine; ICGN, immune complex-mediated glomerulonephritis.
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Figure 10. Comparison of urine protein:creatinine (UPC) between different categories of 
immune complex-mediated glomerulonephritis (ICGN). *P < 0.05 between categories of 
ICGN). MGN, membranous glomerulonephritis; MPGN, membranoproliferative 
glomerulonephritis.
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Figure 11. Comparison of non-normalized urine immunoglobulin M (uIgM) between 
different categories of immune complex-mediated glomerulonephritis (ICGN). *P < 0.05 
between categories of ICGN). MGN, membranous glomerulonephritis; MPGN, 
membranoproliferative glomerulonephritis; GN, glomerulonephritis.
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Figure 12. Comparison of urine immunoglobulin M/creatinine (uIgM/c) between 
different categories of immune complex-mediated glomerulonephritis (ICGN). *P < 0.05 
between categories of ICGN). MGN, membranous glomerulonephritis; MPGN, 
membranoproliferative glomerulonephritis.
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Figure 13. Comparison of the fractional excretion of immunoglobulin M (IgM_FE) 
between different categories of immune complex-mediated glomerulonephritis (ICGN).  
*P < 0.05 between categories of ICGN). MGN, membranous glomerulonephritis; 
MPGN, membranoproliferative glomerulonephritis; GN, glomerulonephritis.
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Figure 14. Comparison of the non-normalized urine N-acetyl-β-D-glucosaminidase 
(uNAG) between different categories of immune complex-mediated glomerulonephritis 
(ICGN). *P < 0.05 between categories of ICGN). MGN, membranous 
glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; GN, 
glomerulonephritis.
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Figure 15. Comparison of the urine N-acetyl-β-D-glucosaminidase/creatinine (uNAG/c) 
between different categories of immune complex-mediated glomerulonephritis (ICGN). 
*P < 0.05 between categories of ICGN). MGN, membranous glomerulonephritis; 
MPGN, membranoproliferative glomerulonephritis; GN, glomerulonephritis.
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Prediction of ICGN
To determine which urinary protein biomarkers might be useful indicators of 
ICGN in dogs with proteinuric renal disease, ROC analysis and sensitivity and 
specificity calculations were performed for each biomarker, with diagnosis of ICGN 
based on kidney biopsy set as the gold standard. Table 8 describes the ROC AUC for 
each biomarker’s ability to diagnose the presence of ICGN. When all cases were 
included in the analysis regardless of stage of disease progression, uIgM demonstrated 
the highest AUC (0.8433), with a sensitivity of 83.5% and a specificity of 75.0% based 
on a cutoff of > 5.3 ng/mL. Cases were also grouped by progression of disease as 
determined by whether the dog was non-azotemic (International Renal Interest Society 
(IRIS) stage 1) or azotemic (IRIS stages 2, 3, or 4) at the time of sample submission. 
AUCs demonstrated a mild decrease for all urine protein biomarkers in non-azotemic 
dogs but a mild increase in azotemic dogs compared to the entire cohort of cases. In 
particular, specificity of uIgM/c increased to 89% in the azotemic cohort. Given the 
relatively high AUCs of uIgM and uIgM/c for detection of ICGN, we were interested in 
determining changes in specificity at cutoff values higher than those which maximized 
the sum of sensitivity and specificity, since a specific non-invasive diagnosis of ICGN 
would be most helpful for clinicians to confidently treat with immunosuppressive drugs. 
When the median values of uIgM and uIgM/c in ICGN dogs (13.6 ng/ml and 14.4 
μg/mg, respectively (Table 5)) were used as cutoff values in ROC analysis, specificities 
of uIgM and uIgM/c for detection of ICGN in all dogs increased to 93.0% and 90.6%, 
respectively. However, sensitivity decreased to 50.6% for both biomarkers. When these 
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same cutoff values for uIgM and uIgM/c were used in the azotemic group, specificities 
of uIgM and uIgM/c for detection of ICGN were 94.5% and 90.4% respectively, while 
sensitivities were 62.8% and 64.7%, respectively. In the non-azotemic group, 
specificities of uIgM and uIgM/c for detection of ICGN were both 90.9%, and 
sensitivities were 32.4% and 29.4%, respectively.
Since clinicians will only be suspecting ICGN when they have a high clinical 
suspicion for glomerular disease, we also performed the same calculations to determine 
the ability of biomarkers to detect ICGN only in those dogs biopsied for suspicion of 
glomerular disease (n = 178 dogs). AUCs for all urine protein biomarkers slightly 
decreased when this truncated population was used (Table A-11); however, when the 
median values of uIgM and uIgM/c in ICGN dogs (13.6 ng/ml and 14.4 μg/mg, 
respectively) were used as cutoff values in ROC analysis, specificities of uIgM and 
uIgM/c for detection of ICGN in dogs with suspicion for glomerular disease were 
between 89 – 93% depending on presence of azotemia.
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Table 8. Ability of urinary protein biomarkers to predict ICGN in all dogs and based on presence of azotemia. Areas under the 
curve, optimal cutoff values, and corresponding sensitivities and specificities, as determined by receiver operator 
characteristic analysis, are displayed. 
All dogs (N=213) Non-Azotemic Dogs (N= 89) Azotemic Dogs (N= 124)
AUC Cutoff (Sens %, Spec %) AUC Cutoff (Sens %, Spec %) AUC Cutoff (Sens %, Spec %)
UPC 0.7199 >2.1 (96.5, 38.3) 0.6193 >2.1 (94.1, 27.3) 0.7826 >5.3 (74.5, 74.0)
uIgM (ng/ml) 0.8433 >5.3 (83.5, 75.0) 0.7422 >5.3 (79.4, 65.5) 0.9065 >4.5 (92.2, 76.7)
uIgM/c (μg/mg) 0.8199 >7.3 (76.5, 71.9) 0.7604 >6.4 (79.4, 70.9) 0.8590 >13.4 (68.6, 89.0)
IgM_FE (%) 0.7245 >0.007 (48.4, 86.0) 0.6855 >0.001 (80.8, 51.1) 0.7799 >0.007 (73.7, 74.5)
uNAG (U/L) 0.7989 >11.2 (80.0, 65.6) 0.6618 >27.6 (44.1, 89.1) 0.8927 >11.1 (88.2, 78.1)
uNAG/c (U/g) 0.7691 >14.9 (72.9, 69.5) 0.6957 >23.5 (52.9, 81.8) 0.8171 >14.9 (78.4, 75.3)
AUC, area under the curve; ROC, receiver operator characteristic, ICGN, Immune Complex-Mediated Glomerulonephritis; 
IRIS, International Renal Interest Society; Sens, sensitivity; Spec, specificity; UPC, urine protein:creatinine; uIgM, urine 
immunoglobulin M; uIgM/c, urine immunoglobulin M/creatinine; IgM_FE, fractional excretion of immunoglobulin M; 
uNAG, urine N-acetyl-β-D-glucosaminidase; uNAG/c, urine N-acetyl-β-D-glucosaminidase/creatinine.
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Survival Analysis
Increases in UPC and IgM_FE were significantly associated with increased risk 
of death due to renal disease according to Cox survival models including age as a 
covariate. UPC had an HR of 1.06 (95% confidence interval (CI) = 1.02 – 1.10; P = 
0.004) and IgM_FE had an HR of 1.34 (95% CI = 1.12 – 1.60; P = 0.002). An increase 
in UPC of 1 unit increased the risk of death by 6%, and an increase in IgM_FE of 0.01% 
increased the risk of death by 34%. Age also had a significant association with the risk 
of death due to renal disease when combined in survival models as a covariate for UPC 
and IgM_FE (a 1 year increase in age increased the risk of death associated with these 
biomarkers). Figures 16 and 17 illustrate the probability of survival modeled in a dog of 
median age at different starting values of UPC and IgM_FE.
Presence of ICGN was not associated with an increased risk of death due to renal 
disease (HR of 0.958 (95% CI = 0.551 – 1.67; P = 0.880)). Dogs with ICGN for which 
survival data was available had a median time to death due to renal disease of 192 days 
(range: 3 – 1,190 days) and dogs with non-ICGN renal disease had a median time to 
death of 179 days (range: 2 – 1,460 days). The median and range for time to death due to 
renal disease for dogs in each non-ICGN subtype are as follows: amyloidosis: 183 (2 – 
305) days; glomerulosclerosis: 194 (2 – 1,460) days; other glomerulonephropathies: 66 
(3 – 1,349) days; primary tubular disease: 328 (22 – 634) days. Median times to death 
due to renal disease for dogs in each ICGN group were as follows: MGN: 19 days 
(range: 3-122 days); MPGN: 244 days (range: 7-1,098 days); mesangioproliferative 
ICGN: 758 days (range: 201-1,190 days); and mixed ICGN: 183 days (range: 8-1,098 
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days). The low number of cases in each group (5 to 7 dogs per ICGN group) precluded 
the ability to perform an accurate analysis of significant differences between the median 
survival times in different ICGN groups.
Figure 16. Probability of survival for a dog at median age (7 years) at different starting 
values of fractional excretion of immunoglobulin M (IgM_FE). 10p: 10th percentile; 25p: 
25th percentile; 50p: 50th percentile; 75p: 75th percentile; 90p: 90th percentile.
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Figure 17. Probability of survival for a dog at median age (7 years) at different starting 
values of urine protein:creatinine (UPC). 10p: 10th percentile; 25p: 25th percentile; 50p: 
50th percentile; 75p: 75th percentile; 90p: 90th percentile.
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Discussion
This retrospective study expands upon previous work exploring the correlation of 
several urinary biomarkers with the degree of glomerular and TI damage on renal 
histology in dogs with naturally occurring proteinuric CKD and the ability of these 
biomarkers to detect specific types of renal diseases.12 Previously, urinary IgM and NAG 
were associated with the presence of ICGN and had moderately high sensitivities and 
specificities for ICGN detection. The current study was designed to further explore the 
ability of these 2 urinary protein biomarkers as indicators of ICGN in a larger cohort of 
dogs with renal disease (n = 213 vs 180) with stricter criteria for exclusion. This study 
confirmed that most of the novel and conventional biomarkers measured were 
significantly greater in dogs with renal disease due to ICGN or non-ICGN causes than in 
healthy dogs, and UPC and urinary IgM and NAG were all significantly higher in dogs 
with ICGN compared to dogs with non-ICGN causes. Of the biomarkers evaluated, 
uIgM demonstrated the greatest ability to detect ICGN, particularly in azotemic dogs. 
IgM_FE and UPC were also significantly associated with reduced survival. Our findings 
support the supposition that urinary biomarkers might be useful to distinguish dogs with 
proteinuric renal disease induced by ICGN. 
In the healthy dogs, measured values of uNAG/c were within the ranges 
previously reported for healthy dogs;101,103 however, normal values for urinary IgM in 
dogs (or any domestic species) have not been previously reported, and thus this study 
serves as the first report to confirm the low concentration of IgM in the urine of healthy 
dogs. To our knowledge, this current study and our previous study are the only ones 
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exploring the use of urinary IgM as a biomarker in dogs with CKD;12 however, there is 
precedence for its use in human medicine where increased urinary IgM excretion was 
associated with increased risk of renal failure and death in people with diabetic 
glomerulonephropathy.130,131
It is interesting that neither sCr nor USG were significantly different between 
healthy dogs and dogs with ICGN despite finding significant differences between 
healthy and non-ICGN dogs. This finding emphasizes the lack of sensitivity of these two 
conventional renal biomarkers for detection of kidney disease and the importance of 
performing a full urinalysis (including detection of proteinuria) with UPC determination 
if indicated rather than relying on elevated sCr or decreased USG to detect development 
of significant renal disease in dogs. Indeed, based on observations from the IVRPS, 
MGN in dogs often only presents with proteinuria, and thus this subtype of ICGN would 
likely have unremarkable sCr and USG upon presentation. 
Comparison of biomarkers between samples with inactive and active urinary 
sediments demonstrated that urinary IgM was significantly higher in dogs with 
concurrent renal disease and hematuria or both hematuria and pyuria/bacteriuria as 
compared with dogs having inactive urine sediments. Cases with only pyuria/bacteriuria 
did not demonstrate significantly higher urinary IgM or other biomarkers compared with 
cases with inactive urine sediments. Thus, it is likely that hematuria contributes to the 
elevation in urinary IgM rather than pyuria/bacteriuria. However, because the dogs in 
this study also had renal disease, it is difficult to make more specific comments 
regarding elevated urinary biomarkers due to conditions that cause active urine 
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sediments. In general, urinary tract infections/inflammation or hematuria could 
compound the evaluation of urinary biomarkers, and currently, it is not recommended to 
perform urinary biomarker analysis if an active urine sediment is present.
A major goal of this study was to determine the ability of selected urinary 
biomarkers to distinguish between dogs with proteinuric renal disease due to ICGN 
versus non-ICGN causes. The novel biomarkers studied (IgM and NAG) and UPC were 
significantly greater in dogs with ICGN versus non-ICGN. Mechanistic studies have not 
yet been undertaken to understand possible causes for the differences in concentrations 
between the disease types. It is possible that in many dogs with ICGN, immune 
complexes generate greater damage to the glomerular filtration barrier and more 
significant loss of permselectivity compared to non-ICGN causes of proteinuric renal 
disease. Another possibility is that there might also be sloughing of cells or immune 
complex components containing IgM into the urine, which would contribute to the 
increased amount of urinary IgM. This latter theory would also explain the difference in 
sensitivity/specificity of uIgM and uIgM/c versus IgM_FE, which takes into account the 
serum IgM concentration. 
Although, urinary IgM and NAG were significantly greater in dogs with ICGN, 
the ability to detect ICGN based on sensitivity and specificity of the tests was not 
perfect, particularly in non-azotemic dogs. Their performance decreased further when 
only dogs biopsied for suspicion of glomerular disease were considered in the analysis. 
However, this is likely because the non-ICGN CKD group included maldevelopment 
and primary tubular disease cases where these HMW proteins were expected to be low 
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in the urine. Sensitivities and specificities were improved in azotemic dogs, and thus, the 
utility of urinary IgM and NAG as early markers of ICGN in dogs might be more limited 
prior to onset of azotemia. However, at higher cutoff values for uIgM and uIgM/c, 
specificity of ICGN increased to ≥ 90% in both non-azotemic and azotemic groups. 
Although sensitivities were poor at higher cutoff values, specificity is more important 
than sensitivity when considering treatment that could have detrimental effects. Based 
on our findings, dogs with markedly elevated uIgM or uIgM/c might be considered 
reasonable candidates for the cautious use of immunosuppressives without biopsy 
confirmation of disease. Furthermore, if multiple biomarkers are significantly elevated, 
this might provide greater evidence for the presence of ICGN, as a panel of biomarkers 
will likely be needed for best detection and distinction of the disease. 
The AUCs for the ROC curve for uIgM and uIgM/c for detection of ICGN were 
greater than that for UPC, demonstrating the ability of novel biomarkers to provide 
predictive information beyond what is currently available with conventional tests. There 
is a significant drive for identifying non-invasive biomarkers in all species that can 
identify the presence of a particular glomerular disease without the need for biopsy for a 
number of reasons.155-158 A non-invasive biomarker might avoid the need for biopsy in 
an unstable patient, provide prognostic information that is beyond what is currently 
available, and help with tracking disease progression and response to therapy.157 Of 
particular interest would be establishing a biomarker that would provide information on 
whether dogs with ICGN will benefit from immunosuppressive therapy. This will be an 
additional undertaking that will require significant exploration.
100
In addition to the biomarker differences observed between ICGN and non-ICGN 
groups, differences were also observed among the classifications of ICGN. Specifically, 
uIgM, uIgM/c, and IgM_FE were all significantly greater in dogs with MPGN versus 
MGN or mesangioproliferative ICGN. The severity of glomerular damage tended to be 
higher with MPGN vs. other forms, which could explain this finding. Because there is 
some disagreement on the ideal way to normalize urinary biomarkers, particularly in 
cases with acute damage, we evaluated the biomarkers both with and without 
normalization to urine creatinine concentration. In doing so, we found that the diagnostic 
performance for uIgM was greater than that for uIgM/c. The significance of this finding 
is unknown, but it supports that biomarkers should be analyzed both with and without 
normalization.
Our findings for the survival analysis in this study are somewhat consistent with 
our previous study in that IgM_FE is still significantly associated with an increased risk 
of death due to renal disease.12 Additionally, we found that UPC was significantly 
associated with an increased risk of death due to renal disease in the current study, 
although the hazard ratio was minimally elevated. In our previous study, the association 
of UPC with risk of death approached statistical significance but the HR was very close 
to 1.0. For the current study, we employed slightly stricter exclusion guidelines for 
hematuria and pyuria/bacteriuria and included more animals with follow-up information, 
all of which are possible reasons for slightly different results. Our current findings are in 
line with a previous report that UPC is associated with survival time in dogs with CKD, 
although the increased risk is much less than what was reported in that study.126 A 
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significant difference was not noted in the risk of death due to renal disease between 
dogs with ICGN or non-ICGN causes of CKD. Treatment protocols between dogs were 
not considered when outcome data was analyzed due to lack of consistent follow-up 
regarding protocols; however, certainly variable treatments and reduction of proteinuria 
in dogs could affect survival times. Therefore, future studies should consider 
categorizing outcome data by different treatment protocols. Although there were not 
enough cases to consider significant differences between risk of death and survival times 
dependent on ICGN groups, it is interesting that dogs in different ICGN groups had 
highly variable survival times, with median survival times for MGN and 
mesangioproliferative ICGN at opposite ends of the range (19 versus 758 days, 
respectively). A larger cohort of dogs with ICGN that includes outcome data is needed to 
determine if these survival time differences are consistent and significant prior to using 
this information for clinical purposes.
Because most of the dogs in this study had proteinuric CKD there was a bias for 
glomerular disease. However, our interest was in exploring biomarkers in dogs for more 
sensitive and specific detection of ICGN compared to other glomerular diseases. Thus, 
the cohort of dogs used would likely be representative of those being evaluated for 
ICGN. Additionally, a limitation of this study is that although most urine samples had a 
corresponding urinalysis (71%), many samples did not. Most samples were collected by 
internists at referral veterinary centers that ideally minimized the likelihood of sediment 
abnormalities. We were also very strict in our criteria of exclusion of cases with 
evidence of hematuria and/or pyuria/bacteriuria; however, it is possible that cases with 
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minimal hematuria or pyuria/bacteriuria were unknowingly included. Finally, for 
purposes of survival analysis, the inclusion of dogs that were euthanized is difficult to 
avoid in veterinary medicine and might skew survival times; however, it reflects the 
situation seen in the clinical setting.
In conclusion, urinary IgM and NAG have at least a moderate predictive ability 
for detecting ICGN in dogs with proteinuric CKD, particularly once azotemia has 
developed, and IgM_FE is a predictor of increased risk of death due to renal disease. 
While renal biopsy is certainly still advocated, these findings lend evidence to the 
hypothesis that urinary biomarkers could be used to support a diagnosis of ICGN so that 
patients might be more confidently started on a carefully monitored trial with 
immunosuppressive drugs when renal biopsy is not possible. Additional studies are 
needed to explore the mechanisms behind these findings, and greater numbers of cases 
with outcome data are needed to determine if there are truly significant differences in 
survival times in dogs with different forms of ICGN.
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CHAPTER IV 
CORRELATION OF ELECTROPHORETIC URINE PROTEIN BANDING 
PATTERNS WITH SEVERITY OF RENAL DAMAGE AND SURVIVAL IN DOGS 
WITH PROTEINURIC CHRONIC KIDNEY DISEASE
Introduction
Chronic kidney disease (CKD) is a common and progressive disease in dogs that 
can result in significant morbidity and mortality.18,124,159,160 Not only is the onset of CKD 
insidious, but current non-invasive methods for evaluating CKD in dogs lack the ability 
to accurately assess severity of glomerular and tubulointerstitial (TI) damage, which 
must be characterized by histologic evaluation of a renal biopsy.14,15,18,77,124 While renal 
histology allows diagnosis of the cause of kidney disease and assessment of the severity 
of glomerular and TI damage, performing a renal biopsy is often not practical for 
patients due to financial constraints, anesthetic requirements, and other risk factors 
related to surgery. Additionally, biopsy findings do not always correspond with kidney 
function, particularly with regard to lesions that can be patchy in nature, such as TI 
fibrosis. Thus, minimally invasive, inexpensive methods for determining the degree of 
renal damage without the need for biopsy might be an attractive option for clinical 
veterinarians.
Urine of healthy dogs contains little to no protein because of the selective 
permeability of the glomerulus and the protein reabsorption capacity of the proximal 
tubules.14,15 In health, the glomerular filtration barrier allows free passage of low 
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molecular weight (LMW) proteins (< 40 kilodaltons (kDa)) but restricts the passage of 
most intermediate molecular weight (IMW) proteins (≥ 40 kDa and < 70 kDa) and 
nearly all high molecular weight (HMW) proteins (≥ 70 kDa).15 
Renal proteinuria, or the abnormal presence of proteins in the urine due to renal 
disease, is common in canine CKD.14,124,160 Major mechanisms of renal proteinuria 
include: the abnormal transglomerular passage of proteins due to increased permeability 
of the glomerular capillary wall, the impaired reabsorption of proteins by proximal 
tubular epithelial cells, and the release of proteins and enzymes from damaged tubular 
epithelial cells.12,15,37,77,126 In addition to being a hallmark sign of kidney disease in dogs, 
renal proteinuria is also associated with kidney disease progression.15,18,126 For example, 
a UPC ≥ 1.0 in dogs with chronic renal failure was significantly correlated with faster 
progression to end stage renal failure compared to dogs with a UPC < 1.0.126 Several 
other studies have shown that the role of proteinuria in CKD and progression to end 
stage renal failure is often underappreciated, and proteinuria might be overlooked as an 
early biomarker of kidney disease.18,124,126,160,161
Gel electrophoresis by various methodologies (e.g. sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and sodium dodecyl sulfate agarose gel 
electrophoresis (SDS-AGE)) has been used to evaluate patterns of proteinuria in 
humans, rats, and dogs with various nephropathies, including correlation of 
electrophoretic protein banding patterns with renal histology and renal function.19-
26,28,162-165 In all species, evaluation of urine protein banding patterns by gel 
electrophoresis has been shown to be a useful clinical tool to determine the site of kidney 
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damage (i.e., glomerular versus tubular versus both).19-26,28,162-166 An abundance of 
HMW proteins and IMW proteins indicates glomerular proteinuria while an abundance 
of LMW proteins signifies tubular proteinuria.20,21,25,28,163-165 Studies in dogs have 
generally agreed that urine protein banding patterns correlate well with histologic renal 
lesions, and protein banding patterns consistent with predominantly glomerular, 
predominantly tubular, and mixed glomerular and tubular damage have been 
established.20,21,23,26 In fact, several LMW proteins (12, 15, and 21 kDa) were found to 
be significantly associated with the degree of TI damage severity, and presence of 12 or 
15 kDa protein bands was highly specific for severe TI damage.26 Limited studies have 
explored the sensitivity and specificity of electrophoretic methods for detection of 
glomerular and TI damage26 or proteinuria19,20,167 in dogs. Good sensitivity but poor 
specificity was found for the ability of SDS-AGE to detect glomerular and TI lesions as 
compared to histology,26 while good sensitivity but variable specificity has been found 
for the ability of SDS-AGE to detect borderline proteinuria or proteinuria as compared to 
UPC measurements19 or quantification of urinary albumin167 or immunoglobulin G.20 
The first major objective of this study was to determine the ability and accuracy 
of urine electrophoretic protein banding patterns to identify the presence and degree of 
glomerular and TI damage as compared to renal histology and widely available 
noninvasive biomarkers in dogs with naturally occurring proteinuric CKD. A second 
objective was to determine whether urine protein banding patterns were associated with 
risk of death due to renal disease in the same cohort of dogs.  
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Materials and Methods
Sample Collection and Processing
Dogs with Proteinuric CKD
Urine supernatant and kidney biopsy and necropsy tissues from dogs with 
clinician determined renal disease were submitted to the International Veterinary Renal 
Pathology Service (IVRPS) between January 2008 and September 2014. All samples 
were shipped chilled and were received and processed within 24 hours post-collection. 
Urine specific gravity (USG)s, urine protein:creatinine (UPC)t,u,v, and serum creatinine 
(sCr)t,u were determined in our laboratory as previously described,12 and urine 
supernatant from each dog was aliquoted and stored at -80°C. Cases with an active 
sediment (hematuria, pyuria/bacteriuria, or both) on the submitted sample or within 4 
weeks of kidney biopsy were excluded from analysis. Hematuria was based on gross 
discoloration or > 5 red blood cells per 40x field on sediment examination. Pyuria was 
based on > 5 white blood cells per 40x field on sediment examination. Bacteriuria was 
present if bacteria were seen on sediment examination or if there was a recent positive 
culture result. Kidney biopsies were processed for light (LM) and transmission electron 
microscopy (TEM) as previously described.23 Renal disease was diagnosed if the dog 
had persistent proteinuria, azotemia, or both, and dogs were determined to have CKD 
(3+ months of evidence of renal disease and/or chronic renal changes on abdominal 
s Rhino VET360 Veterinary Clinical Refractometer, Reichert Technologies, Depew, NY 
t Creatinine LiquiColor Test (Endpoint), Stanbio Laboratory, Boerne, TX
u Sirrus Clinical Chemistry Analyzer, Stanbio Laboratory, Boerne, TX
v Protein, Micro LiquiColor Test (CSF and Urine), Stanbio Laboratory, Boerne, TX
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ultrasound or renal histology, such as fibrosis), acute kidney injury (AKI), AKI 
superimposed on CKD, or insufficient information available to determine renal disease 
chronicity.
Clinically Healthy Dogs
Urine was collected from client-owned dogs that were deemed healthy based on 
history, physical examination, complete blood count, serum chemistry, urinalysis, and 
UPC. Additionally, urine supernatant and kidney biopsy tissue previously collected from 
healthy control dogs from studies of dogs with early onset CKD due to X-linked 
hereditary nephropathy (XLHN) were used.154 Urine was collected by cystocentesis or 
free-catch, and urinalysis was performed within 2 hours of collection. Cases were 
excluded from analysis if hematuria, pyuria/bacteriuria, or both were identified. UPC 
and sCr were determined for each sample as previously described.12 Urine supernatant 
and serum were stored at -80oC prior to analysis. Samples collected from client-owned 
dogs were obtained with client consent.
Histologic Analysis and Scoring of Kidney Biopsies
 Kidney biopsies were evaluated for glomerular and TI damage and scored as 
previously described.12 The score for glomerular damage based on LM used a 0 – 3 
ordinal scale: 0 = normal glomeruli; 1 = mild or focal lesions; 2 = moderate lesions; and 
3 = severe lesions. The glomerular damage score based on TEM also used a 0 – 3 ordinal 
scale: 0 = normal ultrastructure; 1 = mild reversible ultrastructural lesions; 2 = moderate 
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irreversible ultrastructural lesions; and 3 = severe irreversible ultrastructural lesions. TI 
damage scores were determined for different components of damage including TI 
fibrosis (score range: 0 – 5), tubular atrophy (score range: 0 – 3), tubular 
degeneration/necrosis/regeneration (score range: 0 – 5), and TI chronic inflammation 
(score range: 0 – 5) with 0 indicating normal TI/no lesions for each component and 3 or 
5 indicating severe lesions. 
Bis-Tris Gel Electrophoresis of Urine Supernatant
 Non-reducing, denaturing gel electrophoresis was performed on all canine urine 
samples, typically within 2 months of collection, using precast 12-well, 4 – 12% Bis-Tris 
gelsw in the Invitrogen XCell Sure Lock Mini-Cell Electrophoresis system.x Urine 
samples were diluted with ultrapure water based on USG to a volume of 30 µl, followed 
by addition of 10 µl lithium dodecyl sulfate (LDS) sample buffery for a final volume of 
40µl. The urine volume component was calculated as: urine volume (µl) = 0.065/(USG-
1). This formula ensured that for highly concentrated urine samples, a minimum of 1 µl 
of urine was used for dilution. Samples were heated at 70°C for 10 minutes, and 20 µl of 
each sample was loaded into a lane of the precast gel, leaving the first and last lanes for 
the molecular weight standardz (5 µl). Each sample and standard was loaded onto 
duplicate gels, which were run according to manufacturer protocol (200V for 35 
w NuPAGE 4-12% Bis-Tris Gel, Life Technology Corporation, Carlsbad CA
x Invitrogen XCell SureLock Mini-Cell Electrophoresis System, Invitrogen Life Technologies, Carlsbad 
CA
y NuPAGE LDS Sample Buffer [4X], Invitrogen Life Technologies, Carlsbad CA
z Mark12 Unstained Standard, Invitrogen Life Technologies, Carlsbad CA
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minutes) in 2-(N-morpholino)ethanesulfonic acid (MES) sodium dodecyl sulfate (SDS) 
bufferaa. Following water washes, gels were stained with Imperial Protein Stainbb for 2 
hours and destained overnight with ultrapure water. The following day, gels were 
digitally photographedcc and dried by soaking them in a drying solution (prepared as 20 
mL glycerol, 200 mL 100% ethanol, and 780 mL ultrapure water) for 20 minutes. Gels 
were then sandwiched between transparent cellulose sheets.
To determine the repeatability of the gel electrophoresis procedure and the 
protein banding patterns produced, 10 samples were randomly selected from possible 
candidates to represent the range of banding patterns observed from dogs with naturally 
occurring CKD. Samples were run on three different days, randomizing sample lane 
location for each run. Each aliquot used for each run had the same number of freeze-
thaw cycles.
Computer and Visual Analysis of Bis-Tris Gels
Digital photographs of each gel were analyzed using a commercially available 
software for gel fingerprint analysis.dd Standard instructions provided in the software 
manual were followed to remove the background of the digital gel image. 
A reference system was established to assign the molecular weight of the 
standards, and the protein bands for each dog’s urine sample were normalized to this 
aa NuPAGE MES SDS Running Buffer [20X], Invitrogen Life Technologies, Carlsbad, CA
bb Imperial Protein Stain, ThermoFisher Scientific, Rockford, IL
cc Gel Doc XR + System, Bio-Rad Laboratories Inc., Hercules, CA
dd BioNumerics Version 6.6, Applied Maths, Austin, TX
110
reference system. Using default settings to limit manual correction of the bands, the 
software program automatically searched for protein bands. 
Following the software’s automatic assignment of bands for each sample, the 
dried gels were used to verify the presence of bands compared to the digital image. Each 
band was verified by at least two researchers. 
The total number and molecular weights of protein bands for each sample were 
exported to Microsoft Excel. For the repeatability study, the inter-run percent coefficient 
of variation (CV%) was calculated for the total number of bands identified for each 
sample.
Gel Score Analysis
  Digital images of gels and dried gels from all cases used in this study were 
visually reviewed by 3 of the authors (SL, JAH, MBN) with previous experience in the 
analysis of glomerular and tubular protein banding patterns. A scoring algorithm was 
developed for the glomerular (IMW and HMW) and tubular (LMW) banding patterns.  
Glomerular severity scores ranged from 0 – 3: 0 – normal/no glomerular proteinuria; 1 – 
mild glomerular proteinuria; 2 – moderate glomerular proteinuria; 3 – severe glomerular 
proteinuria. Tubular severity scores ranged from 0 – 4: 0 – normal/no tubular 
proteinuria; 1 – minimal tubular proteinuria; 2 – mild tubular proteinuria; 3 – moderate 
tubular proteinuria; 4 – severe tubular proteinuria. Tables 9 and 10 detail the criteria 
used to assign the glomerular and tubular gel scores, and Figure 18 demonstrates 
application of the gel scores for a set of samples with varying degrees of proteinuria.
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Table 9. Glomerular gel scoring system for dogs.
Gel Findings
Glomerular 
Gel Score Albumin band characteristics Other band features
Figure 18 
Example
0 (Normal) Faint and smaller/less prominent 
than the corresponding MW 
standard (~55 kDa) +/- 1-2 
additional faint bands in the same 
region.
+/- 1 faint band at ~ 88-101 kDa (Tamm-Horsfall 
protein). Lane 2 & 9
1 (Mild) At least the size of the 
corresponding MW standard and 
ranges up to 3 times the size of the 
corresponding MW standard.
<10 HMW bands; 1 – 2 bands at ~ 130-150 kDa 
may be prominent but thin (about the same 
size/intensity as a MW standard).
Lanes 3 & 
4
2 (Moderate) a) Prominent, dark staining, and 
extends ≤ 20% of the distance 
between the 55.4 kDa and 36.5 
kDa MW standards.
OR
b) Extends ≥ 25% of the distance 
between the 55.4 kDa and 36.5 
kDa MW standards. 
If option a) from albumin features: AND > 1 
band ≥ 200 kDa. 
If option b) from albumin features: AND less 
than 5 bands ≥ 200 kDa +/- up to 2 dark bands at 
~ 130-150 kDa that approach the 
darkness/intensity of the albumin band.
Lanes 5 & 
6
3 (Severe) Extends ≥ 25% of the distance 
between the 55.4 kDa and 36.5 
kDa MW standards.
≥ 5 bands ≥ 200 kDa and/or
≥ 3 dark bands at ~ 130-150 kDa that approach 
the darkness/intensity of the albumin band.
Lanes 7 & 
8
HMW, high molecular weight; kDa, kilodaltons.
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Table 10. Tubular gel scoring system for dogs.
Gel FindingsTubular Gel 
Score
No or minimal glomerular proteinuria Glomerular proteinuria present Figure 18 
Example
0 (Normal) No LMW bands should be present, unless the dog is 
an intact male, in which case 3 variably prominent 
prostatic fluid protein bands may be present at ~ 8 – 
9.5 kDa, 15 – 16 kDa, and 26 – 27 kDa.
A faint band might be present at ~ 
24-25.5 kDa in addition to the 
prostatic fluid protein bands.
Lane 2
1 (Minimal) 1 – 2 faint LMW bands (excluding prostatic fluid 
protein bands).
≤ 5 faint LMW bands (excluding the 
24-25.5 kDa and prostatic fluid 
protein bands)
Not shown 
3 – 9 LMW bands, with 0 – 1 dark/intense bands 
(excluding prostatic fluid protein bands).
 
≤ 5 LMW bands with exactly 1 
dark/intense band (excluding the 24-
25.5 kDa  and prostatic fluid protein 
bands).
OR
≥ 6 but < 10 LMW bands with 0 to 1 
dark/intense bands (excluding the 
24-25.5 kDa band and prostatic fluid 
protein bands).
2 (Mild)
- If there is more than 1 band below 24-25.5 kDa (excluding prostatic fluid bands), the 
score should be at least mild.
Lanes 3-5
3 
(Moderate)
 ≥ 10 but < 13 LMW bands (excluding prostatic 
fluid protein bands), with ≤ 2 dark/intense LMW 
bands.
< 13 LMW bands with 2 
dark/intense bands (excluding the 
24-25.5 kDa and prostatic fluid 
protein bands).
Lanes 6 & 
9
4 (Severe) ≥ 13 LMW bands (excluding prostatic fluid protein 
bands).
AND/OR
≥ 3 dark/intense LMW bands.
≥ 13 LMW bands (excluding the 24-
25.5 kDa and prostatic fluid protein 
bands).
AND/OR 
≥ 3 dark/intense LMW bands.
Lanes 7 & 
8
LMW, low molecular weight; kDa, kilodaltons.
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Figure 18. Representative urine samples from dogs with a wide spectrum of proteinuria resolved using gel electrophoresis to 
demonstrate application of the gel scoring system.
Lanes 1 and 10: molecular weight standard.
Lane 2: Urine sample from a healthy, non-proteinuric dog. Glomerular and tubular scores = 0. 
Lanes 3 – 9 represent urine samples from proteinuric dogs where glomerular proteinuria predominates.
Lane 3: Glomerular score = 1; Tubular score = 2.
Lane 4: Glomerular score = 1; Tubular score = 2.
Lane 5: Glomerular score = 2; Tubular score = 2.
Lane 6: Urine sample from an intact male dog with proteinuria. Glomerular score = 2; Tubular score = 3.
Lane 7: Glomerular score = 3 (although faint, there are 5 bands ≥ 200 kDa); Tubular score = 4.
Lane 8: Glomerular score = 3; Tubular score = 4.
Lane 9: Urine sample from an intact male dog with proteinuria. Glomerular score = 0 (although the albumin band is slightly 
darker than typically expected for a normal dog, it is faint and likely secondary to tubular damage); Tubular score = 3.
* denotes prostatic fluid proteins.
+ denotes 24-25.5 kDa protein band. 
Black arrow denotes Tamm-Horsfall Protein band.
Red arrow denotes albumin band.
kDa, kilodalton; HMW, high molecular weight; LMW, low molecular weight.
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Survival Data
Primary and referring veterinarians and owners were contacted between 2 
months to up to 8 years post-biopsy at multiple intervals to obtain information regarding 
the dog’s health status following renal biopsy. At the point when the dog was deceased, 
the amount of time to death post-biopsy, type of death (spontaneous versus humane 
euthanasia), and cause of death or decision to euthanize (e.g., renal disease progression) 
were recorded.
Statistical Analysis 
Prediction of Glomerular and Tubular Damage
Sensitivities, specificities, and accuracy were calculated for the ability of 
glomerular gel scores, UPC ≥ 0.5, UPC ≥ 1, and UPC ≥ 2 to predict the presence of 
glomerular damage when either an LM or TEM glomerular damage score > 0 was set as 
the gold standard for presence of glomerular damage. Sensitivities, specificities, and 
accuracy were also calculated for the ability of tubular gel scores, SCr ≥ 1.4 mg/dL, and 
SCr ≥ 1.4 mg/dL + USG < 1.035 to predict the presence of TI damage when a score > 0 
for any of the individual TI damage scores (fibrosis, atrophy, degeneration, chronic 
inflammation) was set as the gold standard for presence of TI damage. Accuracy was 
calculated as: (number of true positives + number of true negatives) / (total number of 
tests). 
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Gel Score and Biomarker Correlations
To determine if the gel scores were correlated with the biopsy damage scores, 
pairwise polychoric correlation analysis was used to estimate the correlation between 
glomerular gel scores and LM and TEM glomerular damage scores and between tubular 
gel scores and the individual TI damage scores. Additionally, pairwise polychoric 
correlation analysis was used to estimate the correlation between the LM and TEM 
glomerular damage scores. Polychoric correlation analysis estimates the correlation 
between 2 theorized normally distributed continuous latent variables from two observed 
ordinal variables.168 Principal component analysis was performed on all of the individual 
TI biopsy scores to generate a composite score, and polychoric correlation analysis was 
performed between the tubular gel score and the composite TI biopsy score. Finally, to 
investigate the overall association between a single composite gel score and a single 
composite biopsy score, canonical correlation analysis was performed based on the 
polychoric correlation matrix. Canonical correlation analysis is a multivariate statistical 
analysis method that assesses the correlation between two sets of data.169 Correlation 
strength for all analyses was defined as: weak: r = 0.0 – 0.39; moderate: r = 0.4 – 0.69; 
or strong: r = 0.7 – 1.0. 
Survival Analysis
For the glomerular and tubular gel scores, LM and TEM glomerular biopsy 
scores and the TI biopsy scores, UPC, sCr, and presence of LMW bands at 
approximately 21 kDa (range: 20.73-21.66 kDa), 15 kDa (range: 15.11-15.77 kDa), 12 
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kDa (range: 12.07-12.78 kDa), and 10 kDa (range: 9.96-10.60 kDa), Cox proportional 
hazard regression models (accounting for the biomarker or score and age as covariates) 
were used to evaluate the relationship between each variable and the hazard ratio (HR) 
or relative risk of death due to renal disease post-biopsy using all follow-up data 
obtained (n = 117 dogs). For variables with significant HRs, the median time to death 
post-biopsy due to renal disease was determined for different cutoff values of each 
variable. 
The ability of gel scores to predict glomerular and TI damage and risk of 
death/survival time analysis was performed using Stata version 11ee, setting P < 0.05. 
Gel score and biomarker correlations were performed in R version 3.2.2 using the 
polycor package 0.7-8ff.
Results
CKD Dogs
Urine supernatant and kidney biopsy and necropsy tissue were submitted and 
initially analyzed from 254 dogs with renal disease. Urinalyses were performed on the 
submitted urine samples by the referring veterinarians or on a sample within 4 weeks of 
biopsy collection in 71% of these cases, of which 30 dogs (16.7%) had hematuria, 4 
dogs had pyuria/bacteriuria (2.22%), and 10 dogs had both hematuria and 
pyuria/bacteriuria (5.55%). These 44 dogs were excluded from the study leaving 210 
ee Stata Version 11, Stata Corp. LP, College Station, TX
ff R version 3.2.2; Polycor package version 0.7-8
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dogs for further analysis. Of the 210 remaining dogs, 92 (43.81%) were spayed females, 
70 (33.33%) were neutered males, 29 (13.81%) were intact males, and 19 (9.05%) were 
intact females. While a variety of breeds were represented, Labrador Retrievers/ 
Labrador Retriever-mixes were the most common (11.92%). Additionally, a broad range 
of ages (2 months-14 years) was represented, and the median age was 6.5 years. 
Outcome/prognostic information was collected post-biopsy for 117 (56%) of the 
dogs included in the analysis. Fifty-eight dogs died or were euthanized due to renal-
related causes with a median time to death following biopsy (excluding 6 necropsy 
samples) of 183 days (range: 2 – 1,460 days). 
Kidney disease was determined to be present based on persistent proteinuria in 
102 dogs (48.6%), azotemia in 22 dogs (10.5%), and both proteinuria and azotemia in 86 
dogs (41.0%). Based on known timeframe of disease symptoms and/or presence of 
chronicity on ultrasound or renal histology, CKD was confirmed for 189 (90%) dogs. Of 
the remaining 21 dogs, 8 had evidence of AKI either alone (3 dogs) or concurrently with 
CKD (5 dogs) while 13 were of unknown duration.
Healthy Dogs
Urine supernatant was collected from 18 healthy client-owned dogs, and urine 
supernatant and kidney biopsy tissue was used from 3 healthy control dogs from the 
XLHN colony. Of these 21 control dogs, 10 dogs (48%) were excluded based on 
hematologic, biochemical, or urinalysis results outside of the laboratory reference 
ranges, leaving 11 control dogs for further analysis. 
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Of the 11 remaining control dogs, there were 4 (36.36%) spayed females, 3 
(27.27%) neutered males, and 4 (36.36%) intact males. The control dogs were composed 
of the following breeds: 6 (54.55%) Labrador Retriever/ Labrador Retriever mixes; 2 
(18.18%) Border Collie/ Border Collie mixes; 1 (9.09%) German Shepherd; 1 (9.09%) 
Catahoula Leopard dog mix; and 1 (9.09%) Golden Retriever mix. The median age of 
the control dogs was 5 years (range: 9 months-10 years). 
Histopathologic Findings and Scores
The number of cases assigned glomerular and TI biopsy damage scores was less 
than the entire set of dogs in the study either due to limited quality of biopsy tissue that 
could be used for scoring or because a histologic diagnosis was achieved based on LM 
and continued analysis by TEM was cancelled by the referring veterinarian. Most dogs 
in the study had at least moderate glomerular damage (score ≥ 2) on both LM and TEM 
(Table 11). In contrast, TI damage was more limited in these samples, with most cases 
receiving damage scores < 2 (normal to mild damage), with few cases receiving a score 
≥ 3 (Table 11).
Gel Electrophoresis
Gels from the 11 clinically normal, non-proteinuric (control) dogs consistently 
displayed a minimal/faint protein band at approximately 55 kDa, in line with the 
albumin standard19-26 and a faint band at approximately 100 kDa, consistent with Tamm-
Horsfall protein.22 All female control dogs and neutered male control dogs displayed no 
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bands in the tubular region. Intact male control dogs displayed 3 slightly prominent 
protein bands in the tubular region at 26-27 kDa, 15-16 kDa, and 8-9.5 kDa, likely 
consistent with prostatic fluid protein bands20,30,170-172 similar to those in Figure 18. 
Gels from the CKD dogs displayed a variety of glomerular and tubular urine 
protein banding patterns, with numbers and intensities of bands varying dramatically. 
Using the developed scoring criteria (Tables 9 and 10), the most frequent glomerular gel 
score was moderate (score = 2), which was similar to the biopsy scores. In contrast to the 
biopsy scores, most tubular gel scores were mild and moderate (score = 2 and 3) (Table 
11). Figure 19 demonstrates that cases with primary glomerular disease had median 
glomerular gel scores and LM and TEM glomerular biopsy scores that were higher than 
cases with primary tubular disease. Medians for averaged TI biopsy scores (averages of 
the fibrosis, atrophy, degeneration, and chronic inflammation scores) were slightly lower 
in cases with primary glomerular versus primary tubular disease, while median tubular 
gel scores were actually higher in cases with primary glomerular versus tubular disease. 
To determine repeatability of the gel electrophoresis method, each of 3 gel runs 
was analyzed both by determining the total number of protein bands detected in each 
sample as well as visual scoring for glomerular and tubular damage. For the total number 
of bands present between runs for individual samples, a CV% of < 10% was achieved 
for all but one sample; the remaining sample had a CV% of 11.2%. Based on visual 
examination, no major differences in the number or intensity of bands were seen among 
the repetitions. Additionally, using the developed gel scoring system (Tables 9 and 10), 
each sample received the same glomerular gel score and all but one received the same 
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tubular gel score at each repeat. For one run of this individual sample, a slightly higher 
tubular gel score was assigned; however, this likely reflects differences in subjective 
scoring rather than true differences in banding patterns, band numbers, and/or band 
intensity. 
Sensitivity and Specificity of Gel Scores for Detection of Glomerular and TI Damage
Using presence of glomerular damage on LM or TEM as the gold standard, 
sensitivities and specificities of a glomerular gel score ≥ 1 and a UPC ≥ 0.5, ≥ 1, and ≥ 2 
were determined (Table 12). Greatest sensitivity was seen with a glomerular gel score ≥ 
1 (96.43%), while all analyses had 100% specificity for glomerular damage. Similarly, 
histologic TI damage was used to determine sensitivities and specificities of a tubular gel 
score ≥ 1, sCr  ≥ 1.4 mg/dl, and combined sCr ≥ 1.4 mg/dl and USG ≤ 1.035 (Table 13). 
All analyses had 100% specificity for presence of tubular damage, but highest sensitivity 
was observed with a tubular gel score ≥ 1 (89.34%) whereas sensitivities for sCr ≥ 1.4 
mg/dl and combined sCr ≥ 1.4 mg/dl and USG ≤ 1.035 were poor.
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Table 11. Numbers/frequency of cases in each gel score and biopsy score category. Gel scores and glomerular biopsy scores 
followed an ordinal scoring system. Tubular/tubulointerstitial biopsy scores followed a continuous scoring system.
Score 0 Score 1 Score 2 Score 3 Score 4
Glomerular Gel Score
N = 221
24 (10.9%) 22 (10.0%) 101 (45.7%) 74 (33.5%) N/A
Tubular Gel Score
N = 221
32 (14.5%) 32 (14.5%) 70 (31.7%) 60 (27.2%) 27 (12.2%)
Glomerular Biopsy Score: Light Microscopy 
N = 201
18 (9.0%) 53 (26.4%) 83 (41.3%) 47 (23.4%) N/A
Glomerular Biopsy Score: Transmission Electron 
Microscopy 
N = 171
4 (2.3%) 41 (24.0%) 77 (45.0%) 49 (28.7%) N/A
Score 0-<1 Score 1-<2 Score 2-<3 Score 3-<4 Score 4-<5 Score ≥5
Tubulointerstitial Fibrosis Biopsy Score
N = 200
103 (51.5%) 46 (23.0%) 30 (15.0%) 15 (7.5%) 5 (2.5%) 1 (0.5%)
Tubular Atrophy Biopsy Score
N = 200
175 (87.5%) 21 (10.5%) 4 (2.0%) N/A N/A N/A
Tubular Degeneration Biopsy Score
N = 197
98 (49.8%) 56 (28.4%) 31 (15.7%) 12 (6.1%) N/A N/A
Tubulointerstitial Chronic Inflammation Biopsy 
Score
N = 199
123 (61.8%) 65 (33.7%) 11 (5.5%) N/A N/A N/A
N/A, not applicable.
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Figure 19. Boxplots representing the range of gel and biopsy scores, with cases 
categorized as primary glomerular or primary tubular disease. LM, light microscopy; 
TEM, transmission electron microscopy; TI, tubulointerstitial. Average TI score 
represents the average of the 4 component scores for TI damage (fibrosis, atrophy, 
degeneration, and chronic inflammation)
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Table 12. Ability of glomerular gel scores ≥ 1 and UPC ≥ 0.5, 1, and 2 to predict 
glomerular damage based on light and electron microscopic analysis of renal biopsies.
Sensitivity Specificity Accuracy PPV NPV
Glomerular Gel Score ≥ 1 96.43% 100.00% 96.47% 100.00% 25.00%
UPC ≥ 0.5 92.61% 100.00% 92.70% 100.00% 13.00%
UPC ≥ 1 88.64% 100.00% 88.76% 100.00% 9.5%
UPC ≥ 2 80.11% 100.00% 88.76% 100.00% 5.7%
UPC, urine protein:creatinine; PPV, positive predictive value; NPV, negative predictive 
value.
Table 13. Ability of tubular gel scores ≥ 1, sCr ≥ 1.4 mg/dl, and combined sCr ≥ 1.4 
mg/dl and USG ≤ 1.035 to predict tubulointerstitial damage based on light microscopic 
analysis of renal biopsies.
Sensitivity Specificity Accuracy PPV NPV
Tubular Gel Score ≥ 1 89.34% 100.00% 89.50% 100.00% 5.00%
sCr ≥ 1.4 mg/dl and
USG ≤ 1.035
51.49% 100.00% 52.20% 100.00% 1.3%
sCr ≥ 1.4 mg/dl 58.91% 100.00% 59.51% 100.00% 1.2%
sCr, serum creatinine; USG, urine specific gravity; PPV, positive predictive value; NPV, 
negative predictive value.
Correlations of Gel Scores with Severity of Glomerular and TI Damage 
Figure 20 displays the r-values for the pairwise polychoric correlations between 
pairs of gel and biopsy scores. The highest r-values were found for the correlation 
between the glomerular gel score and the TEM glomerular biopsy score (r = 0.68), 
followed by the correlations between the LM and TEM glomerular biopsy scores (r = 
0.64) and between glomerular and tubular gel scores (r = 0.57). The glomerular gel score 
was less correlated with the LM glomerular biopsy score (r = 0.43), and the tubular gel 
score correlated only weakly to moderately with the different TI biopsy scores. The 
polychoric correlation between the tubular gel score and the composite TI biopsy score 
124
was also only moderate (r = 0.42). Standard errors for all polychoric correlations ranged 
from 0.05 for the highest correlations to 0.09 for the lowest correlations (data not 
shown). The canonical correlation analysis between the composite gel and biopsy scores 
found a strong correlation (r = 0.73), including between both glomerular and tubular 
damage scores within the same case (data not shown). Further analysis of the canonical 
loading vector coefficients revealed that this composite correlation was primarily due to 
the correlation between the glomerular gel scores and TEM biopsy scores, confirming 
that these two scores play major parts in capturing the overall association between the 
gel scores and the biopsy scores.
Figure 20. Pairwise polychoric correlation analysis between each of the gel and biopsy 
scores. LM, light microscopy; TEM, transmission electron microscopy; TI, 
tubulointerstitial. The X-axis indicates the strength and sign of the correlations. White 
colors indicate lack of correlation. Light to dark red colors indicate weak to strong 
negative correlations. Light to dark blue indicate weak to strong positive correlations.
b.
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Survival Analysis
 Cox proportional hazard models were generated to determine if glomerular and 
tubular gel scores, presence of tubular bands at 21, 15, 12, and 10 kDa, LM and TEM 
glomerular biopsy scores and individual TI biopsy scores, and UPC and sCr were 
associated with an increased risk of death occurring due to renal disease post-biopsy. 
LM glomerular biopsy score, tubular gel score, TI fibrosis score, tubular degeneration 
score, presence of bands at 10 and 15 kDa, sCr, and UPC were all significantly 
associated with an increased risk (increased HR) of death due to renal disease when age 
was included as a covariate (Table 14). Presence of a band at 10 kDa had the highest HR 
of 2.70, translating to a 2.7:1 odds of a shorter survival time in dogs with a 10 kDa band 
versus those without it. Similarly, presence of a LMW band at 15 kDa had an HR of 1.96 
and the tubular gel score had an HR of 1.65, and thus the odds of a shorter survival time 
in each situation is 1.96:1 and 1.65:1. Of note, for most of the clinical variables, age was 
a significant covariate when determining relative risk of death due to renal disease. 
Using the Cox survival models, figures 21-24 illustrate the probability of survival for a 
dog of median age at different starting values of the biomarkers and biopsy/gel scores 
that had a P-value < 0.01 (including the glomerular LM biopsy score, tubular gel score, 
tubular fibrosis score, and sCr).
For each of the variables with significant HRs from the Cox proportional hazard 
models, meaningful cutoff values were determined and the median number of days to 
death due to renal disease post-biopsy was calculated for these cutoff values (Table 15). 
For example, an LM glomerular biopsy score of 0-1 had a median time to death of 634 
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days, while an LM glomerular biopsy score of 2-3 had a median time to death of 139 
days. All biomarkers and scores had a longer time to death for the “lower” cutoff 
category, except for UPC below 2.0, which had a slightly shorter median time to death 
than a UPC ≥ 2.0. 
Table 14. Relative risk (hazard ratios) of death due to renal disease in dogs using 
multivariate Cox survival models for selected biomarkers and biopsy or gel scores 
including age as a covariate. The unit of increase for each biomarker or score and age is 
noted in parentheses in the first column. Each row depicts a separate survival model that 
includes 2 covariables (biomarker or score and age).
N HR for Score/Biomarker HR for Age
Biomarker or Biopsy/Gel Score + Age (1 year) HR (95% CI) P-value HR (95% CI) P-value
Glomerular LM biopsy score (1 score point) 94 1.58 (1.13-2.21) 0.008 1.09 (1.00-1.20) 0.053
Tubular gel score (1 score point) 98 1.65 (1.29-2.11) 0.000 1.10 (1.00-1.20) 0.042
TI fibrosis score (1 score point) 94 1.53 (1.17-2.01) 0.002 1.12 (1.03-1.23) 0.011
Tubular degeneration score (1 score point) 94 1.44 (1.05-1.98) 0.023 1.09 (1.00-1.19) 0.056
Presence of band at 10 kDa 98 2.70 (1.18-6.17) 0.019 1.11 (1.01-1.22) 0.024
Presence of band at 15 kDa 98 1.96 (1.10-3.49) 0.023 1.11 (1.02-1.22) 0.022
UPC (1 unit) 98 1.05 (1.01-1.09) 0.015 1.11 (1.01-1.21) 0.035
sCr (1 mg/dL) 96 1.37 (1.23-1.52) 0.000 1.13 (1.03-1.25) 0.011
HR, hazard ratio; CI, confidence interval; LM, light microscopy; TI, tubulointerstitial; 
kDa, kilodalton; UPC, urine protein:creatinine; sCr, serum creatinine.
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Table 15. Median days to death due to renal disease post-biopsy for selected scenarios as 
based on significant findings from Cox survival models.
Scenario N Days to Death due to Renal Disease
Median (Range)
Glomerular LM biopsy score: 0-1 11 634 (3-1460)
Glomerular LM biopsy score: 2-3 41 139 (2-1190)
Tubular gel score: 0-2 21 259 (3-1460)
Tubular gel score: 3-4 31 122 (2-1190)
TI fibrosis score: < 3 43 244 (2-1460)
TI fibrosis score: ≥ 3 9 22 (3-758)
Tubular degeneration score: < 2 37 259 (2-1460)
Tubular degeneration score:  ≥ 2 15 46 (3-634)
No band at 10 kDa 45 214 (2-1460)
Presence of band at 10 kDa 7 22 (3-365)
No band at 15 kDa 33 244 (2-1460)
Presence of band at 15 kDa 19 122 (2-1190)
UPC < 2.0 6 164 (3-1285)
UPC ≥ 2.0 46 183 (2-1460)
sCr < 1.4 16 192 (2-1460)
sCr ≥ 1.4 36 42 (2-1285)
LM, light microscopy; TI, tubulointerstitial; kDa, kilodalton; UPC, urine 
protein:creatinine; sCr, serum creatinine.
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Figure 21. Probability of survival for a dog at median age (7 years) at different light 
microscopy (LM) glomerular damage scores. 
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Figure 22. Probability of survival for a dog at median age (7 years) at different tubular 
gel scores.
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Figure 23. Probability of survival for a dog at median age (7 years) at different tubular 
fibrosis scores. 10p: 10th percentile; 25p: 25th percentile; 50p: 50th percentile; 75p: 75th 
percentile; 90p: 90th percentile.
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Figure 24. Probability of survival for a dog at median age (7 years) at different starting 
values of serum creatinine (sCr). 10p: 10th percentile; 25p: 25th percentile; 50p: 50th 
percentile; 75p: 75th percentile; 90p: 90th percentile.
Discussion
This study evaluated glomerular and tubular urine protein banding patterns and 
gel scores generated from Bis-Tris gel electrophoresis run on urine samples from 210 
dogs with renal disease (predominantly proteinuric CKD) and 11 healthy, non-
proteinuric dogs. Glomerular gel scores had excellent sensitivity and specificity for 
detection of glomerular damage, and tubular gel scores had good sensitivity and 
excellent specificity for detection of TI damage when the presence of histologic 
glomerular and TI damage were set as the gold standards in the respective analyses. 
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There was a strong correlation between all (glomerular and tubular) gel and biopsy 
scores. Glomerular gel scores were moderately correlated with severity of glomerular 
damage as assessed by LM and moderately (approaching strongly) correlated with 
glomerular damage as assessed by TEM. Tubular gel scores were weakly to moderately 
correlated with the degree of TI damage on renal biopsy, depending on the component of 
TI damage assessed (fibrosis, atrophy, degeneration, or chronic inflammation), with 
tubular degeneration having the highest correlation with tubular gel scores. LM 
glomerular biopsy, tubular gel, TI fibrosis, and tubular degeneration scores, presence of 
bands at 10 and 15 kDa, sCr, and UPC were all significantly associated with an 
increased risk of an earlier death due to renal disease. Our findings support that Bis-Tris 
gel electrophoresis of canine urine can predict presence of glomerular and tubular 
damage and gel scores might be useful to inform severity of such damage and prognosis 
in dogs with proteinuric kidney disease. 
 The few small differences observed in the gel scores on inter-run analysis could 
be explained by subjectivity of the scoring, particularly given that the scoring 
incorporated band intensity, and user experience influenced several factors that 
contributed to the analysis. For that reason, as objective a scoring system as possible was 
defined and associated with an example gel image to help enhance future scoring 
reproducibility. Although use of the glomerular and tubular gel scoring algorithm 
generally provided repeatable results in this study, it could not eliminate disagreement in 
scoring the degree of glomerular and tubular proteinuria. In the future, methods to 
develop a more objective scoring system could be considered. 
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In our experience evaluating urine protein banding patterns, we have appreciated 
several clinical factors that must be considered when scoring gels, including the presence 
of renal maldevelopment, neutering status, hematuria, pyuria, and minimally proteinuric 
samples. Renal maldevelopment usually presents with mild proteinuria, and much of the 
kidney is no longer producing urine. Consequently, the gel banding patterns do not 
reflect the severity of the kidney histology in these cases. Intact males often have protein 
bands at approximately 8-9.5 kDa, 15-16 kDa, and/or 26-27 kDa (Figure 25). These 
bands are thought to be prostatic fluid proteins, one of which has previously been 
determined to be arginine esterase.20,30,170-172 These prostatic fluid protein bands vary in 
intensity or sometimes are not present at all in intact males. Because the bands migrate 
into the LMW region of the gel they can confound assessment of tubular damage if not 
accounted for. Marked hematuria can result in a slightly hazy or smudged LMW band at 
approximately 14 kDa and an increased number of IMW and HMW bands, especially 
above 200 kDa (Figure 25). Similar to hematuria, pyuria increases the number of LMW, 
IMW, and possibly HMW bands (Figure 25). Therefore, presence of either hematuria or 
pyuria could alter both glomerular and tubular gel scores. Because of this, samples with 
evidence of active urine sediments were excluded from analysis in this study. Minimally 
proteinuric samples tend to have protein bands that are faint on the gels after staining, 
which makes analysis difficult. To combat this, minimally to mildly proteinuric samples 
(UPC < 1) are diluted according to the USG but are also run without diluting the urine, 
which helps to visualize faint bands not observed when diluted based on USG. The 
staining protocol used can also alter the number and intensity of protein bands seen. 
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Figure 25. Representative urine samples from dogs with hematuria, pyuria/bacteriuria, and a normal intact male resolved 
using gel electrophoresis to demonstrate the effect of non-renal disease on urinary protein banding patterns. 
Lanes 1 and 10: Molecular weight standards.
Lanes 2 and 3: Urine sample from a healthy, non-proteinuric dog with EDTA blood spiked into the urine sample at a ratio of 
500 µl urine + 1 µl whole EDTA blood. A prominent hemoglobin band at approximately 14 kDa is the classic feature of 
hematuria. Additional LMW, IMW, and HMW proteins can be identified that were not present prior to addition of whole 
blood. The urine sample was diluted based on USG in lane 2 but was not diluted in Lane 3, in which bands are more 
prominent.
Lanes 4 and 5: Urine samples from a proteinuric dog with glomerular and tubular proteinuria. The sample in lane 5 was 
collected immediately post-biopsy while the sample collected nearly 2 weeks later (lane 4) had an inactive urine sediment. 
The 14 kDa hemoglobin band and several additional HMW proteins are evident in the sample in lane 5.
Lanes 6 and 7: Urine sample from an otherwise clinically healthy dog with a urinary tract infection (both pyuria and 
bacteriuria were present). The sample in lane 6 was diluted based on USG and, although difficult to appreciate in the digital 
image, demonstrated faint LMW, IMW, and HMW protein bands on the gel. In lane 7, the urine sample was not diluted and 
more clearly demonstrates the additional LMW, IMW, and HMW protein bands that can be seen with urinary tract infections.
Lanes 8 and 9: Urine sample from a healthy intact male dog. The sample in lane 8 was diluted based on USG and 
demonstrates faint LMW protein bands at approximately 9 kDa, 15 kDa, and 26 kDa, consistent with prostatic fluid proteins. 
The sample was not diluted in lane 9, demonstrating more clearly the prominent prostatic fluid proteins bands. 
* denotes hemoglobin protein band. 
+ denotes prostatic fluid proteins. 
{ denotes LMW bands seen with pyuria/bacteriuria. 
kDa, kilodalton; HMW, high molecular weight; LMW, low molecular weight; USG, urine specific gravity.
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Although silver staining has been used in several studies assessing proteinuria and renal 
damage in humans, dogs, and rats,21,28,163 we opted to use a Coomassie-based stain that is 
highly sensitive, detecting as little as 3 to 6 ng of protein according to the manufacturer. 
Silver staining is also highly sensitive,173 but unlike Coomassie-based stains, band 
intensity on silver stain is an unreliable indicator of the amount of protein in the urine. 
Furthermore, silver staining is technically more difficult to perform than Coomassie-
based staining. 
The sensitivity and specificity of the glomerular gel scores for glomerular 
damage were both excellent, and the sensitivity was greater than that for any of the UPC 
cutoffs considered (≥ 0.5, 1, or 2) for detecting glomerular damage. UPC ≥ 2 is often 
considered to be a marker of glomerular damage;12,124 however, presence of glomerular 
damage will certainly be missed in some cases if UPC ≥ 2 is used as the criteria for 
glomerular damage and a renal biopsy is not obtained. Therefore, in cases where a renal 
biopsy is not feasible, performing Bis-Tris gel electrophoresis on a urine sample might 
provide additional support for presence of glomerular damage, particularly in urine 
samples with minimal to mild proteinuria. Similarly, the sensitivity and specificity of the 
tubular damage score for detection of TI damage were good and excellent, respectively, 
and the sensitivities were higher than those for either a sCr ≥ 1.4 mg/dL or sCr ≥ 1.4 
mg/dL + USG < 1.035, which are commonly used parameters of biomarkers to predict 
presence of tubular insult. This supports that use of sCr ≥ 1.4 mg/dL is insensitive for 
detecting tubular damage in dogs. Of important note, nearly all clinical cases had at least 
minimal to mild glomerular and tubular damage; thus, when calculating specificity for 
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all variables, there were very few true negatives and no false positives which caused 
specificity to be 100%. It is possible that this high specificity would not be accurate in 
another population, and therefore, additional studies to verify specificity of the gel 
scoring system are needed.
Despite the high sensitivities and specificities for glomerular and tubular gel 
scores for detection of glomerular and TI damage, the gel scores were each only 
moderately correlated with severity of damage based on the individual glomerular and 
TI damage scores as determined on biopsy. The glomerular gel score had the highest 
correlation with the glomerular biopsy score based on TEM, which approached a strong 
correlation. This is in contrast to the correlation of the glomerular gel score with the 
glomerular biopsy score based on LM, which was nearing a weak correlation. This 
suggests that the glomerular protein banding pattern is more indicative of the degree of 
damage to the glomerular basement membrane ultrastructure. Certainly, it is expected 
that even minimal changes to the glomerular basement membrane and podocytes could 
result in altered protein filtration but might not be detectable on LM. One theorized 
reason that the severity of proteinuria as assessed on gel electrophoresis is not more 
consistent with the severity of glomerular damage on biopsy is that in cases with marked 
sclerosis of glomeruli, sclerotic glomeruli might not contribute to protein filtration 
whereas glomeruli with a lesser degree of damage are still able to contribute to urine 
production.
The modest correlation of the tubular gel score with the individual or composite 
TI damage scores on biopsy was expected. Many factors contribute to the number of 
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bands present in the LMW protein region besides decreased reabsorption of LMW 
proteins by damaged tubular epithelial cells. It is theorized that glomerular proteinuria, 
especially when marked, contributes to the number of tubular protein bands due to heavy 
and light chains of HMW proteins migrating in the LMW region23-25 and due to overload 
proteinuria resulting in competition of proteins for endocytic receptors and prevention of 
complete reabsorption of LMW proteins by functional tubular epithelial cells.15 Indeed, 
tubular gel scores often overestimated the degree of TI damage, and this discrepancy 
between gel and biopsy scores can be seen in Table 11 and Figure 19. Conversely, TI 
damage can demonstrate a patchy distribution throughout the kidney, in which case a 
biopsy can either under- or over-estimate the overall severity of TI damage. In these 
cases, the gel score can actually be more representative of overall kidney damage. 
Additionally, it is possible that only minimal to mild TI damage on LM is needed to 
cause functional tubular changes as represented by a decreased ability to reabsorb 
proteins. This would also help explain the discrepancy between the gel and biopsy 
scores.
The survival analysis results in this study were interesting. While the tubular gel 
score and sCr were both associated with an increased risk of death due to renal disease, 
the hazard ratio was greater for the tubular gel score than for sCr. The use of the tubular 
gel score for assessment of prognosis might be useful in addition to monitoring sCr, 
especially in cachectic patients or those with limited muscle mass, given the predilection 
of sCr for overestimation of glomerular filtration rate in such patients.174 Based on 
previous studies that have determined the association of specific LMW protein bands 
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with severe TI damage,26,28 we were interested in the association of these particular 
bands with survival in this cohort of dogs. The presence of a band at 10 or 15 kDa was 
significantly associated with increased risk of death due to renal disease, and in fact, a 
band at 10 kDa had the highest HR noted for any biomarker or score evaluated in the 
survival analysis. Furthermore, there was a difference in median survival time of 
approximately 6 months between dogs with and without a 10 kDa band. It is important, 
however, to note the differences in methodologies between this and previous studies and 
that proteins might run at slightly different molecular weights on different types of gels. 
Therefore, further investigation is needed into the ability to use specific urinary protein 
bands on Bis-Tris gel electrophoresis as markers of prognosis in dogs with CKD. 
The finding that UPC was significantly, albeit barely, associated with an 
increased risk of death due to renal disease is in line with findings from a previous study 
by our group as well as a report of the prognostic ability of UPC and the association of a 
UPC ≥ 1.0 at initial evaluation with increased risk of uremic crisis or death in azotemic 
dogs with CKD.12,126 However, when examining median survival times in dogs with 
UPC above or below 2.0, there was actually a slightly shorter survival time in dogs with 
the lower UPC values. This is likely due to the low number of cases in the study that had 
minimal to mild proteinuria and that also had outcome data available, and thus it is 
possible that these results are not completely accurate and should be reconsidered with a 
larger population of dogs with more outcome data. Furthermore, dogs with 
maldevelopment or juvenile onset CKD or dogs with marked TI disease can have 
minimal proteinuria but faster onset of renal failure and time to death, and the inclusion 
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of these cases likely contributed to the shorter survival time in dogs with UPCs below 
2.0.  Finally, in all evaluations performed, age as a covariate was significantly associated 
with an increased risk of death, and thus, increasing age, not surprisingly, contributes to 
an increased likelihood of death due to renal disease.
High reproducibility was observed for the method of urine gel electrophoresis 
described in this study, with both consistent scoring and numbers of protein bands 
generated for individual samples between runs. The few small differences in the total 
number or intensity of protein bands on inter-run analysis of an individual sample can be 
attributed to: ‘spill over’ from one sample into adjacent lanes because of the high protein 
content; under- or over-staining of the gel; and operator error (e.g., pipetting and dilution 
errors). Due to the multitude of factors that can alter gel appearance and subsequent 
analysis of the gel, any gels that ran abnormally, had an abnormal final appearance, or 
were not suitable for scoring were repeated to obtain a suitable gel for analysis.
Several limitations were present in this study. The main objective of this study 
was to explore urine protein banding patterns in dogs with CKD that also received a 
renal biopsy. Most samples submitted were therefore from dogs that were proteinuric 
with a suspicion for glomerular, rather than tubular, disease, creating a bias for cases 
with predominantly glomerular damage. Despite this, a broad range of tubular damage 
scores was assessed in the study. In future studies, it will be important to determine 
sensitivity and specificity of Bis-Tris gel electrophoresis for detection of TI damage in a 
cohort with greater numbers of cases with primary tubular damage. 
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Although the sample size in this study was large, there are several factors that 
might impact the measure of correlation. First, there were only a few (3) biopsy scores 
available for normal canine kidney samples, and these were all analyzed only by LM. 
Thus, there are very few cases with a LM biopsy score of 0 and no cases with a TEM 
biopsy score of 0. Because the correlation analyses were based on predominantly non-
normal samples, this causes a downward bias and a smaller correlation value. Canonical 
correlation analysis for correlation of composite biopsy and gel scores was performed 
only for cases that had all biopsy scores available. However, there were several dogs that 
had an LM but not a TEM biopsy score. In many cases, this occurred because the 
diagnosis was confirmed with LM, and TEM was not deemed necessary by the 
submitting clinician (e.g., amyloidosis). Thus, the exclusion of such cases was not 
random and might have altered the correlation of the composite scores. 
Another limitation of this study is that while most urine samples had a 
corresponding urinalysis with sediment analysis, several cases lacked this information. 
Most samples were collected at referral veterinary centers that ideally minimized the 
likelihood of sediment abnormalities. We were also very strict in our criteria of 
exclusion of cases with evidence of hematuria and/or pyuria/bacteriuria; however, it is 
possible that cases with minimal hematuria or pyuria/bacteriuria were unknowingly 
included. Despite this, the number of additional protein bands that are generated with 
hematuria or pyuria/bacteriuria are limited when based on USG and particularly 
compared with the overwhelming renal proteinuria observed in most cases, and therefore 
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it is unlikely that significant changes in glomerular or tubular gel scores would have 
occurred even with the inadvertent inclusion of cases with active urinary sediments. 
Finally, for purposes of survival analysis, the inclusion of dogs that were 
euthanized is difficult to avoid in veterinary medicine and might skew survival times. 
However, the inclusion of dogs that were euthanized replicates the situation seen in the 
clinical setting and therefore is reasonable.
In conclusion, evaluation of urine samples using Bis-Tris gel electrophoresis 
cannot replace a well collected and analyzed renal biopsy; however, it can complement 
renal biopsy evaluation and may provide a method to assess for presence and degree of 
glomerular and TI damage in renal cases where biopsy is not feasible and there is 
question as to the renal compartment involved. Additionally, while further exploration 
into the association with prognosis is needed, protein banding patterns, particularly 
tubular banding patterns, may inform prognosis.
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CHAPTER V 
CONCLUSIONS 
Evaluation of the degree and type of proteinuria in dogs with CKD can better 
characterize the location and severity of renal disease and predict prognosis. As 
discussed in the introduction, many studies have evaluated proteinuria in its many forms 
(including measurements of UPC and specific proteins in the urine in healthy versus 
CKD dogs), but few before now have considered a panel of urinary protein biomarkers 
as indicators of the actual degree of renal damage, cause of CKD, and prognosis in a 
large group of dogs with naturally occurring CKD. 
The primary goal of Chapter II was to determine if selected novel (IgG, IgM, 
RBP, NGAL, and NAG) and conventional (UPC, sCr, and USG) biomarkers can inform 
clinicians of the severity of glomerular and TI damage as compared to histology. 
Additional goals of this chapter were to determine if these biomarkers are associated 
with specific causes of CKD or prognosis in dogs. Several novel and conventional 
urinary biomarkers and their fractional excretions were found to correlate with the 
severity of glomerular and/or TI damage. In particular, the HMW proteins IgG and IgM 
were better correlated with degree of glomerular damage than UPC, while uNAG/c, a 
marker of tubular damage in AKI, was not correlated with TI damage but was correlated 
with glomerular damage in this study. This raises the question of the clinical utility of 
uNAG/c to indicate tubular damage in cases of canine proteinuric CKD. Furthermore, 
increased uIgM/c and uNAG/c were significantly associated with ICGN, and sCr, 
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IgM_FE, and TEM glomerular damage scores were highly associated with an increased 
risk of death due to renal-related causes. The findings in this first study demonstrate that 
novel urinary biomarkers can support the presence of glomerular or TI damage, help 
predict the presence of ICGN, and inform prognosis in dogs with CKD.
Chapter III served as a follow-up study to Chapter II with the goal of further 
exploring the ability of novel and conventional biomarkers to segregate healthy dogs 
from those with ICGN and non-ICGN causes of CKD, to segregate dogs with different 
forms of ICGN, to predict ICGN in dogs, and to inform prognosis in dogs with ICGN. 
Novel and conventional biomarkers were found to be significantly greater in dogs with 
ICGN or non-ICGN than in healthy dogs, and UPC and uIgM values separate healthy 
dogs from dogs with ICGN. Furthermore, UPC and urinary IgM and NAG were all 
significantly higher in dogs with ICGN compared to dogs with non-ICGN causes of 
renal disease. uIgM demonstrated the greatest ability to detect ICGN, particularly in 
azotemic dogs, and high cutoff values for uIgM or uIgM/c had specificities for ICGN 
above 90%. Thus, in dogs with CKD in which renal biopsy is not feasible, assessment of 
non-invasive urinary biomarkers might provide enough evidence of ICGN to begin a 
closely monitored trial of immunosuppressant drugs. Similar to our study in Chapter II, 
IgM_FE was significantly associated with an increased risk of death due to renal disease, 
confirming the use of this marker as an indicator of prognosis in a larger population of 
dogs. The findings in this second study support the hypothesis that urinary biomarkers 
might be useful to distinguish dogs with ICGN from other causes of proteinuric renal 
disease. 
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The goal of Chapter IV was to evaluate electrophoretic urine protein banding 
patterns from healthy dogs and dogs with proteinuric CKD to determine if banding 
patterns could identify glomerular and/or TI damage and categorize the severity of 
damage as compared with renal biopsy results. Additionally, similar to Chapters II and 
III, we sought to determine if urine protein banding patterns could inform prognosis in 
dogs. This study generated an objective system for scoring the degree of glomerular and 
tubular proteinuria on electrophoretic gels and found that the glomerular and tubular gel 
scores had good to excellent sensitivity and excellent specificity for detection of 
glomerular and/or TI damage. While correlations between gel and biopsy damage scores 
were generally moderate when glomerular or TI compartments were considered 
individually, there was a strong correlation between all (glomerular and tubular) gel 
scores and all biopsy scores. Finally, tubular gel scores and the presence of a LMW band 
at 10 or 15 kDa were significantly associated with increased risk of death due to renal 
disease and shorter survival times were noted for cases with higher tubular gel scores or 
with a LMW band at 10 or 15 kDa. The findings in this study support that gel 
electrophoresis of canine urine can detect glomerular and tubular damage, and gel scores 
and banding patterns can inform prognosis in dogs with proteinuric kidney disease but 
cannot completely replace a renal biopsy for analysis of severity of renal damage. 
One of the overall goals of the studies in this dissertation was to expand on some 
of the initial exploration work in urinary protein biomarkers performed in a colony of 
dogs with XLHN that leads to juvenile onset CKD and determine the utility of these 
minimally invasive markers in dogs that were representative of a true clinical patients. 
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The results from these 3 studies are promising for the future use of conventional and 
novel urinary biomarkers and electrophoretic techniques to inform clinicians and owners 
about the severity and type of renal disease and prognosis in dogs with proteinuric CKD. 
Several future directions should be considered following these results. Exploration into 
biomarkers that are specific for glomerular disease should be considered. While several 
of the biomarkers studied for this dissertation are considered “glomerular” biomarkers, 
they are certainly not specific, and there is a push in human medicine to identify non-
invasive markers that are specific for glomerular injury. It is possible that using global 
protein, mRNA, or small RNA profiling will uncover markers that are more specific for 
different compartments of the kidney and for different etiologies of disease. 
Furthermore, while these studies identified the ability of biomarkers like urinary IgM to 
identify ICGN in dogs, prior to use in a clinical setting, measurement of urinary IgM 
should be applied in a new cohort of dogs with renal diseases to determine if the 
predictive ability remains the same and if it is influenced by or predicts responsiveness 
to therapy. A high throughput technique for the measurement of uIgM (e.g., an 
immunoassay based platform such as the Luminex singleplex or multiplex assays by 
ThermoFisher Scientific) should also be explored and the sensitivity and specificity of 
the method should be calculated to determine if uIgM will truly be useful and cost 
effective in a clinical setting. Additionally, it would be ideal to determine the 
mechanisms behind elevated urinary IgM in dogs with ICGN. One possible theory is that 
damage to the glomerular basement membrane is more severe in dogs with immune 
complex deposition such that very large proteins can be filtered through the glomerular 
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filtration barrier. Another theory is that portions of the deposited immune complexes, 
including IgM, are shed into the urine filtrate. Along these lines, it would be beneficial 
to explore proteins that are specifically related to the pathogenesis of development of 
ICGN and its different forms and to determine if they would be useful as diagnostic 
biomarkers. Thus, while these studies have generated answers to the originally posed 
hypotheses, they have also raised additional questions for future research in CKD that 
may be applicable to both veterinary and human medicine.
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APPENDIX A*
Supplemental Tables for Chapter I
Table A-1. Urinary Biomarkers of Glomerular Damage/Dysfunction in Small Animals174
Renal 
Biomarker
Location of 
Production
Type of Protein/Biomarker Validation / 
species
Values in Healthy Animals Affected in 
AKI, CKD, or 
Both
Non-Renal Influences
Albumin Hepatocytes Negative acute phase protein Dogs50 Dogs: uAlb/c: < 296.5 mg/g;20,41-43,51,64 
Alb_FE: 0%51
Cats: uAlb: 11.2 +/- 8.4 mg/dL175
AKI: Dogs40-
42,52,53 
CKD: Dogs,43-
46,50,51 cats175,176
Treatment with 
hydrocortisone (dogs)38
C-Reactive 
Protein
Hepatocytes Positive acute phase protein Dogs35,177 Dogs: uCRP/c: 1.06 µg/g;177 below 
detection limit of immunoassay35,39-42,50
AKI: Dogs35,39-
42,177 
CKD: Dogs35,177 
IgA Plasma cells in 
spleen, lymph nodes, 
bone marrow
Antibody; HMW protein Not detectable in healthy dog urine 
(Western blot)23-25
AKI: Dogs23-25
IgG Plasma cells in 
spleen, lymph nodes, 
bone marrow
Antibody; HMW protein Dogs35,37,43 Dogs: uIgG/c: < 10 mg/g35,37,39-42; in 
Dogue de Bordeaux - uIgG/c median 
(range): 1.41 (0.26-23.60) mg/g20
AKI: Dogs 23-
25,35,39-42 
CKD: 
Dogs36,37,43-46
Hematuria+; 
Pyuria/bacteriuria+; 
Treatment with 
hydrocortisone38
IgM Plasma cells in 
spleen, lymph nodes, 
bone marrow
Antibody; HMW protein Dogs36 CKD: Dogs36 Hematuria+; 
pyuria/bacteriuria+
TXB2 Glomerular mesangial 
cells and podocytes
Cycloxygenase lipid metabolite; 
marker of altered intra-renal 
hemodynamics
Dogs35 Dogs: uTXB2/c: < 4.7 µg/g35,41,42 AKI: dogs41,42
Transferrin Primarily liver; other 
tissues as well
Iron transport protein Cats: uTf: 0.09 +/- 0.42 mg/dL175 CKD: Dogs,44,45 
Cats175,176
+Personal observations
AKI, acute kidney injury; Alb_FE, fractional excretion of albumin; CKD, chronic kidney disease; HMW, high molecular weight; IgA, immunoglobulin 
A; IgG, immunoglobulin G; IgM, immunoglobulin M; TXB2, thromboxane B2; uALB, urinary albumin concentration; uALB/c, urinary 
albumin/urinary creatinine; uCRP/c, urinary C-reactive protein/urinary creatinine; uIgG/c, urinary immunoglobulin G/urinary creatinine; uTf, urinary 
transferrin concentration; uTXB2/c, urinary thromboxane B2/urinary creatinine.
* Tables A-1, A-2, and A-3 are reprinted with permission from Renal Biomarkers in Domestic Species by J. Hokamp and M. Nabity, 2016. Veterinary 
Clinical Pathology 45, 28-56, Copyright 2016 by American Society for Veterinary Clinical Pathology.
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Table A-2. Urinary Protein and Enzyme Biomarkers of Tubular Damage/Dysfunction in Small and Large Animals174
Renal 
Biomarker
Location of Production Type of 
Protein/Biomarker
Mechanism for altered excretion Validation / 
species
Values in Healthy Animals Affected in AKI, CKD, or Both Non-Renal Influences
Urinary Proteins
Clusterin Renal tubules Glycoprotein Increased production Dogs178 Dogs: uClu/c: 0.27 (unitless);178
uClu: 38.5ng/ml;178 
AKI: Dogs52,178
Cystatin C All nucleated cells LMW protein and 
proteinase inhibitor
Decreased reabsorption Dogs179 
Cats180
Cats: below limit of quantification of assay181 AKI: Dogs53
CKD: Dogs,179,182 cats180,181
Diabetes in cats181
KIM-1 Renal tubules Glycoprotein Increased production Undetectable in healthy cats183 Both, but mostly with acute 
processes 
AKI: Dogs,52 cats,183 a lamb184
NGAL Neutrophils, kidney, bronchus, 
stomach, small intestine, pancreas, 
prostate gland, thymus
LMW glycoprotein Decreased reabsorption and increased 
production
Dogs36,37,81,82 Dogs: uNGAL/c: < 6 µg/g;37,81,84 uNGAL: < 
21.2 ng/mL78,81-83,86
AKI: Dogs52,53,78,82,84-86,88,90,91,185 
CKD: Dogs36,37,78,82-84,86
Inflammation/urinary tract infection/pyuria (dogs);78,81,84 uNGAL/c decreased 
with body mass (dogs);81 Age (dogs)37,81
RBP Primarily liver; also other organs 
(kidney, lungs, spleen, brain, stomach, 
heart, skeletal muscle)
Vitamin A carrier 
protein
Decreased reabsorption Dogs35,37,63 
Cats66
Dogs: uRBP/c: < 0.15 mg/g;20,35,37-43,46,50,51,65 
Cats: Undetectable66 Sheep: Undetectable186
AKI: Dogs,35,40,42,69 sheep;186 
CKD: Dogs,
35-37,43-46,51,69,70 cats66-68,176
Marked hematuria;64 Pyuria/bacteriuria (RBP_FE)*; Negative correlation 
with age in young adolescent dogs;37
Treatment with hydrocortisone (dogs)38
THP Epithelial cells of thick ascending limb 
of loop of Henle and distal convoluted 
tubule
Glycoprotein Decreased production Cats187 Dogs: uTHP/c: 10 – 65 mg/g113
Cats: uTHP: 49.2 +/- 35.5 µg/ml187
CKD: Dogs,44,63,69,112,113 cats176 Urolithiasis (cats)187
Urinary Enzymes
AAP Renal tubular brush border enzyme Enzyme Released from brush border Dogs101 Dogs: uAAP/c: 0.7-9.0 U/g101 AKI: Dogs52
ALP Renal tubular brush border enzyme, 
highest in renal proximal convoluted 
tubule; Also in tubular lysosomes 
Enzyme Released from brush border Dogs: uALP/c: 0.25 +/-1.17 U/g;188
uALP: 5.8 (0.4-12) U/L/mmol189 
Horses: uALP/c: 6.7 +/- 3.9 IU/g;190 
uALP: 10.2 +/- 4.0 IU/L;190 < 3.55 
U/mmol191,192 
AKI: Dogs,65,189,193
sheep194
Cauxin Proximal straight tubular cells in cats Carboxylesterase 
protein
Uncertain whether increased or decreased 
with tubular damage
Cats195 CKD: Cats176,195,196
GGT Renal tubular brush border enzyme, 
highest in renal proximal straight 
tubule
Enzyme Released from brush border Horses197 Dogs: 
uGGT/c: < 42 U/g;103,108,188,198-200
3.4 (0.6-6.0) U/L/mmol189
uGGT: 6-112 U/L200
Cats: 
uGGT/c: < 36.4 U/g201
Horses:
uGGT/c: < 36.54 U/g;190,191,197,202  0.33 +/- 0.8 
U/L/mmol203
uGGT: 3.3 +/- 3.0 IU/L;190 < 1.85 
IU/mmol191,192,197
Calves: 
uGGT: 3.2 +/- 2.6 U/µmol204
AKI: Dogs,65,106,189,193,200,205 
horses,206,207 sheep194
NAG Lysosomal enzyme in proximal renal 
tubules and other tissues;
2 renal forms: NAG-A and NAG-B; 
circulates in the serum
Enzyme Cellular leakage (+/- glomerular damage, 
possibly due to lysosomal turnover and/or 
leakage through glomerular filtration barrier) 
Dogs37,50,64,101 
and cats208
Dogs and cats: uNAG/c: < 11 U/g14,101,103,201; 
Dogue de Bordeaux – uNAG/c median 
(range): 5.74 (2.75 – 13.396) U/g20  
AKI: Dogs,41,42,52,53,88,90,102,105,106 
cats,209 sheep194 
CKD: Dogs,36,37,43,50 cats209
Alkaline urine (reduced activity);201 Hematuria and hemoglobinuria 
(inaccurate measurement due to similar color of hemoglobin to m-crescol 
purple released by some substrates);201 Gender (higher in male dogs)101,103
*Personal observations
AAP, alanine aminopeptidase; AKI, acute kidney injury; ALP, alkaline phosphatase; CKD, chronic kidney disease; GGT, gamma glutamyl-transpeptidase; KIM-1, kidney injury molecule-1; LMW, low molecular 
weight; NAG, N-acetyl-β-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; RBP, retinol binding protein; RBP_FE, fractional excretion of retinol binding protein; THP, Tamm-Horsfall protein; 
uAAP/c, urinary alanine aminopeptidase/urinary creatinine; uALP, urinary alkaline phosphatase concentration; uALP/c, urinary alkaline phosphatase/urinary creatinine; uClu, urinary clusterin concentration; uClu/c, 
urinary clusterin/urinary creatinine; uGGT, urinary gamma glutamyl-transpeptidase; uGGT/c, urinary gamma glutamyl-transpeptidase/urinary creatinine; uNAG/c, urinary N-acetyl-β-D-glucosaminidase/urinary 
creatinine; uNGAL, urinary neutrophil gelatinase-associated lipocalin concentration; uNGAL/c, urinary neutrophil gelatinase-associated lipocalin/urinary creatinine; uRBP/c, urinary retinol binding protein/urinary 
creatinine; uTHP, urinary Tamm-Horsfall protein concentration; uTHP/c, urinary Tamm-Horsfall protein/urinary creatinine.
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Table A-3. Summary of Serum and/or Plasma Renal Biomarkers in Dogs and Cats174
Renal 
Biomarker
Location of 
Production
Type of 
Protein/Molecule
Type of 
Biomarker
Validation / 
Species
Values in Healthy Animals Affected in AKI, 
CKD, or Both
Non-Renal Influences
Creatinine Muscle Cyclic derivative of 
creatine 
Endogenous 
indirect GFR 
marker
Dogs
Cats
Dogs: 0.5-1.5 mg/dL210
Cats: 0.8-1.8 mg/dL210 (but 
depends on 
breed/species/instrument)
Both Muscle mass; meat diet; 
hydration status 
Cystatin C All nucleated cells LMW protein and 
proteinase inhibitor
Endogenous 
indirect GFR 
marker
Dogs118,120,211,212 
Cats213,214
Dogs: < 2.28 mg/L118-
120,182,211,215-217
Cats: < 1.95 mg/L213,214,218,219 
CKD: Dogs,118-
120,182,211,215-217 
cats213,218,219
(Presumably 
also AKI)
Obesity and weight loss 
in dogs212
SDMA All nucleated cells Methylated amino 
acid (arginine)
Endogenous 
indirect GFR 
marker
Dogs122,220,221   
Cats123,220,221
Dogs and cats: < 14 µg/dL 
122,123,222-226
CKD: 
Dogs,122,226 
cats123,227,228 
(Presumably 
also AKI)
FGF-23 Osteocytes and 
osteoblasts
Phosphaturic 
hormone
Marker of 
altered 
phosphorus 
metabolism
Cats229 Cats: 56-700 pg/mL229 CKD: Cats229-232 Dietary phosphorus;231 
hyperthyroidism232
NGAL Neutrophils, 
kidney, bronchus, 
stomach, small 
intestine, pancreas, 
prostate gland, 
thymus
LMW glycoprotein Endogenous 
indirect GFR 
marker 
Dogs82 Dogs: < 21.2 ng/mL82,83,86 AKI: Dogs82,86
CKD: 
Dogs82,83,86
Inflammation233
C-Reactive 
Protein
Hepatocytes Positive acute phase 
protein
Inflammatory 
marker
Dogs234 Dogs: 3.21 mg/l (range: 
2.09-8.60 mg/l)234
Renal diseases 
in dogs (AKI 
versus CKD not 
specified)234
Homocysteine All nucleated cells Amino acid; 
Intermediate product 
of methionine 
metabolism
Endogenous 
indirect GFR 
marker
Dogs212,235,236 Dogs: 4.35 +/- 2.69 
µmol/L236
AKI: Dogs235 
CKD: Dogs235,236
Obesity and weight loss 
in dogs;212 icterus, severe 
hemolysis and lipemia;235 
cardiac disease235
Big-
Endothelin-1
Blood vessels, 
lung, other tissues 
including kidney 
medulla
Precursor to 
endothelin-1, a 
vasoconstrictor 
peptide
Inflammation Dogs236 Dogs: 6.51 +/- 1.86 pg/mL236 CKD: Dogs236 Hypertension and 
systemic inflammation236
AKI, acute kidney injury; CKD, chronic kidney disease; FGF-23, fibroblast growth factor-23; GFR, glomerular filtration rate; 
LMW, low molecular weight; NGAL, neutrophil gelatinase-associated lipocalin; SDMA, symmetric dimethylarginine.
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Table A-4. Median (range) for biomarkers comparing pyuric and bacteriuric samples, hematuric samples, and all other 
samples (i.e., those without pyuria, bacteriuria, or hematuria) from dogs with naturally occurring chronic kidney diseases.
 Pyuria/Bacteriuria Hematuria All Other Samples
n Mean (Range) n Mean (Range) n Mean (Range)
sCr (mg/dL) 8  2.9 (0.9 - 9.5) 14  2.0 (0.4 - 4.6) 179  1.5 (0.3 - 21.8) 
USG 8  1.017 (1.014 - 1.026) 15  1.022 (1.004 - 1.042) 180  1.017 (1.003 - 1.048) 
UPC Ratio 8  7.0 (0.7 - 23.6) 15  8.0 (2.9 - 26.7) 180  5.0 (0.0 - 36.8) 
IgG
uIgG/c (µg/mg) 8  963 (118 – 9,532) 15  1,286 (261 – 15,223)* 180  554 (1 – 37,649) 
sIgG (µg/mL) 7  10,338 (2,235 – 27,077) 10  10,015 (2,637 – 47,627) 137  11,320 (3,199 – 41,798) 
IgG_FE % 7  0.3 (0.0 - 4.6)* 10  0.2 (0.0 - 1.7) 137  0.1 (0.0 - 8.6) 
IgM
uIgM/c (µg/mg) 8  23.2 (2.4 - 240.8)* 15  22.4 (5.0 - 546.1)* 180  6.4 (0.3 - 557.0)
sIgM (µg/mL) 7  2,144 (421 – 10,879) 10  1,776 (645 – 13,978) 137  2,864 (867 – 20,070) 
IgM_FE % 7  0.042 (0.007 - 0.122)* 10  0.020 (0.002 - 0.163)* 137  0.003 (0.000 - 0.172) 
RBP
uRBP/c (µg/mg) 8  59.3 (0.7 - 294.6) 15  12.0 (1.1 - 111.0) 180  8.7 (0.0 - 1013.4) 
sRBP (µg/mL) 7  83.9 (33.2 - 111.8) 10  76.4 (29.9 - 160.6)* 137  106 (23 – 414)
RBP_FE % 7  6.6 (0.1 - 11.2)* 10  0.4 (0.0 - 7.7) 137  0.1 (0.0 - 24.9)
NGAL
uNGAL/c (ng/mg) 7  335 (74 – 1,957)* 14  98.7 (43.3 – 2,535.0) 153  93.6 (0.0 – 1,533.4)
sNGAL (ng/mL) 6  36.2 (22.4 - 84.7)* 9  12.4 (3.8 - 190.0) 124  12.1 (2.4 - 149.1)
NGAL_FE % 6  43.0 (1.0 - 227.2) 9  16.7 (1.0 - 145.9) 124  10.8 (0.0 - 505.9) 
uNAG/c (U/g) 8  33.6 (2.6 - 92.5) 14  16.0 (3.8 - 98.7) 170  13.5 (0.4 - 427.7) 
Pyuria/bacteriuria: >10 WBC/40× field, presence of bacteriuria, or both; Hematuria: >100 RBC/40× field; *P < 0.05 
significant difference between samples with pyuria/bacteriuria or hematuria and all other samples; sCr, serum creatinine; 
USG, urine specific gravity; UPC, urine protein:creatinine ratio; uIgG/c, urine immunoglobulin G/urine creatinine; sIgG, 
serum immunoglobulin G; IgG_FE, fractional excretion of immunoglobulin G; uIgM/c, urine immunoglobulin M/urine 
creatinine; sIgM, serum immunoglobulin M; IgM_FE, fractional excretion of immunoglobulin M; uRBP/c, urine retinol 
binding protein/urine creatinine; sRBP, serum retinol binding protein; RBP_FE, fractional excretion of retinol binding protein; 
uNGAL/c, urine neutrophil gelatinase-associated lipocalin/urine creatinine; sNGAL, serum neutrophil gelatinase-associated 
lipocalin; NGAL_FE, fractional excretion of neutrophil gelatinase-associated lipocalin; uNAG/c, urine N-acetyl-β-D-
glucosaminidase/urine creatinine.
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APPENDIX B*
Supplemental Materials and Methods for Chapter II
Assay Validation12
For the immunoglobulin M (IgM) assay, intra- and interassay variability, 
dilutional linearity, and spiking recovery were determined using canine urine samples. 
For the neutrophil gelatinase-associated lipocalin (NGAL) assay, interassay variability 
and dilutional linearity were determined using canine urine samples. Intraassay 
variability was determined by analyzing 10 repetitions of 3 samples with low, middle, 
and high concentrations within a single run. Interassay variability was determined by 
analyzing 3 samples with low, middle, and high analyte concentrations in 8 (IgM) or 13 
(NGAL) consecutive runs. For dilutional linearity, 3 – 4 samples with low, middle, and 
high analyte concentrations were serially diluted. For spiking recovery, a known amount 
of protein standard was added to 6 samples with known IgM concentrations. 
Additionally, 5 canine urine samples with low, middle, and high IgM concentrations 
were mixed in various combinations. Intra- and interassay variability were calculated 
using coefficient of variation (CV). Dilutional linearity and spiking recovery were 
calculated using observed to expected ratios (O/E%).
* Supplemental material in this appendix is reprinted with permission from Correlation of Urine and 
Serum Biomarkers with Renal Damage and Survival in Dogs with Naturally Occurring Chronic Kidney 
Disease by J.A. Hokamp, R.E. Cianciolo, M. Boggess, G.E. Lees, S.L. Benali, M. Kovarsky, and M. B. 
Nabity, 2016. Journal of Veterinary Internal Medicine 30, 591-601, Copyright 2016 by Wiley Periodical, 
Inc.
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Supplemental Tables for Chapter II
Table A- 5. Glomerular scoring system based on light microscopy.12
Score Lesions
0 Normal glomeruli or mild mesangial expansion
1
Mild or focal lesions: focal segmental glomerulosclerosis in small numbers of 
glomeruli; obsolescence of a small number of glomeruli; mild or early ICGN; 
mild or early amyloidosis (most capillary loops remain patent); other non-
specific glomerular lesions (e.g., mesangial expansion; mild mesangial cell 
proliferation; glomerular atrophy; podocyte hypertrophy without sclerosis; 
fetal glomeruli; glomerular hypertrophy)
2
Moderate lesions: focal segmental sclerosis in many glomeruli; moderate 
ICGN with GBM remodeling and secondary sclerosis; moderate amyloidosis 
(effacement of about ½ of the capillary loops by amyloid); other non-specific 
glomerular lesions (e.g., glomerular obsolescence/atrophy with associated 
secondary compensatory hypertrophy and sclerosis)
3
Severe lesions: advanced focal segmental glomerulosclerosis; active or 
fulminant ICGN with abundant inflammatory cells, crescents or pyknotic 
nuclear debris; severe amyloidosis (most capillary loops effaced by amyloid); 
advanced global glomerulosclerosis; end-stage lesions with secondary 
compensatory hypertrophy and sclerosis
ICGN, immune complex-mediated glomerulonephritis; GBM, glomerular basement 
membrane.
Table A-6. Glomerular scoring system based on TEM.12
Score Lesions
0
Normal ultrastructure or minimal, nonspecific/reversible lesions identified in a 
few TEM images (e.g., segmental foot process effacement, microvillus 
transformation)
1
Mild, reversible ultrastructural lesions (identified in many TEM images but 
still segmental in distribution): foot process effacement, global podocyte 
swelling, or global microvillus transformation
2
Moderate irreversible ultrastructural lesions (identified in many TEM 
images): segmental glomerular basement membrane remodeling, podocyte 
dropout, scattered/focal immune deposits, mild amyloidosis or global foot 
process effacement 
3
Severe irreversible ultrastructural lesions (identified in most TEM images): 
global glomerular basement membrane remodeling, marked podocyte dropout, 
global immune complex deposition, or moderate to severe amyloidosis  
TEM, transmission electron microscopy.
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Table A-7. Tubulointerstitial scoring system based on light microscopy.12
Score Interstitial Fibrosis* Tubular Atrophy** Tubular Degeneration/Necrosis/Regeneration** Interstitial Chronic Inflammation+
0 None None None None
1
Mild non-diffuse 
fibrosis: surrounds ≤ 2 
tubules
Mild non-diffuse 
atrophy: ≤ 2 tubules
Mild non-diffuse cell stress: ≤ 2 tubules degenerating 
and/or regenerating
Mild non-diffuse chronic 
inflammation: ≤ 2 mononuclear cell 
foci (<10 cells)
2 Mild diffuse fibrosis: surrounds ≥ 3 tubules
Moderate non-diffuse 
atrophy: 3 - 5 tubules
Mild non-diffuse cell death: ≤ 2 tubules with 
necrotic/apoptotic cells
Mild diffuse chronic inflammation: ≥ 
3 mononuclear cell foci (<10 cells)
3
Moderate non-diffuse 
fibrosis: surrounds ≤ 2 
tubules
Severe atrophy: all 
tubules in a field or > 6 
tubules
Moderate diffuse cell stress: ≥ 3 tubules 
degenerating and/or regenerating
Moderate non-diffuse chronic 
inflammation: ≤ 2 mononuclear cell 
foci (>10 cells)
4
Moderate diffuse 
fibrosis: surrounds ≥ 3 
tubules
N/A Moderate diffuse cell death: ≥ 3tubules with necrotic/apoptotic cells
Moderate diffuse chronic 
inflammation: ≥ 3 mononuclear cell 
foci (>10 cells)
5 Severe fibrosis (fibrosis replacing tubules) N/A
Severe tubular necrosis: entire tubule in field is 
necrotic or contains cellular cast
Severe chronic inflammation: any 
field where inflammatory foci replace 
tubules
For each category, 10 random 40× fields for core biopsies and 30 random 40× fields for wedges were evaluated. 
*Evaluated with trichrome; **evaluated with periodic acid-Schiff; +evaluated with hematoxylin and eosin; N/A, not 
applicable.
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Table A-8. Results from IgM and NGAL assay validation including mean inter- and intra-assay variability for low, middle, 
and high concentration urine samples, dilutional linearity, and spiking recovery.12
Mean Interassay Variability (CV) Mean Intraassay Variability (CV)
[Low] [Middle] [High] [Low] [Middle] [High]
Dilutional Linearity 
(O/E%)
Spiking 
Recovery
(O/E%)
IgM Assay 10.8% 12.6% 14.6% 2.7% 3.3% 3.4% 95-125%* 87-119%
NGAL 
Assay 13.4% 13.6% 11.7% ND ND ND 86-118% N/A
*Dilutional linearity of the IgM assay was acceptable when the values obtained fell within 125-1,000 ng/mL on the standard 
curve. When values were below this, the final concentration was overestimated by 40 – 130%. IgM, immunoglobulin M; 
NGAL, neutrophil gelatinase-associated lipocalin; CV, coefficient of variation; O/E%, observed to expected ratio; ND, not 
performed.
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Table A-9. Median (range) for biomarkers within each IRIS stage.12
 IRIS Stage 1 IRIS Stage 2 IRIS Stage 3 IRIS Stage 4
n Median (Range) n Median (Range) n Median (Range) n Median (Range)
sCr (mg/dL) 73 0.9 (0.3 - 1.3)abc 50 1.6 (1.4 - 2.0)de 41 2.8 (2.1 - 4.9)f 15 8.5 (5.3 - 21.8)
USG 73 1.020 (1.003 - 1.048)bc 50 1.018 (1.003 - 1.045)de 41 1.013 (1.005 - 1.029) 15 1.013 (1.006 - 1.020)
UPC Ratio 73 5.2 (0.1 - 31.0) 50 6.8 (0.0 - 31.6) 41 3.4 (0.0 - 36.8) 15 3.7 (0.2 - 16.2)
IgG
uIgG/c (µg/mg) 73 558 (1 – 7,183) 50 625 (1 – 37,649) 41 356 (2 – 11,845) 15 278 (22 – 2,954)
sIgG (µg/mL) 58  11,288 (3,742 – 29,686) 38  11,369 (3,294 – 41,798) 30  9,400(3,576 – 25,399) 11  14,916 (3,199 – 31,108)
IgG_FE % 58 0.043 (0.000 - 0.628)bc 38 0.086 (0.000 - 3.233) 30 0.114 (0.000 - 5.056) 11 0.157 (0.039 - 8.587)
IgM
uIgM/c (µg/mg) 73 6.2 (0.8 - 58.2) 50 7.0 (0.3 - 150.6) 41 5.5 (0.5 - 557.0) 15 7.9 (0.4 - 29.7)
sIgM (µg/mL) 58  2,724 (868 – 12,042) 38  2,937 (1,051 – 16,031) 30  3,030 (1,066 – 20,070) 11  2,759 (1,688 – 10,922)
IgM_FE % 58 0.002 (0.000 - 0.021)abc 38 0.003 (0.000 - 0.027)de 30 0.008 (0.001 - 0.089) 11 0.015 (0.002 - 0.172)
RBP
uRBP/c (µg/mg) 73 1.9 (0.0 – 1,013.4)bc 50 8.0 (0.0 - 699.0)e 41 17.4 (0.1 - 427.5)f 15 38.4 (9.5 - 306.1)
sRBP (µg/mL) 58 94 (27 - 258)c 38 101 (23 - 281)e 30 113 (24 - 238) 11 153 (44 - 414)
RBP_FE % 58 0.0 (0.0 - 0.8)abc 38 0.1 (0.0 - 3.2)de 30 0.4 (0.0 - 18.0)f 11 5.1 (0.5 - 24.9)
NGAL
uNGAL/c (ng/mg) 62 74 (0 – 1,533) 40 93 (4 - 493) 39 103 (1 - 912) 11 140 (11 - 677)
sNGAL (ng/mL) 53 9.9 (2.5 - 65.7)bc 33 13.5 (2.4 - 73.2) 30 14.5 (2.6 - 149.1) 8 30.5 (3.2 - 62.9)
NGAL_FE % 53 5.8 (0.0 - 115.2)abc 33 11.1 (1.0 - 43.3)de 30 17.9 (1.6 - 82.8)f 8 49.5 (10.8 - 505.9)
uNAG/c (U/g) 70 14.4 (2.0 - 253.1) 46 12.4 (1.3 - 109.9) 40 10.7 (0.4 - 427.7) 13 12.8 (0.4 - 37.7)
Significant differences (P < 0.05) exist for biomarkers between IRIS stages a1 and 2, b1 and 3, c1 and 4, d2 and 3, e2 and 4, f3 
and 4 as determined by linear regression modeling comparing groups. IRIS, International Renal Interest Society; sCr, serum 
creatinine; USG, urine specific gravity; UPC, urine protein:creatinine ratio; uIgG/c, urine immunoglobulin G/urine creatinine; 
sIgG, serum immunoglobulin G; IgG_FE, fractional excretion of immunoglobulin G; uIgM/c, urine immunoglobulin M/urine 
creatinine; sIgM, serum immunoglobulin M; IgM_FE, fractional excretion of immunoglobulin M; uRBP/c, urine retinol 
binding protein/urine creatinine; sRBP, serum retinol binding protein; RBP_FE, fractional excretion of retinol binding protein; 
uNGAL/c, urine neutrophil gelatinase-associated lipocalin/urine creatinine; sNGAL, serum neutrophil gelatinase-associated 
lipocalin; NGAL_FE, fractional excretion of neutrophil gelatinase-associated lipocalin; uNAG/c, urine N-acetyl-β-D-
glucosaminidase/urine creatinine.
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Table A-10. Correlation among biomarkers for dogs with naturally occurring CKD.12
USG UPC uIgG/c sIgG IgG_FE uIgM/c sIgM IgM_FE uRBP/c sRBP RBP_FE uNGAL/c sNGAL NGAL_FE uNAG/c
sCr -0.32** -0.15* -0.12 0.02 0.31** -0.01 0.09 0.59** 0.41** 0.19* 0.62** 0.09 0.26** 0.46** -0.11
USG 0.24** 0.21** -0.06 0.08 0.17* 0.06 -0.06 -0.11 -0.18* -0.13 -0.06 -0.09 -0.16 0.24**
UPC 0.90** -0.25** 0.65** 0.65** 0.06 0.42** 0.46** 0.11 0.46** 0.44** 0.13 0.00 0.73**
uIgG/c 0.00 0.90** 0.72** 0.18* 0.55** 0.42** -0.04 0.42** 0.59** 0.19* 0.49** 0.68**
sIgG -0.24** 0.06 0.49** -0.13* -0.22** -0.06 0.07 -0.04 0.10 -0.09 -0.26**
IgG_FE 0.66** 0.07 0.75** 0.64** 0.05 0.66** 0.62** 0.24** 0.64** 0.66**
uIgM/c 0.52** 0.77** 0.39** -0.08 0.46** 0.23** 0.23** 0.09 0.29**
sIgM 0.09 0.00 -0.21 0.07 0.12 0.23** 0.03 0.03
IgM_FE 0.66** 0.12 0.74** 0.30** 0.27** 0.32** 0.45**
uRBP/c 0.35** 0.95** 0.62** 0.30** 0.66** 0.44**
sRBP 0.16 0.23* 0.27** 0.14 -0.20*
RBP_FE 0.57** 0.30** 0.69** 0.45**
uNGAL/c 0.45** 0.78** 0.50**
sNGAL -0.02 0.15
NGAL_FE 0.38**
* P < 0.05; ** P < 0.001; Shading depicts correlations with P < 0.001. sCr, serum 
creatinine; USG, urine specific gravity; UPC, urine protein:creatinine ratio; uIgG/c, 
urine immunoglobulin G/urine creatinine; sIgG, serum immunoglobulin G; IgG_FE, 
fractional excretion of immunoglobulin G; uIgM/c, urine immunoglobulin M/urine 
creatinine; sIgM, serum immunoglobulin M; IgM_FE, fractional excretion of 
immunoglobulin M; uRBP/c, urine retinol binding protein/urine creatinine; sRBP, serum 
retinol binding protein; RBP_FE, fractional excretion of retinol binding protein; 
uNGAL/c, urine neutrophil gelatinase-associated lipocalin/urine creatinine; sNGAL, 
serum neutrophil gelatinase-associated lipocalin; NGAL_FE, fractional excretion of 
neutrophil gelatinase-associated lipocalin; uNAG/c, urine N-acetyl-β-D-
glucosaminidase/urine creatinine.
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Supplemental Figures for Chapter II
Figure A-1. Probability of survival for dogs with combinations of sCr and IgM_FE at the 
25th percentile (1.0 mg/dl and 0.001%, respectively) and 95th percentile (5.0 mg/dl and 
0.075%, respectively) based on transmission electron microscopy (TEM) scores: A) 
TEM score 0/1 and B) TEM score 2/3 (n=60). Abbreviation explanations in Table A-6 
and A-9 legends.12
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APPENDIX C
Supplemental Table for Chapter III
Table A-11. Ability of urinary protein biomarkers to predict ICGN in dogs with proteinuric renal disease that were biopsied 
for suspicion of glomerular disease. Areas under the curve, optimal cutoff values, and corresponding sensitivities and 
specificities, as determined by receiver operator characteristic analysis, are displayed.
All IRIS Stages (N = 178) IRIS Stage 1 (N = 83) IRIS Stages 2, 3, 4 (N = 95)
AUC Cutoff (Sens %, Spec %) AUC Cutoff (Sens %, Spec %) AUC Cutoff (Sens %, Spec %)
UPC 0.6299 >7.0 (58.8, 62.4) 0.5762 >8.9 (35.3, 79.6) 0.6627 >5.3 (74.5, 59.1)
uIgM (ng/ml) 0.8106 >5.3 (83.5, 68.8) 0.7305 >5.3 (79.4, 63.3) 0.8748 >5.1 (86.3, 75.0)
uIgM/c (μg/mg) 0.7880 >10.8 (62.4, 81.7) 0.7527 >6.4 (79.4, 69.4) 0.8124 >14.0 (66.7, 88.6)
IgM_FE (%) 0.7098 >0.007 (48.4, 85.3) 0.6846 >0.002 (69.2, 62.5) 0.7271 >0.008 (71.1, 71.4)
uNAG (U/L) 0.7478 >15.3 (71.8, 65.6) 0.6459 >27.6 (44.1, 87.8) 0.8409 >11.1 (88.2, 68.2)
uNAG/c (U/g) 0.7098 >14.9 (72.9, 60.2) 0.6705 >23.5 (52.9, 79.6) 0.7366 >14.9 (78.4, 63.6)
AUC, area under the curve; ROC, receiver operator characteristic, ICGN, Immune Complex-Mediated Glomerulonephritis; 
IRIS, International Renal Interest Society; Sens, sensitivity; Spec, specificity; UPC, urine protein:creatinine; uIgM, urine 
immunoglobulin M; uIgM/c, urine immunoglobulin M/creatinine; IgM_FE, fractional excretion of immunoglobulin M; 
uNAG, urine N-acetyl-β-D-glucosaminidase; uNAG/c, urine N-acetyl-β-D-glucosaminidase/creatinine.
